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6ABSTRACT
Nef is an accessory protein encoded by the human and simian immunodeficiency
viruses (HIV/SIV) and is a major factor in promoting viral pathogenesis. Several
cellular functions of Nef, including downregulation of the surface molecules CD4
and MHC I, increase in viral infectivity, and Nef-mediated effects on intracellular
signaling favor survival and propagation of the virus. Nef does not possess any
intrinsic enzymatic activity; instead, it functions by interacting with a number of
endogenous proteins within the host cell.
One of the well-characterized Nef-associating protein partners and a central
molecule in this study is p21-associating kinase 2 (PAK2). Previously, association
of the HIV-1 Nef with PAK2 has been proposed to play a role in T cell activation,
viral replication, apoptosis and progression of HIV infection to AIDS. Despite
intense research, there is no consensus on the relevance of Nef-PAK2 association
and its function in virus pathogenesis. Furthermore, selective association of Nef with
a minute but highly active subpopulation of total cellular PAK2 has raised questions
on the molecular requirements of Nef-PAK2 association. This work elucidated the
interplay of Nef and PAK2 in cellular signaling by studying the mechanism of
PAK2 activation and its role in Nef association. To clarify the role of additional
proteins during Nef-PAK2 complex formation, the involvement of p21-GTPases and
guanine nucleotide exchange factor (GEF) proteins was studied. Finally, the
functional role of charge distribution within the putative Nef interaction surface was
characterized.
Here, we describe a new signaling pathway that potentiates PAK2 activation by
converging signal transduction via Src tyrosine kinases with p21-GTPase-induced
PAK activation. The p21-GTPase-induced conformational opening of PAK2 was
associated with the ability of PAK2 to interact with Nef, and their association was
stabilized  by  reduced  kinase  activity.  The  Nef-PAK2  (NAK)  complex  was
specifically localized to detergent-resistant membranes (DRM), and Vav1 was
identified as a GEF component of Nef-PAK2 complex, recruited to the DRMs by
Nef. The reciprocal charges present at the putative dimer interface (PDI) of Nef
were indispensable for Nef-dependent increase in viral infectivity. In addition,
several other Nef activities, including NAK association, membrane localization, and
activation of Hck were coordinated by charged residues at the Nef PDI.
In conclusion, our results provide new insight on the cellular signaling upstream of
Nef-PAK2 association, as well as on the molecular domains and binding partners
that are important for the formation of the Nef-PAK2 complex. In addition, our data
elucidate how Nef functions are related to charge distribution at the PDI surface.
Detailed knowledge on the molecular mechanisms involved in Nef-PAK2-mediated
7signaling may provide clues for potential target sites that can be used to develop
HIV inhibitory drugs.
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Aa amino acid
ADF actin depolymerizing factor
AID autoinhibitory domain
AIDS acquired immunodeficiency syndrome
AP adaptor protein
APC antigen-presenting cell
ATP adenosine triphosphate
ATPase adenosine triphosphatase
ARF ADP ribosylation factor
bp base pair
b-COP b subunit of COPI coatomers
CA capsid protein
CAT COOL-associated, tyrosine phosphorylated
CD cluster of differentiation
Cdc42 cell division cycle 42
COOL cloned out of library
CRIB Cdc42/Rac interactive binding domain
CTL cytotoxic T lymphocyte
CTx cholera toxin
DNA deoxyribonucleic acid
DRM detergent-resistant membrane
ECL enhanced chemiluminescence
ELISA enzyme-linked immunosorbent assay
Env envelope protein
ER endoplasmic reticulum
FCS fetal calf serum
G-CSF granulocyte colony-stimulating factor
GEF guanine nucleotide exchange factor
GIT G protein-coupled receptor kinase-interactor
Gp glycoprotein
GST glutathione S-transferase
GTP guanosine triphosphate
GTPase guanosine triphosphatase
HAART highly-active anti-retroviral therapy
Hck hematopoietic cell kinase
HEK human embryonic kidney
HIV human immunodeficiency virus
HSC hematopoietic stem cell
hTE human thioesterase
HTLV human T cell leukemia virus
IN integrase
IP3R inositol trisphosphate receptor
IS immunological synapse
IVKA in vitro kinase assay
JNK c-Jun N-terminal kinase
Kb kilobase
kD kiloDalton
LNTP long-terminal non-progressor
LTR long terminal repeat
MA matrix protein
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MAP/ERK mitogen-activated protein/extracellular signal-regulated protein kinase
MHC I major histocompatibility class I
MLCK myosin light chain kinase
mRNA messenger-RNA
NAK Nef-associated kinase
NC nucleocapsid protein
Nef negative factor
NF-kB nuclear factor kB
NFAT nuclear factor of activated T cells
ORF open reading frame
PACS phosphofurin acidic cluster sorting protein
PAGE polyacrylamide gel electrophoresis
PAK p21-activated kinase
PBD p21-GTPase binding domain
PBS phosphate-buffered saline
PCR polymerase chain reaction
PDGF platelet-derived growth factor
PDI putative dimer interface
PDK pyruvate dehydrogenase kinase
PI3K phosphoinositide-3-kinase
PIC preintegration complex
PIP3 phosphatidylinositol (3,4,5)-trisphosphate
PIX PAK-interacting exchange factor
PKC protein kinase C
PKL paxillin kinase linker
PMSF phenylmethylsulfonyl fluoride
Pol polymerase protein
POPX partner of PIX
PR protease
PP1 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]- pyrimidine
P-TEF-b positive transcriptional elongation factor b
PTP-1B protein tyrosine phosphatase 1B
PV pervanadate
PVDF polyvinylidene difluoride
Rev regulator of viral protein expression
R-MLC regulatory myosin light chain
RNA ribonucleic acid
RRE Rev-responsive element
RT reverse transcriptase
SDS sodium dodecayl sulfate
SFK Src-family tyrosine kinase
SH3 Src homology 3
SIV simian immunodeficiency virus
SMAC supramolecular activation cluster
SP slow progressor
Tat transactivator protein
TcR T cell receptor
TfR transferrin receptor
TGN trans-Golgi network
TNF tumor necrosis factor
Vif viral infectivity factor
Vpr viral protein R
Vpu viral protein U
ZAP-70 zeta chain associated protein 70 kDa
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INTRODUCTION
Nef is an accessory protein of the human and simian immunodeficiency viruses
(HIV/SIV). In vivo, Nef has an essential role in promoting viral replication and the
subsequent evasion of host immune defense to develop AIDS. The critical property
of Nef is its ability to associate with a number of endogenous proteins and by doing
so, modulate cellular signaling cascades within the host cell to the benefit of the
virus. The Nef functions that have been best characterized include downregulation
of  the  T  cell  surface  marker  CD4  and  major  histocompatibility  class  I  (MHC  I)
molecules, enhancement of viral replication kinetics, and intrinsic infectivity of HIV
particles. In addition, Nef has various effects on T cell signaling.
One potentially important cellular interaction partner of Nef is Nef-associating
serine/threonine kinase, identified as p21-activated kinase 2 (PAK2). The ability to
associate with active PAK2 is a conserved property of Nef alleles derived from both
HIV-1/-2 and SIV strains. However, Nef interacts with only a small subpopulation
of the total cellular pool of active PAK2, suggesting that the differences in
molecular properties, such as the phosphorylation status and conformation of PAK2,
govern this selective association.
Nef associates with lipid rafts, which are specific membrane microdomains
important for docking various proteins that are involved in signal transduction. In
that view, it is not surprising that Nef association with PAK2 has been described to
take place within a multiprotein complex, also referred to as ‘signalosome’ and
several GEFs may be components of this complex. As an adaptor for many signals
initiated by ligand binding and subsequent dimerization of receptor molecules, Nef
has been also suggested to form oligomers in order to increase the intensity of
downstream signaling.
The purpose of this work was to study the detailed molecular mechanism of PAK2
activation and the determinants of PAK2 and Nef association. In addition, we have
characterized the intracellular localization of Nef-PAK2 complex and identified the
GEF component of this complex. By studying the putative Nef dimerization
interface, we have clarified the role of complementary charges within this interface
in some of the most important Nef functions.
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REVIEW OF THE LITERATURE
1. Human and simian immunodeficiency viruses
Human immunodeficiency viruses 1 and 2 (HIV-1 and -2) and their primate
counterpart, simian immunodeficiency virus (SIV) belong to the lentivirus genus
within the Retroviridae family. The genus name, Lentiviridae,  refers  to  the
characteristically slow and progressive infection caused by these RNA viruses. The
transmission of SIV from its original hosts, the African monkeys, to humans gave
rise to different strains of HIV-1, which closely resemble the SIVcpz strain that
infects chimpanzees (Gao et al., 1999; Hahn et al., 2000). The less pathogenic HIV-
2 originates from a separate transmission of the SIVsm strain from sooty mangabeys
to humans (Gao et al., 1992; Marx et al., 1991).
Lentiviruses became general knowledge in 1983, when researchers at the Pasteur
Institute identified a novel T-lymphotropic retrovirus from a patient with
lymphadenopathy (Barre-Sinoussi et al., 1983). Soon, Robert Gallo’s group at the
NIH confirmed this finding, and the virus was associated with the acquired
immunodeficiency syndrome, AIDS (Gallo et al., 1983).
In 26 years, HIV infection has become a worldwide pandemic with an estimated 33
million people globally living with the virus (www.unaids.org). HIV-infected
individuals develop severe defects in their immune system, suffer from various
opportunistic infections and often develop cancer. Eventually, the immune
dysfunction resulting from gradual depletion of CD4(+) T helper cells leads to
disturbed function of cytotoxic T lymphocytes (CTL) and B cells. If untreated,  the
silent infection can become the terminal phase of the full-blown disease, AIDS, in
approximately 10-12 years. Highly-active anti-retroviral therapy (HAART) has
successfully treated infected patients by restricting virus replication. However,
current drug regimens do not eradicate the virus from the body, thus making HIV
treatment a life-long commitment. Furthermore, current drugs are economically
inaccessible to the majority of patients living in developing countries, indicating the
need for new approaches in drug development.
1.1. HIV-1 genome
The 9.4-kB RNA genome of HIV consists of nine open reading frames (ORF)
(Figure 1.). Three genes, gag, pol, and env, encode polyproteins that require further
proteolysis into individual proteins. The HIV-1 proteins can be divided by their
functions into three separate groups: structural (Gag, Env), regulatory (Pol, Rev,
Tat), and accessory (Vif, Vpr, Vpu, Nef) proteins.
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The gag gene encodes a polyprotein precursor, Pr55Gag, which is cleaved by the
viral protease to yield the mature Gag proteins dubbed matrix (also known as
MA/p17), capsid (CA/p24), nucleocapsid (NC/p7), and p6, as well as two small
spacer peptides (p1 and p2). The N-terminal component of Pr55Gag, matrix, is
required for targeting Gag and Gag-Pol polyprotein precursors to the host cell
membrane prior to viral assembly (Yuan et al., 1993; Zhou et al., 1994). Capsid
protein forms the core of the viral particle, but it is also important for viral
infectivity, possibly due to role in viral uncoating in association with cyclophilin A
(Luban, 1996). NC coats the viral RNA genome within the virion. It binds to the
packaging signal (y-site), typically located in the region of the 5’ RNA of the gag
initiation codon (Clever et  al., 1995), and targets the RNA into the assembling
virion. The very C-terminal portion of Pr55Gag polyprotein encodes for p6, which is
important for the incorporation of the accessory protein Vpr during viral assembly
(Kondo et al., 1995; Paxton et al., 1993).
The envelope (Env) glycoproteins are also synthesized as a polyprotein precursor,
gp160. The precursor protein is processed by a cellular protease during Env
trafficking to the cell surface, resulting in the generation of the surface and
transmembrane Env glycoproteins gp120 and gp41, respectively. Gp120 contains
the determinants that interact with receptor and coreceptor on the target cell surface,
while gp41 anchors the gp120/gp41 complex in the membrane. In addition, gp41
contains domains that are critical for catalyzing the membrane fusion between viral
and host lipid membranes during virus entry (reviewed by Freed and Martin, 1995).
The newly synthesized and cleaved gp120 and gp41 are occasionally retained at the
endoplasmic reticulum (ER) by interactions with CD4 molecules (Kimura et al.,
1994). The accessory protein Vpu (viral protein U) promotes CD4 degradation in
these complexes (Willey et al., 1992), allowing the Env proteins to be transported to
the cell surface for virion assembly.
The regulatory enzymes protease (PR), reverse transcriptase (RT), and integrase
(IN) encoded by the pol gene are initially synthesized as part of a large polyprotein
precursor, Gag-Pol, whose synthesis results from a frameshifting event during Gag
translation. Individual pol-encoded proteins PR, RT, and IN are then cleaved from
Gag-Pol by the viral protease. Functionally, RT is required to yield duplex DNA
from the viral RNA genome for its integration into the host chromosome. RT
catalyzes both RNA- and DNA-dependent DNA polymerization, and it contains an
RNase H domain that cleaves the RNA portion from RNA-DNA hybrids that are
formed during the reaction (Prasad and Goff, 1990). After reverse transcription, the
integrase catalyzes the removal of 3’ nucleotides from each newly formed DNA
strand as well as their covalent joining to the target genome. IN is also involved in
the removal of viral DNA 5’ nucleotides and joining it to the 3’ of the host target
sequence (Hindmarsh and Leis, 1999). Other regulatory proteins, specifically Tat
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(transactivator protein) and Rev (regulator of viral protein expression), enhance viral
protein expression: Tat is critical for transcription from the HIV-1 long terminal
repeat  (LTR),  and  Rev  plays  a  central  role  in  transporting  viral  RNAs  from  the
nucleus to the cytoplasm. Their functions are further discussed in the next chapter in
the context of viral replication.
Besides Vpu, Vif (viral infectivity factor), Vpr (viral protein R) and Nef have also
been termed “accessory” or “auxiliary” proteins to reflect the fact that they are not
uniformly required for virus replication. Vpr transports the viral nucleoprotein
complexes to the host cell nucleus after the viral entry and its “uncoating” in the
cytoplasm, whereas Vif contributes to the high infectivity of the maturing virions
(Malim and Emerman, 2008). However, the mechanism of Vif function is poorly
defined.  The role of accessory protein Nef in viral pathogenesis is discussed in
more detail in chapter 2.
Figure 1. Genomic structure of HIV-1.  ORFs are presented as boxes.
Modified from Levy, 1998.
1.2. HIV replication
HIV-1 replication is an ordered process, where most of the events proceed in
consecutive and stepwise manner. The viral cycle initiates when the Env gp120
binds to the CD4 surface molecules present on the CD4(+) HIV target cells.
However, CD4 alone is not enough for membrane fusion and subsequent viral entry;
in addition, entry requires a chemokine receptor that functions as a coreceptor
during virus binding. Two chemokine receptors, the a-chemokine receptor CXCR4
and the b-chemokine receptor CCR5 are HIV coreceptors (Berger et al., 1999). The
viruses replicating in macrophages (M-tropic) are referred to as R5 isolates, and
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strains that infect mainly T cells (T-tropic), are called X4 viruses. The R5 isolates
are usually predominant during the early phases of infection, but X4 isolates become
more common as the disease progresses.
After viral entry mediated by interactions of viral surface glycoproteins and
receptors on the host cell membrane, the “uncoating” of virus follows. Removal of
the viral lipid bilayer results in the formation of a large nucleoprotein complex (also
referred to as preintegration complex, PIC), where MA, RT, IN, and Vpr proteins
remain associated with the viral genome (Bukrinsky et  al., 1993). The viral RNA
genome is converted into double-stranded DNA in the next step of reverse
transcription, and is subsequently transported to the nucleus as part of the PIC.
Following nuclear import, IN catalyzes the stepwise insertion process of the linear,
double-stranded viral DNA into the host cell chromosome (Kulkosky and Skalka,
1994). The integrated provirus can now serve as the template for the synthesis of the
viral RNAs that will encode all the HIV-1 proteins used to direct replication of new
virus. The basal transcriptional activity from the HIV-1 LTR is low but can be
markedly increased by the transcriptional activator protein Tat and associated
transcriptional coactivators (Kiernan et al., 1999; Mujtaba et  al.,  2002;  Ott et al.,
1999; Wei et al., 1998; Zhu et al., 1997).
Most cellular mRNAs are spliced prior to their transport out of the nucleus, but HIV
requires unspliced RNAs for its polyprotein precursors. To overcome this problem,
the HIV-1 Rev protein and the cis-acting RNA sequence called Rev-responsive
element (RRE), present in env gene, function in concert to form a complex that is
capable of interacting with the cellular nuclear export machinery (Pollard and
Malim, 1998). Consequently, RRE-containing RNA can be transported unspliced
into the cytoplasm, and Rev uses its nuclear localization signal to shuttle back to the
nucleus.
With all viral proteins synthesized, the assembly process begins at the plasma
membrane of an infected cell, where host cell membrane-associated HIV-1 Gag is a
major player in this process. Mediated by interactions with the NC protein, the HIV
y-site, and additional regions of the genome, the RNA genome is packed within the
newly forming virion (reviewed in D'Souza and Summers, 2005). As a final step in
the process of virus assembly and release, virus particles bud from the host cell
plasma membrane. During or shortly after virus release from the plasma membrane,
viral protease cleaves the Gag and Gag-Pol polyprotein precursors to generate the
mature Gag and Pol proteins. Once the processing is initiated, the capsid protein
forms a conical shell around the RNA/protein complex. Finally, a series of structural
rearrangements leads to virion maturation (reviewed in Ganser-Pornillos et  al.,
2008). Failed virion maturation results in the loss of infectivity.
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2. The Nef protein
Nef is a small, 27-34-kDa, protein unique to primate lentiviruses. Structurally, HIV-
1 Nef consists of an N-terminal arm of approximately 70 residues followed by a
well-conserved core domain (aa 71-203 in NL4-3 Nef) (Geyer et al., 1999; Grzesiek
et al., 1996). The high conservation of the core residues implies that the core
domains of HIV-1/2 and SIV Nef adopt similar tertiary structures. Within the core
domain is the flexible loop region (aa 148-178), which possesses several binding
motifs. HIV-2 and SIV Nefs have an additional 10-30 amino acid C-terminal stretch.
When first characterized, this protein was named Nef (negative factor), because it
was expressed during the early phase of infection and was described to decrease the
virus production by functioning as a transcriptional silencer (Ahmad and
Venkatesan, 1988; Niederman et al.,  1989).  Later,  however,  the general  idea of  its
functions has switched from gene silencing to boosting viral pathogenesis. Despite
being dispensable for replication of HIV in vitro, Nef is a critical factor for AIDS
pathogenesis, but the underlying molecular mechanisms behind this have remained
elusive. Research has also been complicated by the ability of Nef-defective viruses
to replicate in transformed cells most often used for research purposes. Nef protein
does not possess any intrinsic enzymatic activity, but it interacts with many
endogenous host cell proteins and can thus modulate cell functions and intracellular
signaling cascades to create a beneficial environment for the virus (Figure 2., p. 20).
The daunting multiplicity of Nef functions has been an obstacle in drug
development, as it is unlikely that any drug will block all of them. Therefore, it
would be of crucial importance to identify which Nef functions are most relevant for
HIV pathogenesis.
Animal models are a feasible tool to study the functional effects of a foreign gene
product introduced to the host genome. The consequences of Nef expression for the
host cell have been studied in vivo both in murine and primate models. Studies on
primates other than humans or chimps usually use SIV as the infectious agent.
However, a great proportion of primates, such as macaques, that are infected with
SIV remain without symptoms which makes the SIV model suitable for studying the
implications of a chronic infection (Daniel et al., 1987). The importance of Nef
protein in viral pathogenesis was first addressed in macaques infected with SIV that
contained non-functional nef gene  with  a  premature  stop  codon  (Kestler et al.,
1991). Soon after infection, Nef sequences had reverted back to functional
genotypes, and the revertants with a coding codon became dominant, indicating the
importance of a functional SIV Nef for pathogenesis. Notably however, the
artificially introduced stop codon did not alter the virus replication in cultured cells
(Kestler et al., 1991). From this point on, Nef was noted as an important factor for
HIV pathogenicity and also as a possible candidate for drug targeting. These early
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findings were followed by other primate studies using either viruses with a 12-bp
deleted Nef (Whatmore et al., 1995) or PAK-binding defective Nef mutant viruses
(Sawai et al., 1996) as infectious agents. In both cases, the introduced mutant nef
genes were soon reverted: The 12-bp Nef deletion was repaired in vivo by sequence
duplication and its evolution was continued until the repair was almost
indistinguishable from wild type sequence. Similarly, in macaques that were
infected with Nef-mutated SIV, the isolation of recovered viruses from these
animals revealed that mutant viruses rapidly reverted to functional Nef sequence. In
contrast to these findings however, another study reported that a minority of adult
and most infant macaques progressed to simian AIDS even after infection with nef-
defective SIV strains (Baba et al., 1999). Thus, Nef is not an absolute requirement
but rather a strong accelerator for progression of simian immunodeficiency. An
important functional site in Nef has been mapped to its proline-rich SH3-binding
domain PxxP (where P is a proline and x any amino acid residue). Inoculation of
macaques with proline-mutated SIVmac239-P104/107A viral clone reverted back to
PxxP genotype within 8 weeks after viral infection (Khan et  al., 1998), revealing
selective pressure for functional SH3-binding during HIV pathogenesis.
In cohort studies of HIV-infected patients, approximately five percent of participants
are long-term non-progressors (LTNP) or slow progressors (SP), i.e. individuals
who have been infected for over ten years and remain asymptomatic without
receiving any anti-HIV treatments. Characteristically, LTNPs usually show stable
CD4+ T cells counts and low viral loads (Rodes et al., 2004). Several LTNP- and SP
individuals with HIV-1 infection carry a functionally defective nef gene (Alexander
et al., 2000; Deacon et al., 1995; Kirchhoff et al., 1995; Mariani et al., 1996; Salvi
et al., 1998). A well-studied patient group is Sydney Blood Bank cohort, consisting
of eight blood transfusion recipients infected with nef-attenuated HIV-1 acquired
from a single donor. Despite the single source of infection, the outcome of infection
has been unique in each individual (Birch et al., 2001; Churchill et al., 2006; Verity
et al., 2007). Furthermore, despite deletions in Nef sequence, declining CD4 counts
have been observed from an LTNP patient, suggesting that Nef alone is not
responsible for lowering CD4 cell counts (Greenough et al., 1999). With respact to
drug development, these results rule out the possibility of using an attenuated virus
vaccine approach that would be based solely on deleting Nef from the virus.
The  high  mutational  rate  of  HIV makes  the  Nef  sequence  also  highly  variable.  A
comparative study on the frequency of disrupted nef genes and specific amino acid
substitutions in Nef protein of patients with long-term non-progressing disease and
individuals with progressing infection revealed that some amino acid changes
correlated with low CD4(+) T cell counts and the high viral load (Kirchhoff et al.,
1999). Variations of T15, N51, H102, L170, and E182 were frequently observed
among non-progressors, whereas an additional N-terminal PxxP-motif, A15, R39,
T51, T157, C163, N169, Q170 and M182 were the residues most frequently mutated
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in progressors. These findings suggested that specific changes in Nef protein can be
correlated with the immune status of an individual patient. Moreover, the rarity of
defective nef genes in HIV patients supports the idea that functional Nef is required
for HIV pathogenesis.
In mouse studies, the transgenic expression of Nef was targeted into T cells through
CD3d, CD2 or the T cell receptor (TcR) b chain regulatory regions (Brady et al.,
1993; Lindemann et al., 1994; Skowronski et al., 1993). All of these expression
models resulted in perturbed CD4(+) T cell development in the thymus and
subsequent depletion of peripheral CD4(+) T cells in Nef-expressing animals. Later,
the work from Hanna et al. defined Nef as a determinant for AIDS-like symptoms in
a murine model by reporting that expression of transgenic Nef in CD4(+) cells led to
the development of a severe human AIDS-like disease in CD4C/HIV transgenic
mice (Hanna et al., 1998). The same group also analyzed the importance of one
particular Nef-binding protein, the Src-kinase Hck, for AIDS-like symptoms in their
mouse model. To this end, they used a Nef allele with a mutated Hck SH3-binding
domain (PxxP). The engineered Nef-AxxA protein abolished the pathogenicity of
Nef, indicating that an intact Hck-binding site, the PxxP domain, is essential for
inducing of AIDS-like symptoms. However, when the importance of this interaction
was tested by crossbreeding Nef-expressing HIV-1 Tg mice with the hck-/hck-
background, the pathological phenotype was only slightly delayed in the absence of
Hck, in contrast to the results obtained with the Nef-AxxA transgene, thus
implicating Hck as an important but not an essential effector of Nef in the HIV
pathogenesis (Hanna et al., 2001). A later introduction of both laboratory-adapted
and patient-derived Nef alleles into transgenic mice resulted in markedly different
pathogenicities, suggesting that the pathogenic capacity of a particular allele does
not directly correlate with its virulence (Priceputu et al., 2007). In summary, in vivo
data obtained from mice, primates and humans alike indicate Nef as a central, but
not the sole determinant for disease progression.
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3.  Cellular functions of Nef
3.1. Viral replication and enhanced viral infectivity
After the first dispute of the role of Nef in HIV replication, in vitro studies found
that the allelic variants of Nef could exhibit different characteristics during viral
replication (Terwilliger et al., 1991). In addition, the origin of the Nef protein was
considered to cause differential functions: transfer of a laboratory-adapted isolate
HIVBRU Nef into CD4 (+) cells by retroviral transduction did not alter cell surface
marker expression, proliferation or cytokine expression (Schwartz et al., 1992). In
contrast, nef genes isolated from freshly collected peripheral blood mononuclear
cells of infected patients could accelerate virus production in primary human
lymphocytes but not in T cell lines (de Ronde et al., 1992).
Nef is not an essential factor for virus replication in vitro, but it markedly enhances
virus spreading in primary cells (Miller et al., 1994; Spina et al.,  1994).   Nef  also
enhances the intrinsic activity of progeny virions independently of CD4 down-
regulation, but requires the presence of Nef in virus-producing cells (Aiken and
Trono, 1995; Chowers et al., 1994; Chowers et al., 1995; Miller et al., 1994;
Pandori et  al., 1996). Virions are endocytosed via clathrin-coated pits, and both
clathrin and an essential guanosine triphosphatase (GTPase) of clathrin-mediated
endocytosis, dynamin, are essential for Nef-dependent enhancement of infectivity
(Pizzato et  al., 2007). Furthermore, the route of virus entry may affect infectivity
enhancement as Nef is unnecessary for infectivity of HIV virions with envelopes
that mediate entry through endocytic compartments (Aiken, 1997; Chazal et al.,
2001).
Small amounts of Nef are taken up into assembling virions (Pandori et  al., 1996;
Welker et  al., 1998), but Nef uptake into the virions is not required for increased
infectivity (Fackler et al., 2006). The ole of Nef in enhancement of HIV infectivity
has been addressed to reduced susceptibility of virions to proteasomal degradation in
target cells (Qi and Aiken, 2007), enhancement of cytoplasmic delivery of virions
by increased entry of HIV-1 (Schaeffer et al., 2001), increased viral budding from
the lipid rafts with concomitant Nef-mediated alterations in raft lipid composition
(Zheng et  al., 2001; Zheng et  al., 2003), recruitment of a signalosome promoting
transcriptional derepression (Witte et al., 2008; Wolf et al., 2008b), or facilitated
transport of the viral genome through the cortical actin network (Campbell et al.,
2004). However, conflicting results have been obtained using T cells that are acutely
infected with Nef viruses, where Nef had no effect on segregation of the viral
structural proteins. Thus, this questions whether Nef localizes viral proteins to rafts
for virus particle assembly (Sol-Foulon et al., 2004).
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Antigen-presenting cells (APCs) can significantly increase the viral replication in T
cells by providing activation signals to T cells. In coculture models of T cells and
endothelial or dendritic cells, Nef boosted viral replication efficiency (Choi et al.,
2005a; Messmer et al., 2000; Petit et al., 2001). Interestingly, the increase of HIV-1
replication by Nef and Vpr-dependent mechanism can also take place in non-
proliferating CD4(+) T cells that are minimally activated through their T cell
receptor.  This  may  imply  a  mechanism  in  which  a  reservoir  of  the  virus  is
maintained and contributes to viral rebound in patients with changes in drug
regimen (Choi et al., 2005b).
Figure 2. Overview of the most essential Nef functions in infected T cells (modified from a
review Kirchhoff et al., 2008).
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3.2. Downregulation of cell surface molecules
3.2.1. CD4
Cell surface marker CD4 is an HIV receptor required for infection. However, CD4
must be removed from the cell surface after the host cell is infected because CD4
interferes with viral replication, proper budding of progeny virions, and correct
trafficking of the viral envelope (Lama et al., 1999; Lundquist et al., 2002; Ross et
al., 1999). The importance of CD4 downregulation for HIV-1 is reflected by the use
of three different viral proteins, Vpu, Env and Nef, that downmodulate CD4
(reviewed in Lama, 2003). The observation that HIV-1 Nef expression could
downregulate cellular surface marker CD4 was one of the earliest functions
associated with Nef, and this function is a shared property of Nef isolates (Anderson
et al., 1993; Garcia and Miller, 1991; Garcia et al., 1993; Guy et al., 1987; Iafrate et
al., 1997; Mariani and Skowronski, 1993). The mechanism of Nef-induced CD4
downmodulation involves internalization of surface CD4 and subsequent targeting
to the endosomal pathway for degradation. In line with this, Nef has been reported
to localize to clathrin-coated pits and increase the number of CD4-containing pits
(Foti et al., 1997; Greenberg et  al., 1998a). The N-terminal attachment of a
myristoyl, required for proper membrane targeting of Nef (Yu and Felsted, 1992), is
also necessary for CD4 downregulation (Peng and Robert-Guroff, 2001).
Current data on CD4 downregulation suggests that association of Nef with the
cytoplasmic tail of CD4 (Anderson et al., 1993; Garcia and Miller, 1991; Grzesiek
et al., 1996; Hua and Cullen, 1997) connects the surface molecule with the
endocytic machinery of the cell (Mangasarian et al., 1997). Nef association with the
heterotetrameric clathrin-associated adaptor protein (AP) complexes enhances CD4
endocytosis (Bresnahan et al., 1998; Piguet et al., 1998) by recruiting CD4 to
adaptor proteins and subsequently targeting it to lysosomes. AP-1, AP-2 and AP-3
all bind to the canonical motif 161EXXXLL165 in the structurally flexible loop
formed by residues 148-180 in Nef (Aiken et al., 1994; Craig et al., 1998; Erdtmann
et al., 2000; Janvier et  al., 2003). Recently, the association of Nef with AP-2 has
been reported to require yet another Nef motif of two acetic residues 174(E/D)/D175
(Lindwasser et al., 2008). In addition, bi-ubiquitinylation of Nef on K144 is required
for CD4 downregulation (Jin et  al., 2008), which may function as an additional
sorting signal in Nef-mediated receptor endocytosis or trafficking.
The capacity of Nef to downregulate CD4 has been correlated with its association
with  human  thioesterase  II  (hTE)  (Liu et  al., 1997). Like so many other Nef
interactions, the Nef-hTE interaction has been mapped to residues D108, L112,
F121, P122 and D123 within the 'hydrophobic patch’ in the Nef core domain, and
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mutations to these amino acids also abolished the capacity of Nef to downregulate
CD4 (Cohen et al., 2000; Liu et al., 2000). A more detailed understanding of the
Nef-hTE complex and its connection to Nef-mediated downregulation of CD4 is
lacking. However, the Nef-hTE complex has been shown to localize to peroxisomes,
where thioesterase has been suggested to participate in fatty acid oxidation and lipid
metabolism.
Data obtained from an LTNP patient infected by an HIV-1 with a uniquely defective
nef gene, containing a small deletion of 36-bp and a compensating 33-bp
duplication, suggested that inhibition of CD4 downregulation could delay HIV
pathogenesis (Carl et al., 2000). In vitro studies demonstrated that the deletion itself
led to inactivation of CD4 and MHC I downregulation, inhibition of infectivity, and
to partial destabilization of the protein. This implies that Nef-induced CD4
downregulation could be a target for therapeutical intervention.
3.2.2. MHC class I and II
Another surface molecule downmodulated by Nef is MHC I (Akari et al., 2000; Le
Gall et al.,  1997;  Le  Gall et  al., 2000; Schwartz et al., 1996). After infection, the
early expression of Nef and subsequent sequestration of MHC I from the surface of
an infected cell can provide cell with a means to evade destruction by the immune
system once active viral replication initiates. In favor of this, Nef expression reduces
the susceptibility of HIV-infected cells to cytotoxic T cell and NK cell-mediated
killing in vitro (Cohen et al., 1999; Collins et al., 1998; Lewis et al., 2008; Yang et
al., 2002). Rather early on, it was noted that Nef-induced CD4 and MHC-I
downregulation constituted genetically and mechanistically separate entities. Nef
was shown to induce targeting of MHC I to the trans-Golgi network (TGN) and to
the peripheral vesicles positive for endosomal markers (Le Gall et al., 1998;
Schwartz et al., 1996). Mutations in the Nef myristoylation site at G2 residue and
the N-terminal alpha-helical region, as well as in the polyproline and acidic motifs
(EEEE65)  have  been  found  to  selectively  affect  MHC  I  downmodulation
(Greenberg et al., 1998b; Mangasarian et al., 1999; Peng and Robert-Guroff, 2001).
Studies that analyzed MHC I downregulation have presented two different pathways
utilized by Nef to reduce MHC I expression on the cell surface: (i) the endocytosis
of MHC I from the plasma membrane to the TGN in PACS-1 (phosphofurin acidic
cluster sorting protein-1), AP-1 and clathrin-dependent manner, and (ii) binding of
AP-1 to the cytoplasmic tail of MHC I to re-route it from the TGN to lysosomes.
Interaction of Nef with PACS-1 was initially shown by Piguet et al. as a requirement
for MHC I downmodulation by Nef (Piguet et al.,  2000).  Later,  the  Nef/PACS-1
interaction was reported to lead to hijacking of the ARF6 (ADP-ribosylation factor
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6) endocytic pathway in the phosphoinositide-3-kinase-dependent process, which
ultimately led to the retention of MHC I in the TGN (Blagoveshchenskaya et al.,
2002). This cascade was dependent on two Nef motifs; the acidic region EEEE65
required for binding to the cytosolic sorting protein PACS-1 and the proline domain
PxxP75 important for Nef association with Src-family tyrosine kinase (SFK) (Lee et
al., 1995; Piguet et al., 2000).  Recent studies have elucidated this cascade in further
detail, and the EEEE65 motif has been shown to enable Nef binding to the sorting
protein PACS-2 which targets Nef to the perinuclear region (Hung et al., 2007).
There, PACS-2 is disengaged and Nef binds via its PxxP domain to a trans-Golgi
localized SFK. The Nef-SFK interaction is followed by binding and subsequent
tyrosine phosphorylation of the tyrosine kinase ZAP-70 (Zeta chain associated
protein 70 kDa). Activation of ZAP-70 initiates signaling that eventually leads to
increased activation of GTPase ARF6, thus increasing the endocytosis rate of MHC
I. This updated model does not explain, however, the direct interaction found
between Nef, AP-1 and cytoplasmic tail of MHC I recently reported by other groups
(Noviello et al., 2008; Wonderlich et al., 2008). According to their data, the Nef-
MHC I complex recruits the clathrin adaptor protein complex AP-1, which targets
MHC I from the TGN to the endo-lysosomal network, where it is degraded.
Recruitment of AP-1 is dependent on Met20 residue in the N-terminal helical
domain of HIV-1 Nef, and a tyrosine residue in the cytoplasmic tail of MHC I (Le
Gall et al., 1998; Roeth et al., 2004). Because MHC I cytoplasmic tail does not bind
directly to AP-1, Nef has been suggested to serve as a facilitator in this complex. In
support of the latter model, Baugh et al. have reported that association of Nef with
PACS was not mediated by the EEEE65 stretch; instead, the Nef domain plays a
stabilizing role in the complex formed by Nef, AP-1, and the cytoplasmic domain of
MHC I (Baugh et  al., 2008). To date, the final consolidation of these two models
remains unclear. However, a recent study from Schaefer et al. (Schaefer et al., 2008)
has proposed that despite differences in intracellular trafficking, both MHC I and
CD4 eventually end up in similar Rab7(+) lysosomal vesicles due to the interplay of
Nef and Nef-interacting protein, b-COP (Benichou et al., 1994).
Later, Nef was shown to downregulate MHC class II (MHC II) surface expression
and thus affect the antigen presentation by MHC II (Stumptner-Cuvelette et  al.,
2001). MHC II is expressed on APCs, such as dendritic cells, macrophages, and
activated CD4(+) T cells. The activation of T helper (Th) cells by APCs is necessary
for the proper humoral and cellular anti-HIV immune response (Brander and
Walker, 1999; Gandhi and Walker, 2002). Furthermore, Nef has been reported to
upregulate the MHC II-associated invariant chain, Ii (Schindler et al., 2003). The
stable expression of Ii prevents antigen presentation and may therefore contribute to
the impaired Th responses observed in AIDS patients (Betts et al., 2001; Roche et
al., 1992; Stumptner-Cuvelette and Benaroch, 2002). Ii upregulation may also
provide an advantage for viral replication in SIV-infected macaques (Schindler et
al., 2004). The physiological relevance of Ii upregulation is supported by the finding
24
that some Nef alleles found from LTNP patients are deficient in upregulation of Ii
(Schindler et al., 2003). However, despite the conserved domain structure of Nef
among different clades of HIV, clade C and F Nef alleles have recently been
reported impaired for Ii upregulation (Turk et al., 2009).
3.2.3. CD80 and CD86
Surface molecules CD80 and CD86 provide the costimulatory signals necessary for
proper T cell activation upon APC contact. Nef downregulates CD80 and CD86 via
dynamin- and clathrin-independent pathway (Chaudhry et al., 2005). However, the
Rab11-dependent endocytic machinery targeting CD80 and CD86 to Golgi does not
fully resemble any other described receptor internalization mechanism affected by
Nef (Chaudhry et al., 2007; Chaudhry et al., 2008). Functionally, sequestration of
costimulatory molecules from the cell surface may postpone the activation of naïve
T cells  and the onset  of  T cell  response in  the early stages of  HIV infection,  thus
providing the virus with prolonged time for propagation.
3.2.4. CD3 and CD28
In addition to CD4 and MHC I, some Nef alleles can downregulate CD28 and even
CD3, the T cell receptor molecule. Efficient downregulation of these molecules is
characteristic of HIV-2 and SIV Nef alleles (Bell et al., 1998; Bell et al., 2001;
Swigut et al., 2001; Swigut et al., 2003; Wildum et al., 2006). CD28 is a major
costimulatory factor of T cell activation and crucial for normal antigen-specific T
cell responses. In infected cells, its sequestration from the cell surface may suppress
the immune response and cause anergy. Both HIV and SIVmac Nef proteins have
been shown to interact with CD28, and the downregulatory mechanism occurs
through accelerated endocytosis via the AP-2 clathrin adaptor pathway (Swigut et
al., 2001). The importance of CD28 downregulatory function in vivo has been
demonstrated  by  a  selective  mutation  H196Q  in  SIV  Nef  that  disrupts
downregulation of CD28 (Bell et al., 2001). This mutation slowly reverts in infected
rhesus macaques, supporting the selective advantage gained by CD28 modulation
(Schindler et al., 2004; Whatmore et al., 1995).
In contrast to the severe pathologic manifestations of HIV-1 infection, many simian
lentiviruses do not induce the pathological effects in their natural hosts. The
downregulatory effect of CD3 by SIV, but not by HIV, has been suggested by
Schindler et al. to  be  an  adaptive  property  of  SIV  to  limit  the  viral  pathogenicity
(Schindler et al., 2006). According to their hypothesis, primate infection with the
virus encoding Nef, which downregulates CD3, prevents activation of infected T
cells. Subsequently, activation-induced T cell death is prevented. In contrast, HIV-1
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does not downregulate CD3 in infected humans enabling the hyperactivation of T
cells, collapse of the immune system and progression to AIDS.
However, exceptions to the rule of CD3 downregulation by SIV (but not by HIV-1)
exist. Despite its name, HIV-2 is related to SIV, possessing reduced pathogenicity as
compared to HIV-1. However, progress to AIDS can occur (Brun-Vezinet et al.,
1987). HIV-2 downregulates CD3 which is in concert with the less pathogenic
properties of both SIV and HIV-2 (Munch et al., 2005). In contrast with this model
are the results obtained from patients who were infected with different strains of
HIV-2 that progressed to AIDS and who all had their CD3 downregulated by Nef
(Munch et al., 2005). Similarly, rhesus macaques infected with HIV-2 have
manifested a pathogenic phenotype, although not consistently (Dormont et al., 1989;
Stahl-Hennig et al., 1990).
3.2.5. Chemokine receptors
Chemokine receptors mediate cell responses to chemokines, a family of proteins that
regulate leukocyte migration and activation (reviewed in Moser and Loetscher,
2001; Stein and Nombela-Arrieta, 2005). Active secretion of chemokines controls
homing and recruitment of leukocytes into tissues, and the ordered movement of
leukocytes constitutes an essential function for the development and maturation of
the immune response.
Chemokine receptors CCR5 and CXCR4 function as coreceptors for entry of HIV
and SIV. In vivo-transmitted HIV-1 strains generally prefer CCR5 (R5 viruses), but
strains  that  use  CXCR4  (X4  viruses)  as  their  entry  coreceptor  emerge  in
approximately 50 % of late stage AIDS patients (review in Philpott, 2003). X4
viruses are associated with a rapid decline in CD4(+) cell counts and progression of
the disease. Strong genetic evidence on the importance of this functional coreceptor
in HIV-1 is provided by the naturally occuring 32 bp-deletion mutant of CCR5
(CCR5D32), which generates a non-functional receptor that does not support viral
entry of either R5 or dual tropic viruses (Samson et al., 1996). Taking advantage of
the requirement of coreceptor in HIV-1 infection, CCR5 receptor ligands are
currently considered as endogenous anti-virals and potential inhibitors of viral entry
(Lusso, 2006).
HIV-1 Nef has been implicated in the downregulation of several chemokine
receptors, including the viral coreceptors CCR5 and CXCR4 (Hrecka et al., 2005;
Michel et al., 2005; Michel et al., 2006). This downregulatory function is a shared
property among HIV-1 and – 2 Nefs, as well as SIV alleles (Michel et al., 2005), yet
many HIV-2 and SIV alleles are more efficient in downregulation of CXCR4 than
HIV-1 Nefs (Hrecka et al., 2005; Wildum et al., 2006). In concert, some SIV Nef
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alleles also strongly inhibit lymphocyte chemotaxis towards the CXCR4 ligand
chemokine SDF-1a. Although weaker than SIV Nefs, HIV-1 alleles also possess the
ability to inhibit chemotaxis to SDF-1a (Choe et al., 2002), reportedly by activating
Rac1/2 signaling via the bipartite GEF DOCK2/ELMO1 (Hrecka et al., 2005;
Janardhan et al., 2004). Disruption of the functional PxxP domain or Nef residue
R106 which is associated with PAK2 interaction, reduced the ability to inhibit
migration (Lee et al., 2008). Because no PAK protein was detected during the initial
mass spectrometric analysis of Nef-associated proteins by Janardhan and colleagues
(Janardhan et al., 2004), the role of PAK in Nef-affected chemokine signaling
remains obscure. Despite an efficient downregulatory effect on ectopically
expressed chemokine receptors on cultured cells, relatively modest effects on
chemokine receptor expression in HIV-1 infected human cell lines and in PBMC
have been observed (Michel et al., 2005; Michel et al., 2006; Wildum et al., 2006).
3.3.   Modulation of cellular signaling by Nef
3.3.1. Nef and Src-family tyrosine kinases
The first interactions mediated by the proline-rich PxxP-motif in Nef that were
characterized were the interactions with SFKs Hck and Lyn (Saksela et al., 1995).
Year later, the role of the PxxP domain in the Nef-Hck interaction was confirmed by
studies utilizing Nef/SH3 cocrystals and NMR of Nef (Grzesiek et al., 1996; Lee et
al., 1996). Besides Hck, Nef interactions with SFKs Lck, Fyn and Src have also
been reported (Arold et al., 1997; Arold et al., 1998; Cheng et al., 1999; Collette et
al., 1996; Dutartre et al., 1998; Greenway et al., 1996; Greenway et al., 1999; Lang
et al., 1997; Lee et al., 1995). However, interactions with Fyn or Lck are clearly
weaker than the association of Nef with Hck or Lyn (Saksela et  al., 1995). The
interactions of Nef alleles with SFK SH3-domains are reported to be dependent on
the viral origin of Nef; the HIV-2 and SIV Nef proteins primarily target Fyn and
Src, while the primary association of HIV-1 Nef is with Hck and Lyn. The altered
avidity of HIV-1 versus SIV/HIV-2 Nef towards Src kinases is governed by change
of three amino acids within the SH3-binding hydrophobic ‘pocket' of Nef (Collette
et al., 2000). Later, the contribution of other residues within the hydrophobic patch
of  HIV-1  Nef  was  also  reported  to  be  important  for  its  association  with  and
activation of Hck (Choi and Smithgall, 2004).
Among SFKs, The primary target of HIV-1 Nef, Hck, is expressed in macrophages
and neutrophils. Hck is implicated in several actin-dependent phagocytic functions
involving plasma membrane and lysosome mobilization, such as phagocytosis and
migration (Lowell and Berton, 1999). Hck is expressed in two isoforms, p59 and
p61, the latter having an additional 21-amino acid peptide at its N-terminus. These
isoforms are targeted differentially within cells; p59 is N-terminally myristoylated
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and palmitoylated, whereas p61 is only myristoylated. This results in the mainly
lysosomal localization of p61. On the contrary, palmitoylation of the p59 isoform
results in its localization to the plasma membrane-enriched fractions, more
specifically to caveolae or rafts (Carreno et al., 2000; Robbins et al., 1995).
Stimulation of phagocytosis and subsequent Hck activation can be induced by use of
appropriate chemicals or particles, such as microorganisms. Hck is involved in the
signal transduction downstream of the Fcg receptor which mediates phagocytosis of
IgG-coated particles (Durden et al., 1995; Ghazizadeh et al., 1994; Ibarrola et al.,
1997; Wang et  al., 1994). This internalization can be abolished by using the
dominant negative form of p59Hck but not with the dominant negative p61 isoform,
suggesting that both isoforms have different functions. Similarly, ectopic expression
of constitutively active p59 and p61Hck triggers distinct phenotypes and functions:
active p59Hck induces the formation of membrane protrusions, whereas active
p61Hck triggers the formation of large F-actin-rich structures, the podosome rosettes
(Carreno et al., 2002; Cougoule et al., 2005). Hck may also downregulate
granulocyte colony-stimulating factor (G-CSF) induced proliferation of granulocytic
precursor cells by binding to G-CSF receptor phosphotyrosines via its SH2 domain,
leading to receptor phosphorylation and inhibition of signaling. In HIV, treatment of
differentiated macrophages with Hck antisense oligonucleotides has been shown to
inhibit viral replication (Komuro et al., 2003). Hck activated by Nef accumulates to
the Golgi apparatus (Hiyoshi et al., 2008), suggesting that, in addition to stimulation
of Hck activity, Nef can also modulate Hck signaling by altering where the protein
is targeted.
3.3.2. Nef and T cell receptor signaling
T cell activation is a hierarchical process, where different events of the cascade are
performed sequentially with increasing stimulation via T cell receptor (TcR). In HIV
infection, the activation status of a target cell is the major factor in dictating whether
the virus can readily spread in an infected host. The main target cells of HIV,
macrophages and quiescent T lymphocytes, are efficiently infected by the virus, but
active replication after viral entry is blocked (Stevenson et  al., 1990; Stevenson,
2003; Zack et al., 1990). Partial activation can, however, allow viral propagation,
whereas host cell death by hyperactivation or immunological recognition by
cytotoxic T cells limits virus spread. Accumulating data suggests that, with respect
to T cell activation, Nef balances cell activation and prevention of apoptosis by
hyperactivation.
Physiologically, stimulation of T cells by antigens via TcR leads to the clustering of
TcRs, coreceptors, adhesion and signaling molecules, as well as cytoskeleton
components. Together, these molecules form supramolecular activation clusters
(SMACs) at T cell and APC contact site, termed the immunological synapse (IS).
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The IS is a dynamic structure for ensuring efficient antigen recognition, controlled T
cell activation and provision of stimulus to the APC. The SFK Lck is among the first
molecules to be activated upon TcR stimulus and leads to the  orchestrated
recruitment of other signaling and adaptor components (reviewed in Dustin, 2009).
The ability of HIV Nef to modulate TcR signaling has been extensively studied. In
infected cells, the formation of IS is impaired by a Nef-dependent mechanisms
affecting actin polymerization and altered localization of Lck and N-Wasp (Haller et
al., 2006; Haller et  al., 2007). In  addition,  Nef  increases  activity  of  ERK  MAP
kinase pathway, as well as transcription factors NFAT (nuclear factor of activated T
cells) and NF-kB (nuclear factor kB) (Fortin et al., 2004; Manninen et al., 2001;
Schrager et  al., 2002; Wang et al., 2000). In addition to PxxP motif in Nef,
myrisotylation is required for increased aCD3/aCD28-induced IL-2 secretion via
both NFAT and NF-kB transcription factors (Wang et al., 2000).
Nef  associated  with  several  molecules  involved  in  TcR  signaling.  In  cells,  the
interaction of Nef with Vav is associated with actin rearrangement and subsequent
impairement of IS (Fackler et  al., 1999; Quaranta et al., 2003), whereas the
association of Nef with inositol triphosphate receptor (IP3R) has been implicated as
a TcR-independent mechanism that promotes T cell activation (Manninen and
Saksela, 2002). Other Nef binding partners involved in T cell activation and
proliferation include Raf-1 kinase (Hodge et al., 1998) and PKC (protein kinase C)
family kinases (Manninen et al., 2001; Smith et al., 1996; Wolf et al., 2008a).
While several Nef-binding proteins in the TcR pathway are characterized, the effect
of these interactions on T cell activation remains controversial. Generally, Nef is
considered an enhancer of T cell signaling that sensitizes T cells for activation and
leads to their increased permissiveness for HIV infection (Keppler et  al., 2006;
Schrager and Marsh, 1999; Wang et al., 2000). Findings from Fenard et al. show
that Nef can increase the number of activated cells, but it does not affect the level of
activation achieved by each individual cell (Fenard et al., 2005). In addition, the
transcriptional status of a cell can be similarly altered by Nef expression as through
a aCD3 stimulation (Simmons et  al., 2001). On the other hand, Nef negatively
affects T cell activation by remodeling actin cytoskeleton, disrupting the formation
of the immunological synapse and affecting the membrane trafficking of signaling
molecules (Fackler et al., 2007; Fenard et al., 2005; Haller et al., 2006; Haller et al.,
2007; Schindler et al., 2006; Thoulouze et al., 2006). These differences may be
linked with the localization of Nef; the cytoplasmic form mainly inhibits TcR
signaling, whereas membrane-targeted Nef is stimulatory (Baur et al., 1994).
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3.3.3. Association of Nef with PAK2
The initial studies on the association of Nef determined that it binds to a
serine/threonine kinase that is activated by GTPases Cdc42/Rac1; this protein was
characterized some years later as PAK family kinase (for more detailed description
of PAKs, see chapter 4) (Lu et al., 1996; Nunn and Marsh, 1996; Sawai et al., 1994;
Sawai et al., 1995). However, the precise identity of the kinase remained elusive
because  two  family  proteins,  PAK1  and  PAK2,  were  suggested  as  HIV-1  Nef-
associating kinases (also referred to as NAK) (Arora et al., 2000; Fackler et al.,
2000; Renkema et al., 1999). Later studies established PAK2 as the canonical NAK.
The ability to associate with active PAK2 seems to be a shared feature of HIV and
SIV Nef alleles (Kirchhoff et al.,  2004),  but  the  capacity  of  Nefs  to  themselves
activate PAK2 is more variable (Agopian et al., 2007). Before the Nef-associating
kinase was characterized, mutational analysis on Nef determined the critical amino
acids for this interaction (Manninen et al., 1998; Sawai et al., 1995; Wiskerchen and
Cheng-Mayer, 1996). These studies identified domains rich in proline (P69/72/75;
residue numbering according to NL4-3 Nef) and arginine (R105/R106) as crucial
determinants for NAK association. The first reports also nailed down the importance
of Nef myristoylation residue (G2) for association with PAK2 (Sawai et al., 1995;
Wiskerchen and Cheng-Mayer, 1996).
Later, similar approaches of introducing series of mutations into Nef have also been
used for more extensive functional analysis (Agopian et al., 2006; Fackler et al.,
2006). In addition to confirm the previous findings on the molecular requirements of
Nef-PAK2 interaction, Agopian et al. recently proposed an important role for
hydrophobic binding surface amino acids L85, H89, S187, R188, and F191 of Nef in
PAK2 association (Agopian et al., 2006). Unlike Nef mutations on G2, P72/P75 and
R105/R106, which affect association with PAK2, substitution of the more recently
identified residues by Agopian and colleagues did not affect other Nef functions,
such as the CD4 or MHC class I downregulation. Amino acids of this putative
interaction patch also reside on a different surface on the core domain than the
residues critical for SH3-binding or oligomerization, suggesting that Nef uses
different parts of its core domain to for PAK versus SH3-binding. In addition,
parallel results have been obtained from studies using Nef from primary isolates
(Foster et al., 2001; Luo and Garcia, 1996). Mutations present in these Nefs (F193I
and S189R) totally inhibit PAK2 association. However, S189R also decreased MHC
class I downregulation, which F193I did not do, suggesting that the F193 residue
specifically contributes to Nef-PAK2 interaction.
Nef myristoylation has been estimated to target approximately 10% of total cellular
Nef to the plasma membrane compartment, specifically to lipid rafts (Alexander et
al., 2004; Wang et al., 2000). Efficient localization to membranes is associated with
Nef functionality, but additional domains contribute to its sustained membrane
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association. In a study by Alexander et al., palmitoylation of two cysteine residues
has been linked to its localization to membranes (Alexander et al., 2004). Additional
targeting motifs are also required for membrane association and raft localization,
such as a stretch of arginines in the N-terminus of Nef (Bentham et al., 2006; Giese
et al., 2006; Welker et al., 1998). Mutating the myristoylation site severely impairs
Nef association with PAK2, suggesting that membrane localization is one of the
prerequisites for formation of the NAK complex. This idea is further supported by
the diminished association of Nef and PAK2 by mutating Nef N-terminal lysines,
which are also implicated in membrane localization of Nef (Giese et al., 2006). In
contrast, the same arginines whose mutation reduces membrane localization of Nef
do not affect PAK2 association, suggesting that lost membrane targeting of Nef per
se may not explain loss of PAK2 association. Supporting this idea are reports on
conformational change of Nef based on its location within cells, which can
contribute to its differential interaction properties (Arold and Baur, 2001; Hoffmann
et al., 2007).
After the identification of NAK as PAK2, the Nef-PAK2 association was also
studied by introducing mutations to PAK2. Mutation of the binding sites of the GEF
b-PIX (b-PAK-interacting exchange factor) or the SFK (PxxP/A) did not affect Nef-
PAK2 association (Renkema et al., 2001), suggesting that neither Nck nor b-PIX
plays a direct role in Nef-PAK2 association. However, mutation of the Cdc42/Rac1-
interactive binding domain (CRIB) totally abolished Nef-PAK2 association
underlining the importance of p21-GTPases for the association of Nef and PAK2
(Renkema et al., 2001).
Functionally, the biological importance of Nef-PAK2 is not well understood. Nef-
PAK2 interaction may  have a role in T cell activation, and subsequent stimulation
of viral replication (Alexander et al.,  1997;  Lu et al., 1996; Schrager and Marsh,
1999; Wang et al., 2000; Wu and Marsh, 2001). In addition, association of Nef and
PAK2 has been demonstrated to have a role in apoptotic mechanisms (Wolf et al.,
2001; Xu et al., 1999). However, a recent study using PAK-binding deficient mutant
Nef F191R demonstrated that association of Nef and PAK2 neither affects HIV-1
replication efficiency nor has an effect on T cell activation or apoptosis (Schindler et
al., 2007).
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3.3.4. Role of the putative Nef dimer interface in vitro and in vivo
Several in vitro-studies have suggested self-assembly of Nef molecules by formation
of dimers and higher oligomers. Oligomerization of Nef molecules was first
reported by Kienzle et al., who presented NMR and immunoblotting evidence for
self-association of Nef proteins (Kienzle et al., 1993). Crystallization studies
suggested that the molecular contacts established between Nef molecules were
formed by R105, D108, I109, L112, Y115, H116, F121, P122, and D123, the well
conserved residues among HIV-1 Nef isolates (Arold et  al., 2000). This
hydrophobic core involves a “hot spot” of Y115, F121, and P122, which is
surrounded by charged amino acids R105, D108, and D123. The charge
complementarity achieved by electrostatic interactions between the positively and
negatively charged residues R105 and D123, respectively, may be a coherence
factor that promotes Nef dimerization (Arold et al., 2000).
Introducing mutations to this PDI have been shown to abolish many cellular
functions of Nef. Liu et al. reported abolished increase in virion infectivity and
MHC I down-regulation by Nef mutant D123G. In addition, mutating Nef residues
D108, L112, F121, and P122 caused defective in binding to human thioesterase II
and down-regulation of CD4 (Liu et al., 2000). Similarly, mutations of R106A,
L112R and F121R all abolished binding of Nef to PAK2 (Fackler et  al., 2006;
Manninen et al., 1998). Evidence of Nef dimerization has also been obtained from
study using fluorescence complementation, where two Nef molecules fused to a
regulatable dimerization domain were differently tagged with N- and C-terminal
sequences of green fluorescence protein (GFP). The proximity of two non-
fluorescent GFP termini brought together by dimerization of Nef molecules restored
the fluorescence signal. Furthermore, this dimerization also potentiated the
transformation of fibroblasts via Hck activation (Ye et al.,  2004).  However,  this
study did not address the importance of the Nef PDI for the observed in vivo effects,
neither did it rule out the possibility that the interaction of the GFP termini markedly
contributed to the observed association of Nef molecules. A very recent study from
the same group reported that the intact PDI is required for Nef-mediated CD4
downrgulation and HIV replication (Poe and Smithgall, 2009), but it did not clarify
in more detail the role of charge complementarity in Nef-PDI for these functions.
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3.4. Nef and apoptosis
The coexistence of pathogens and their hosts leads unavoidably to an arms race
where both evolve mechanisms to attack and defend. Induction of controlled cell
death, apoptosis, is an ancestral host-survival mechanism upon microbial attack.
During coevolution, many pathogens have developed mechanisms to promote
apoptosis of host immune cells as well as to suppress apoptosis in infected cells
which is required for the persistence and replication of pathogen itself. HIV
infection inhibitd apoptosis triggered by DNA-damaging mechanisms (Schindler et
al.,  2005).  However,  HIV  infection  also  causes  apoptosis  of  both  infected  and
uninfected T lymphocytes by various mechanisms, some of which are mediated by
HIV-encoded proteins, e.g., Nef, Env, and Tat (reviewed in Badley et al., 2000).
One major apoptotic cascade initiated by activation of cell-surface receptors is the
Fas/CD95/APO-1 pathway. Nef expression in infected cells has been reported to
induce both Fas receptor and Fas ligand (CD95L) expression (Xu et al., 1999; Zauli
et al., 1999). Increased FasL may protect infected cells from apoptosis by virus-
specific cytotoxic T cells, which express Fas (Mitra et al., 1996; Xu et al., 1997).
To repress host cell apoptosis, Nef has also evolved the ability to interact with
cellular kinases involved in cell death. Apoptosis signal regulating kinase ASK-1 is
downstream kinase of both tumor necrosis factor-a (TNF-a) and Fas-mediated pro-
apoptotic pathways. Interaction of HIV-1 Nef with ASK-1 inhibits both of these
pathways and, in addition, suppresses the activation of the downstream c-Jun amino-
terminal kinase (Geleziunas et al., 2001). A report by Wolf et al. showed that  Nef
mediates phosphoinositide-3-kinase (PI3K) and PAK activation, which leads to
phosphorylation and subsequent inactivation of a proapoptotic Bcl-2 family protein
Bad and consequently increases anti-apoptotic Bcl-2 and enhances cell survival
(Wolf et  al., 2001). These seemingly opposing mechanisms by Nef have been
described as the “armor and sword” of cell (Ameisen, 2001) because they provide
protection not only from endogenous and exogenous death signals, but also help to
attack the immune cells.
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4. p21-activated kinases
Protein kinases are an essential group of proteins in relaying signals from outside the
cell to control complex intracellular processes that lead to changes in cell
metabolism, migration, or proliferation. An essential theme in signal transduction
within a cell is the controlled formation and release of protein complexes. Signals
received from the cellular environment induce changes in protein-protein
associations that relocalize proteins within the cell and modulate their activities.
Kinases possess a key role in signal transduction by acutely and reversibly
phosphorylating their downstream target proteins and, thus, relaying the signal. To
date, more than five hundred putative human protein kinase genes have been
identified (Johnson and Hunter, 2005; Manning et al., 2002), and in vivo studies
suggest that up to one-third of all cellular proteins are covalently modified by
phosphorylation (Sefton, 2001). Furthermore, mounting evidence points to the key
role of kinases in numerous diseases, from cancers to immunological aberrations,
making them an attractive focus of drug design (Grant, 2008; Zhang et al., 2009).
The PAK family is a highly conserved group of serine/threonine kinases. Nearly all
eukaryotic organisms encode one or more PAK genes,  indicating  their  common
origin and importance in the cell. The first characterized PAK family member was
found in screens for binding partners of Rac1 and Cdc42 GTPases in the rat brain
(Manser et al., 1994) and was an ortholog of the budding yeast Saccharomyces
cerevisiae kinase Ste20 (Leberer et al., 1992; Ramer and Davis, 1993).
In  higher  eukaryotes,  the  PAK  family  consists  of  six  members,  PAK1-6,  each
encoded by a distinct gene. PAKs are divided into two subfamilies: group A (PAK1-
3) and group B (PAK4-6) (reviewed in Arias-Romero and Chernoff, 2008). The
overall structure of all PAKs is similar, consisting of an N-terminal regulatory
domain and a C-terminal kinase domain. However, PAKs differ in their primary
structure, with most homology in the C-terminal structures, and the least
homologous regions in the N-termini. Group A PAKs typically have N-terminal
proline-rich (PxxP) motifs that mediate association with several SH3-domain
containing proteins, a p21-binding domain (PBD; aa 67-113 in PAK1), and a C-
terminal kinase domain. Group A kinases bind both Cdc42 and Rac1 and are highly
activated upon binding these GTPases. The minimal binding site for p21-GTPases is
referred  to  as  the  CRIB  domain  because  it  is  shorter  (aa  75-90  in  PAK1)  in
comparison to the whole PBD. Group B PAKs contain a CRIB domain on their very
N-terminus, and the C-terminal kinase domain. These kinases bind Cdc42 and, to a
lesser extent, also Rac1 but are not markedly activated upon binding. The interaction
of group B PAKs with Cdc42 induces PAK localization to different cellular
compartments, suggesting regulatory differences in group A and B PAKs (Abo et
al., 1998; Cotteret et al., 2003; Cotteret and Chernoff, 2006). In addition, a newly
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characterized Cdc42-homologous GTPase Wrch-1 activates PAK1. However, it has
a distinct activation mechanism in comparison to conventional Rho GTPases Rac1
and Cdc42 (Shutes et al., 2004), possessing intrinsic GEF activity and
intramolecular auto-inhibitory function that is regulated by the adaptor protein Grb2.
Moreover, the distinct subcellular localization of Wrch-1 suggests that its role in
signal modulation is different from that of Cdc42 (Berzat et al., 2005).
PAK family members differ in their site of expression. PAK1 is highly expressed in
brain, muscle, and spleen, although other tissues, such as the mammary gland and
liver, show basal expression (Jaffer and Chernoff, 2002; Manser et al., 1994). PAK2
is ubiquitously expressed in all tissues, whereas PAK3 and PAK5 expression is
mostly brain-specific (Dan et al., 2002; Knaus and Bokoch, 1998; Manser et al.,
1995; Pandey et al., 2002; Teo et al., 1995). PAK4 is most abundantly present in the
prostate, testis and colon (Abo et al., 1998; Callow et  al.,  2002).  PAK6  is  also
expressed in several tissues, but it is most abundant in testis, prostate, kidney,
placenta, and brain (Lee et al., 2002; Yang et al., 2001).
Figure 3. PAK domain structures. Representative structures of eukaryotic group A and B
PAKs and Saccharomyces cerevisiae Ste20 are shown. Modified from Hofmann et al.,
2004.
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5.  PAK functions
The most common functions of PAK family proteins are related to modulation of
signaling cascades leading to transcriptional regulation, cytoskeletal remodeling and
regulation of apoptotic events. The variety of PAK functions is reflected by the vast
number of interaction partners, phosphorylation substrates, and mechanisms that
regulate PAK activity. Due to the role of PAKs in regulating cell movement and
apoptosis, increasing attention has been drawn to their importance in different types
of cancer (reviewed in Kumar et al., 2006). Here, some central functions of PAKs
have been discussed in more detail, with an emphasis on group A proteins.
5.1. Cytoskeletal regulation
Cytoskeletal regulation is a central function of PAKs, with physiological relevance
in cell motility, neurogenesis, angiogenesis and tumor metastasis. In T cells, actin
dynamics are of key importance in T cell migration, activation and formation of the
immunological synapse. The initial evidence of the role of PAK1 as a regulator in
cytoskeletal dynamics came from studies showing that PAK1 was redistributed from
the cytosol into cortical actin structures after cell stimulation by PDGF, insulin,
wounding of a cell monolayer, or transformation by v–Src (Dharmawardhane et al.,
1997). These cortical actin structures included lamellae at the leading edge of the
polarized cell and ruffling. Later, several studies have reported  that PAK1 localizes
to focal adhesions (Frost et al., 1998; Manser et al., 1997; Sells et  al., 2000). In
addition, constitutively active PAK1 induces formation of filopodia, accumulation
of membrane ruffles, and retraction of the trailing edge, as well as loss of actin stress
fibers in cell cultures (Sells et al., 1997). Signaling from active PAKs results in
alterations of cytoskeleton and cell motility is often mediated further by PAK
substrates that function as signal modulators. The proteins discussed below do not
constitute a comprehensive list but introduce some of the downstream effectors of
mainly PAK1 and PAK2 involved in cytoskeletal dynamics.
PIX/GIT/paxillin. A  fraction  of  PAKs  are  constitutively  associated  with  the  PIX
GEFs (alternatively named COOL, cloned out of library). For binding, PIX uses a
nonconventional proline-rich sequence in PAK (see Figure 3) (Bagrodia et al., 1998;
Manser et al., 1998). The PAK-PIX complex is also associated with two serine- and
threonine-phosphorylated 90- to 95-kDa proteins that were first termed PKLs
(paxillin kinase linker) or CAT-1/2 (COOL-associated, tyrosine-phosphorylated)
(Bagrodia et al., 1999; Turner et al., 1999). Later, these proteins were identified as
GIT proteins (G protein-coupled receptor kinase-interactor) (Premont et al., 1998;
Premont et al., 2000) and shown to be directly phosphorylated by PAK in vitro
(Chong et al., 2001). A focal adhesion protein, paxillin, recruits PAK to adhesion
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sites via indirect binding through GIT/PKL and PIX (Brown et al., 2002; Turner et
al., 1999; Zhao et  al., 2000b). In addition, PAK-GIT-PIX complexes are found in
cytoplasmic vesicular compartments and in the leading edge of motile cells (Di
Cesare et al., 2000; Manabe et al., 2002). GITs maintain the direction of cell
movement, possibly due to their interaction with active Rac1 on the leading edge of
the cell (Manabe et al., 2002). During wound healing, PAK and PIX regulate contact
inhibition (Zegers et al., 2003). In T cells, the PIX–GIT complex has been implied
in PAK activation and downstream transcriptional responses upon formation of the
immunological synapse (Ku et al., 2001; Phee et al., 2005). Interestingly, a recent
study has shown that PAK2-PIX-Rac1 signaling may also contribute to cell
adhesion and spreading in benign tumors of the nervous system, called
schwannomas (Flaiz et al., 2009). These tumors are deficient in expression of PAK
substrate protein merlin (Xiao et al., 2002) discussed in the next paragraph.
Nf2/merlin/schwannomin. The Nf2 (neurofibromatosis type2) tumor suppressor
gene product merlin (also dubbed schwannomin) is related to the proteins of the
band 4.1 superfamily of ezrin, radixin, and moesin, known as ERM proteins
(Tsukita and Yonemura, 1997). Mutations in and loss of heterozygocity of the Nf2
gene are involved in the pathogenesis of various sporadic tumors, such as
schwannomas, meningiomas and ependydomas. All ERM proteins function as
linkers between the plasma membrane and the actin cytoskeleton, and they localize
to cortical actin structures near the plasma membrane such as microvilli, membrane
ruffles, and lamellipodia (Tsukita and Yonemura, 1997; Tsukita et al., 1997). Merlin
binds to several proteins that localize to cell adhesion sites, including paxillin, focal
adhesion kinase, b-1-integrin, and microtubules (reviewed in Scoles, 2008). The
significant number of merlin interactions with proteins involved in GTPase, MAPK
and PI3K pathways suggests that these signaling cascades contribute to the cellular
adhesion properties regulated by merlin.
Parallel to PAK activation, merlin activity is regulated by the intramolecular binding
of the N- and C-terminal domains. This binding conformationally regulates merlin
by masking the binding sites for interacting proteins. Phosphorylation of merlin on
the major target site S518 results in inactive protein and subsequent inhibitory
effects on cell proliferation and cell cycle (Kissil et al., 2003; Xiao et al., 2005). In
cells, merlin is phosphorylated on S518 by PKA, as well as both group I and II
PAKs has been reported (Alfthan et al., 2004; Kissil et al., 2002; Xiao et al., 2002).
However, the interplay between merlin and PAK is bidirectional: merlin may inhibit
PAK activity by binding to PAK1 PBD sequence and disturbing PAK recruitment to
focal adhesions (Kissil et al., 2003). In addition, merlin negatively regulates Rac-
induced signaling (Shaw et al., 2001). Notably, HIV-1 Nef has also been shown to
induce merlin phosphorylation in primary T cells in a PAK activation-dependent
manner (Wei et  al., 2005), but establishing the possible role for Nef in merlin-
mediated signaling requires further study.
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LIM kinases. The LIMK family of serine kinases consists of LIM kinases -1 and -2,
which regulate actin dynamics through their ability to phosphorylate cofilin/actin
depolymerizing factor (ADF) family members (for review, see Bernard, 2007). LIM
kinase-1 activity was first associated with stimuli that activate Rac GTPase (Arber et
al., 1998; Yang et al., 1998), and PAK1 was later identified as a mediator in this
signaling cascade (Edwards et al., 1999). In addition to PAK1, PAK2 and PAK4
also regulate LIM kinases (Dan et al., 2001; Misra et al., 2005). Functional LIM
kinase and its downstream effector protein cofilin/ADF are required in several
processes that require rapid rearrangements of actin cytoskeleton, such as
microtubule dynamics (Arber et al., 1998; Gorovoy et al., 2005; Yang et al., 1998),
the cell cycle (Amano et al., 2002; Sumi et al., 2002) and axon growth (Tursun et
al., 2005). In T cells, signaling via LIMK and cofilin is required for chemokine-
stimulated migration (Nishita et al., 2005).
Filamin A. Filamins are actin-binding proteins that stabilize cytoskeletal structures
and integrate the actin network to cell signaling (reviewed in Stossel et al., 2001).
Physiologically, they are essential for cell movement and fetal development. Filamin
A was initially identified as a PAK1 binding partner by two-hybrid screen and the
interaction was later confirmed by pulldown and coimmunoprecipitation assays
(Vadlamudi et al., 2002). The binding site of filamin A overlaps with the
CRIB/PBD domain in PAK1, and filamin binding relieves autoinhibition of PAK1
and, therefore, increases the intrinsic activity of PAK1. Filamin-induced PAK1
activation also stimulates cofilin phosphorylation, possibly through LIMK-mediated
signaling. Because filamin itself can also bind Cdc42/Rac1, it may serve both as a
direct PAK activator and/or as a platform for GTPase-mediated activation (Ohta et
al., 1999). In a later study by Schiller et al. filamin may bridge a GEF protein
Kalirin with PAK, resulting in lamellipodia formation through activation of PAK
(Schiller et al., 2005). The capacity of filamin A to interact with proteins involved in
TcR signaling suggests that it has a role as a regulator of T cell function (Hayashi
and Altman, 2006; Tavano et al., 2006).
5.2. Cell death and survival
PAK family members participate in apoptotic pathways to promote both pro- and
antiapoptotic events (Strasser et  al., 2000). The proapoptotic PAK2 is activated in
response to stimuli that results in cytostasis or cell death as well as other types of
cellular stress, such as hyperosmolarity, heat shock or UV irradiation (Chan et al.,
1998; Chan et al., 1999; Roig and Traugh, 2001; Tang et al., 1998).
After induction of apoptotic cascade, PAK2 is cleaved by activated caspases into 28-
kDa N-terminal and 34kDa C-terminal fragments (Lee et  al., 1997; Rudel and
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Bokoch, 1997; Walter et al., 1998). The C-terminal cleavage product contains the
complete catalytic kinase domain, which is constitutively active after proteolytic
removal of the regulatory domain. This GTPase-independent activation mechanism
may regulate morphological and biochemical alterations that are necessary for
apoptosis. In support of this idea is the finding that transfection of active PAK2 C-
terminus induces changes in cellular and nuclear morphology that promote apoptosis
(Lee et al., 1997). The C-terminal PAK2 fragment also activates the c-Jun N-
terminal kinase pathway in vivo (Rudel et al., 1998). Expression of a dominant
negative PAK2 mutant delayed apoptosis and decreased formation of apoptotic
bodies (Rudel and Bokoch, 1997).
In contrast to the proapoptotic functions of PAK2, PAK1 inhibits proapoptotic
events in cells. As a consequence of PAK1 activation, the death-promoting protein
of the Bcl-2 family, Bad, is phosphorylated (Schurmann et al., 2000; Tang et al.,
2000). This phosphorylation causes Bad to dissociate from Bcl-2 or Bcl-xL, freeing
them to exert their antiapoptotic actions. Moreover, PAK1-mediated Bad
phosphorylation has been reported to be Nef-dependent (Wolf et al., 2001).
5.3. Cell growth and transformation
The ability of PAKs to regulate many cellular activities that closely intertwine with
transformation, such as growth factor and steroid-receptor signaling, transcription
and mitosis have made PAKs an attractive target of cancer studies and therapeutical
approaches. Initially, the evidence that indicated a possible role for PAK signaling
in cellular transformation came from the observation that the CRIB domain of
PAK1 inhibited Ras- and Rac-induced transformation of Rat-1 fibroblasts (Osada et
al., 1997). Further studies showed that PAK kinase activity was required for the
Ras-induced transformation of fibroblast cells (Frost et al., 1996; Frost et al., 1997;
Tang et al., 1999). Later, PAK1 was determined to be essential for Rac- and Vav-
induced transformation (Mira et al., 2000; Sachdev et  al., 2002), placing PAK
signaling as a downstream convergence point in transformation induced by small
GTPases activated by mitogenic factors.
The  yeast  PAK  analogue,  Ste20,  acts  as  a  MAP  kinase  kinase  kinase  kinase
(MAPKKKK) in the yeast mating pathway (Dan et al., 2001). This suggested that
PAK may be a regulator of MAP kinase pathway. Previously, PAK-1 to -3 had been
found to regulate c-Jun N-terminal kinase (JNK) and p38 MAP kinase activities
(Bagrodia et al., 1995a; Rudel et al., 1998; Zhang et al., 1995). The activatory effect
of PAK on MAP/ERK kinase pathway was first presented by Lu et al. (Lu et al.,
1997), who reported that membrane targeting and subsequent activation of PAK
correlated with p38, JNK, and ERK1 stimulation. Active PAK is also required for
the synergistic activation of ERK by Ras and Rho GTPases (Frost et al., 1996; Frost
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et al., 1997; Tang et al., 1999). Phosphorylation of MAP/ERK S298 is critical for
binding of Raf-1, and PAK2 was later identified as the kinase that phosphorylates
Raf1 at Ser338, the essential regulatory site for Raf-1 activation (King et al., 1998).
The role of PAK-1, -2, and -3 in phosphorylation of Raf-1 Ser338 is central for a
number of signaling cascades initiated by growth factors and integrins (Chaudhary
et al., 2000; Zang et al., 2002). Later studies have identified numerous transcription
factors and transcriptional coregulators (Barnes et al., 2003; Orton et al., 2004;
Vadlamudi et al., 2005; Yang et al., 2005), as well as cell cycle-regulating proteins
(Maroto et  al., 2008; Zhao et  al.,  2005),  as  PAK  substrates  (Figure  4.)  that  are
involved in tumor progression via regulation of gene activity and mitosis.
Figure 4. Overview of PAK signaling. PAK activation leads to its interaction with
numerous substrate proteins contributing to cytoskeletal regulation, cell migration, signaling
and transcriptional activity.
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6. Regulation of PAK activity
6.1. Regulation by GTPases
The original study that identified PAKs as GTPase-associating proteins was
followed by a series of reports confirming that at the molecular level the kinase
activity of PAK1 to -3 was regulated by binding of Rho GTPases (Bagrodia et al.,
1995b; Knaus et al., 1995; Martin et al., 1995). Several structural (Gizachew et al.,
2000; Hoffman and Cerione, 2000; Lei et al., 2000; Morreale et al., 2000;
Thompson et al., 1998) and biochemical (Benner et  al., 1995; Buchwald et al.,
2001; Chong et al., 2001; Gatti et al., 1999; Tu and Wigler, 1999; Yu et al., 1998;
Zenke et al.,  1999;  Zhao et al., 1998) studies supported a model in which the
binding of GTPase disrupts the dimerization of the termini and leads to a series of
conformational changes that stabilize the inhibitory switch domain. The crystal
structure of PAK1 in an autoinhibited conformation was determined, and PAK1 was
found to exist as a homodimer both in cells and in solution (Lei et al., 2000; Parrini
et al., 2002; Pirruccello et al., 2006). In this trans-inhibited conformation the N-
terminal regulatory domain of one PAK molecule binds and inhibits the C-terminal
catalytic domain of another molecule. The dimerization segment was mapped within
the PBD/CRIB, just upstream of the autoinhibitory domain. PAK1 residues Leu107,
Glu116 and Asp126 were implicated as critical residues contributing to the
inhibitory interface (Lei et al., 2000). A mutation introduced to any of these amino
acids destroys the interaction between the inhibitory switch domain and the catalytic
domain, resulting in constitutive conformational change and kinase activity.
Activation by GTPases results in autophosphorylation of specific amino acids T402,
S141, and S165 (in PAK2), which are key residues for full protein kinase activation
(Jung and Traugh, 2005). In vitro studies by Gatti et al. have shown that stimulation
by Cdc42 induces phosphorylation at five other serine residues on PAK2 (S19, S20,
S55, S192 and S197) (Gatti et al., 1999). Phosphorylation of Thr402 maintains the
relief of autoinhibition and full catalytic activity towards exogenous substrates
(Gatti et al.,  1999; Yu et al., 1998; Zenke et al., 1999). Binding of p21-GTPase to
PAK inhibits its intrinsic and GAP-stimulated GTP hydrolysis (Manser et al., 1994),
whereas full activation leads to the dissociation of Cdc42 and PAK2.
Autophosphorylation of some N-terminal regulatory sites occurs in cis, but
phosphorylation of the activation loop threonine (T402) is an intermolecular process
that occurs by phosphorylation of one PAK kinase domain by another.
Despite the high sequence similarity in the PBD of PAKs, different PAK isoforms
have different affinity for Rho GTPases. PAK1 can be activated by Rac1, Rac2,
Rac3 or Cdc42 (Knaus et al., 1998; Manser et al., 1994; Mira et al., 2000), as well
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as Chp, TC10 and Wrch-1 (Aronheim et al., 1998; Neudauer et al., 1998; Shutes et
al., 2004). The amino acids affecting GTPase selectivity have been mapped mostly
within the overall PBD domain (Reeder et al., 2001). However, residues outside the
PBD may also have an effect; the stretch of lysines (aa 66-68 in PAK1) just
upstream of the CRIB domain has been implicated in efficient Rac binding and
optimal stimulation of PAK kinase activity by bound GTPase (Knaus et al., 1998).
Figure 5. Simplified model for the activation-associated conformational change of PAK2
by p21-GTPase.
6.2. Regulation by GTPase-independent mechanisms
While stimulation by p21-GTPases is considered the most important activation
mechanism of PAKs, GTPase-independent stimuli have also been described.
Initially, PAK autophosphorylation and kinase activity were reported to increase by
partial protease-mediated digestion (Benner et  al., 1995; Roig and Traugh, 2001).
This phenomenon was characterized in more detail by studies describing that PAK2
can be cleaved at a single site (aa 212 in PAK2) between the N-terminal regulatory
domain and the C-terminal catalytic domain by caspases during apoptosis,
generating a constitutively active PAK2 fragment (Walter et al., 1998). The
proteolytic activation of PAK2 allows the regulation of morphological changes that
are seen in apoptotic cells (Rudel and Bokoch, 1997). The physiological
consequences of this activation mechanism are discussed in more detail below in
chapter Cell death and survival.
Association of PAK1 with an SH3-containing adaptor protein Nck and subsequent
membrane localization of PAK increase its kinase activity (Lu et al., 1997). The
interaction of PAK with Nck has been mapped in detail to PAK sequence
PxxPxRxxS21, where phosphorylation of Ser21 inhibits Nck binding (Zhao et  al.,
2000a). In addition, increase in PAK activity has been shown by addition of a
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specific membrane-targeting sequence (Daniels et al., 1998).  Membrane targeting
of PAK may involve its interaction with lipids, e.g. sphingosine, or phosphorylation
of the critical PAK1 Thr402 residue by pyruvate dehydrogenase kinase, both of
which have been reported as GTPase-independent mechanisms of PAK activation
(Bokoch et al., 1998; King et al., 2000).
Other protein kinases are involved in PAK activity modulation: Cdk5, a neuron-
specific kinase, associates and phosphorylates PAK1 at Thr212. This
phosphorylation, however, does not seem to significantly alter PAK kinase activity
(Rashid et al., 2001). Similarly, the non-receptor tyrosine kinase Etk/Bmx, tyrosine
kinase Abl, as well as PI3K associate with and phosphorylate PAK1/2 (Bagheri-
Yarmand et al., 2001; Papakonstanti and Stournaras, 2002; Roig et al., 2000).
Tyrosine phosphorylated PAK1 has also been identified from a multiprotein
complex in constitutively activated v-ErbB receptor transformed cells, but the
protein responsible for PAK phosphorylation protein within the complex has
remained uncharacterized (McManus et al., 2000).
Phosphorylation of PAK is critical for its full activity, but dephosphorylation plays
an equally important role in shutting off kinase activity. Two phosphatases of the
same protein family, POPX1 (partner of Pix 1) and POPX2, dephosphorylate PAK1,
including the key residue Thr402 (Koh et  al., 2002). Both of these phosphatases
bind to several forms of Rac- and Cdc42-specific GEFs called PIX to form
multimeric protein complexes containing PAK. The a-PIX binds both PAK1 and
PAK2, and to induce PAK1 activation independently, but synergistically, of Rac or
Cdc42 (Feng et al., 2002). In contrast to the stimulatory effect of a-PIX, b-PIX
inhibits Cdc42- and Rac-stimulated PAK activity (Bagrodia et al., 1998; Feng et al.,
2002). In a similar manner, hPIP1, a WD-domain containing regulator protein binds
PAK1 and inhibits its ability to be activated by Rac or Cdc42 (Xia et al., 2001). The
physiological significance of PAK negative regulation, however, remains unclear.
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STUDY AIMS
The association of Nef with active PAK2 kinase is common to diverse Nef proteins
of  both  HIV-1/2  and  SIV  origin.  Among  the  total  cellular  pool  of  PAK2,  only  a
small, highly active fraction of this kinase associates with Nef, suggesting that
activation of PAK2 promotes its interaction with Nef. However, the exact molecular
mechanisms involved in the generation of superactive PAK2 and in the formation of
NAK complex have remained elusive. PAK2 localizes to the plasma membrane
upon activation. Because part of the cellular pool of Nef protein is also present in
the membraneous compartment, we wanted to study in more detail the intracellular
location of the NAK complex. Previously, several binding partners including Src-
family kinases and p21-GTPase-activating GEF proteins, have been described for
Nef. However, the contribution of SFKs or GEFs for PAK2 activity and the Nef-
PAK2 complex has not been fully determined.
Detailed aims of the present study are:
- to characterize the role of Src tyrosine kinases in PAK2 activation
- to examine the molecular requirements of the Nef and PAK2 association
- to identify GEF protein partners associated with the Nef-PAK2 complex
- to study the role of self-association in Nef biological functions
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MATERIALS AND METHODS
This chapter briefly describes the main methods used. For more detailed
descriptions of the methods, please refer to the original communications I-IV.
1. Mammalian cell culture and transfection (I-IV)
Human embryonic kidney fibroblast cells (HEK 293T) and TZM cells were cultured
in Dulbecco’s modified Eagle’s medium (DMEM, BioWhittaker) supplemented
with 10% fetal calf serum (FCS), 1% L-glutamine and 1% penicillin/streptomycin
(all from Invitrogen). TZM cells are a HeLa cell line that expresses b-galactosidase
and luciferase under  the control  of  HIV-1 long terminal  repeat.  The human T-cell
leukemia cell line Jurkat Tag (JTag) and its derivatives JVav and BEa16-3 were
cultured in RPMI 1640 supplemented with 10% FCS, 1% L-glutamine and 1%
penicillin-streptomycin (Invitrogen). JVav and BEa16-3 cell lines lack expression
of Vav1 or DOCK2 (Cao et  al., 2002; Sanui et al., 2003), and they were kindly
provided by Drs. D. Billadeau and Y. Fukui, respectively.
Transient transfections of 293T cells were done using Lipofectamine transfection
reagent (Invitrogen) according to the manufacturer’s instructions. Jurkat Tag, JVav
and BEa16-3 cells were transfected by electroporation (230 V for BEa16-3 or 250
V for JTag and JVav, 950 µF, ???) in GenePulser Xcell (BioRad) and incubated for
24-72 h depending on the cell type and construct used.
2. Plasmid constructs (I-IV) and RNAi oligonucleotides (III)
The expression vector for dominant active (V12) Cdc42V12 and a pEBB eukaryotic
expression vector derived from pEF-BOS plasmid (Mizushima and Nagata, 1990)
were kindly provided by Dr. B. Mayer (University of Connecticut, Farmington, US).
The insert encoding PAK2 was cloned in pEBB with either a Myc-His-HA
(hemagglutin) multiepitope (ME) tag (Renkema et al., 2001) or Myc-His (MH) tag.
All PAK2 mutants (for list of mutated PAK2 derivatives, see also Table 1) were
created by overlap PCR using a specific mutant primer pair and common outer
primers containing restriction sites used for cloning. The PAK2 double mutants with
E115K or D125R autoinhibitory mutations combined to HH (H82/85) or ISP
(I74N/S75P/P77A) mutation were made by cloning the HH- or ISP-mutated N-
terminal fragment to the pEBB-PAK2-ME vector containing the respective
autoinhibitory mutation. As a substrate for PAK2-kinase assays (Tuazon et  al.,
1997), three tandem copies of the 7-amino acid peptide of the Rous sarcoma
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nucleocapsid (KKRKSGL) in frame with glutathione S-transferase (GST) were
cloned into the bacterial expression vector pGEX-4T-1 (Amersham Biosciences).
The NL4-3, 8161 and 13127 HIV-1 Nef alleles and SIVmac239 Nef used in
communication II were a gift from Frank Kirchhoff (University of Ulm, Germany)
(Kirchhoff et al., 2004). SIV SYK51 Nef allele was provided by Dr. B. Hahn
(University of Alabama at Birmingham, USA), and HIV-2 cbl Nef was amplified
from an HIV-2-infected culture obtained through NIH AIDS Research and
Reference Reagent Program. Wild type SF2 Nef and SF2 Nef mutants G2A and
AxxA were a gift from Mark Harris (University of Leeds, UK). To generate
Nef.GFP plasmid, the SF2 Nef allele was cloned into the pEGFP-N1 vector
(ClonTech) and the expression constructs of NefF195A.GFP or NefF191I.GFP were
generated using site-directed mutagenesis (QuickChange Site-Directed Mutagenesis
Kit, Stratagene). The Nef allele used in communication IV was obtained from the
HIV-1 SF2 strain, which has a 4-aa duplication in its N-terminal region (residues
22-25 of the HIV-1 Nef consensus sequence), but we used the established amino
acid numbering matching to the widely used strains like HXB2 and NL4-3 when
discussing the mutated residues in the core domain of SF2 Nef. R105D, D123R, and
R105D/D123R mutations were introduced into Nef by overlap PCR using specific
mutant primers and common outer primers with restriction sites for cloning into
both a pEBB vector with a C-terminal myc-tag, and also into a bicistronic vector
pWPI-PP expressing IRES-GFP and a C-terminal 123-amino acid biotin acceptor
sequence (PP) from Propionibacterium shermanii transcarboxylase obtained from
PinPoint-Xa1 T-vector (Promega) (Heikkinen et al., 2008). All Nef alleles and SF2
Nef mutants used in this study are also listed in Figure 6. The original expression
vector pWPI was provided by Tapio Visakorpi (University of Tampere, Finland).
The full-length cDNA of vav1 was subcloned into the pEF-BOS expression vector.
The pLacZ reported plasmid was created by inserting b-galactosidase cDNA into
pEBB. Expression plasmids for b-Pix.myc, Flag.DOCK2 and ELMO1.His were
kindly provided by Drs. Ivan Dikic, Shinya Tanaka and Yoshinori Fukui,
respectively (Nishihara et al., 2002; Sanui et al., 2003; Schmidt et al., 2006). The
cDNA of Hck isoform p61 was PCR-amplified from an IMAGE clone
(http://www.geneservice.co.uk; ID 4855747/Accession BC014435) and subcloned
into the pEBB expression vector, and a C-terminal biotinylation tag (PP) was added.
Targeted sequences by RNAi were as follows: 5’- UCU GUA UAC ACA CGG
UCU  GTT  -3’  for  PAK1; 5’- AGA AGG AAC UGA UCA UUA ATT -3’ for
PAK2; 5’- CGU CGA GGU CAA GCA CAU UTT -3’ for Vav1; 5’- AGU CCG
GUC CAU AGU CAA CTT -3’ for Vav2; 5’- ACC ACU GUC UGC AAU AAU
ATT -3’ for ELMO1, 5’- GGA ACG ACA UCU ACA UUA CTT -3’ for DOCK2;
5’- GGA UGA AGU UCA AGA AUU ATT -3’ for b-PIX; and 5’-
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AGGUAGUGUAAUCGCCUUGTT -3’ as a non-specific control (all from MWG-
Biotech).
PAK2 mutant Acronym Reported functional consequences Reference
H82/85L CRIB p21-GTPase-binding deficient Zhao et al., 1998
I74N/S75P/P77A ISP p21-GTPase-binding deficient Zhao et al., 1998
L106F  - Conformationally autoactivated kinase Lei et al.., 2000
E115K  - Conformationally autoactivated kinase Lei et al., 2000
D125R  - Conformationally autoactivated kinase Lei et al., 2000
Y130F
Y139F
Y194F
 -
Disrupted phosphorylation of tyrosine
residues
Renkema et al.,
2002
P185G/R186A PIX- b-PIX-binding deficient Manser et al.,
1998
K278R KD Deficient in kinase activity (‘kinase inactive’) Tang et al., 1997
T402E DA Autoactivated kinase (‘dominant active’) Sells et al., 1997
Table 1. The PAK2 mutants used in this study.
3. Antibodies (I-IV)
Sheep polyclonal Nef antiserum was provided by Dr. Mark Harris (Leeds
University, UK). The mouse monoclonal anti-HIV-1 Nef antibody was a gift from
Professor K. Krohn (FIT Biotech, Finland). Polyclonal rabbit serum against GFP
was kindly provided by Prof. Hans-Georg Kräusslich (University of Heidelberg,
Germany). Anti-AU1 antibody was obtained from Biosite, and monoclonal anti-myc
antibody 9E10 was purchased from either Sigma-Aldrich (used in communications I
and II) or Santa Cruz Biotechnology (in comm. III). The rabbit polyclonal
antibodies for ELMO1 and Vav2, as well as the anti-phosphotyrosine antibody
PY20 were purchased from Santa Cruz Biotechnology. Monoclonal mouse anti-flag
(M2) and anti-GFP (GFP20) were obtained from Sigma-Aldrich, and polyclonal
rabbit anti-PAK1/2/3 and anti-Vav were purchased from Cell Signaling Technology.
Polyclonal rabbit anti-b-Pix and monoclonal mouse anti-His6 (BMG-His-1) were
47
obtained from Roche; polyclonal rabbit anti-LAT was obtained from Upstate
Biotechnology; and monoclonal mouse anti-transferrin receptor (clone H68.4) was
purchased from Zymed Laboratories. The secondary fluorescent antibodies and
Alexa Fluor 555-conjugated cholera toxin subunit B used in cholera toxin clustering
studies (comm. III) were obtained from Molecular Probes. The horseradish
peroxidase-conjugated cholera toxin subunit B used in raft fractionation studies
(comm. II) was purchased from Sigma-Aldrich.
Figure 6. Amino acid sequence alignment of HIV/SIV Nef alleles used in this study. The
mutated SF2 Nef residues are boxed; G2, P76/79 (PxxP), R109, D127, F195.
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4. Cell lysates and fractionation (I-IV)
To prepare whole cell lysates, cells were washed with ice-cold standard phosphate-
buffered saline (PBS) and lysed in in vitro kinase assay (IVKA) lysis buffer (50 mM
N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES) pH 7.4, 150 mM
NaCl, 10% glycerol, 1% Triton X-100, 1 mM ethyleneglycol-O,O’-bis-[2-amino-
ethyl]-N,N,N’,N’-tetraacetic  acid  (EGTA),  1,5  mM  MgCl2, containing 1 mM
phenylmethylsulfonyl fluoride (PMSF), 10 µg/ml aprotinin, 1 mM sodium
orthovanadate). For fractionation into cytosolic and particulate fractions (comm. II),
cells were washed with PBS, suspended into hypotonic buffer (50 mm Tris pH 7.5, 5
mM MgCl2,  1 mM EDTA, and 1 mM EGTA) for 10 min on ice and homogenized
with a Dounce homogenizer, and supernatant was cleared by centrifugation. The
particulate fraction was washed with hypotonic buffer and resuspended in IVKA
lysis buffer. After lysis, the extract was centrifuged and the solubilized particulate
fraction collected.
5.   Pervanadate treatment (I)
Pervanadate was freshly made for every experiment by incubating 100 µl of 100
mM sodium orthovanadate with 9 µl of 30% H2O2 in a final volume of 200 µl for 15
min at room temperature and was kept on ice until use. Pervanadate was added to
the transfected cells at a final concentration of 250 µM for 15 min, after which the
cells were placed on ice, washed with cold PBS, and lysed.
6. Membrane flotation by ultracentrifugation (II, III)
Cells were washed with PBS and lysed with isolation buffer (150 mM NaCl2, 5 mM
EDTA,  25  or  50  mM  Tris-HCl  pH  7.4,  1%  Triton  X-100)  on  ice.  Samples  were
adjusted to 40% Optiprep (LifeTechnologies), loaded into centrifuge tubes, and
overlaid with a middle layer of 28% Optiprep and a top layer of isolation buffer.
After centrifugation (3 h, 35 000 rpm, 4°C), eight 500-µl fractions were collected
and subjected to immunoprecipitation followed by IVKA. To detect the raft marker
GM1 (in comm II), an aliquot of each fraction was transferred to polyvinylidene
difluoride membranes by slot blotting and probed with horseradish peroxidase-
conjugated cholera toxin. In communication III, fraction 2 representing the raft-
containing fraction, and fraction 8, representing the soluble fraction were analyzed
by western blotting. The quality of flotation was addressed by analyzing the
localization of transferrin receptor (excluded from rafts) and LAT (incorporated in
rafts).
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7. Cholera toxin clustering in Jtag cells (III)
At 48 h posttransfection, Jurkat Tag cells were incubated with 25 µg of Alexa 555-
conjugated cholera toxin (CTx)/ml in 0.1% bovine serum albumin–PBS for 30 min
at 4°C. Cross-linking was performed by incubating cells with anti-CTx antibody at a
1:200 dilution for 30 min at 4°C followed by 10 min at 37°C. Cells were seeded on
poly-L-lysine-coated coverslips and fixed for 10 min with 3% paraformaldehyde-
PBS. Cells were permeabilized with 0.1% Triton X (1 min, RT) and stained with the
anti-tag antibodies, followed by Alexa 660-conjugated secondary antibody. Samples
were analyzed with a confocal laser scanning microscope (Zeiss, LSM 510) using a
100x oil immersion objective lens.
8. Immunoprecipitation and in vitro kinase assay (IVKA) (I-IV)
Lysates were precipitated with anti-PAK (comm. I and II) and anti-Nef (comm. II-
IV) antibodies by using protein A sepharose beads (Sigma-Aldrich). For IVKA,
after washing immunoprecipitates with IVKA lysis buffer and kinase assay buffer
(50  mM  HEPES  pH  7.4  and  5  mM  MgCl2), 32[P]gATP (2.5 µCi; Amersham
Biosciences) was added to the immunoprecipitates followed by a 30-minute
incubation at 37°C. When indicated, bacterially produced GST-substrate peptide
fusion  protein  was  added  to  the  IVKA  reaction  mixture.  For  the  tyrosine
phosphorylation studies in communication I, radiolabeled NAK was eluted from
anti-PAK immunoprecipitates after IVKA by incubation for 1 h at 37°C in PBS with
0.1% SDS. The eluate was diluted 10-fold with PBS and cleared with protein G-
Sepharose before splitting the sample to three identical fractions subsequently re-
immunoprecipitated with either empty beads (negative control), anti-
phosphotyrosine antibodies (PY20), or anti-PAK antibodies. The beads were washed
with PBS and boiled in Laemmli sample buffer, followed by 8-12% SDS-
polyacrylamide gel electrophoresis (PAGE) and detection by autogradiography. In
communication III, radioactive signals were normalized against the amount of
isolated Nef in the western blot, and Nefwt.GFP signals were arbitrarily set to 100
percent. Statistical significance was determined using student's T-test.
9. Tyrosine dephosphorylation using PTP-1B (I)
Protein  tyrosine  phosphatase  1B  (PTP-1B)  was  expressed  in  bacteria  as  a  GST
fusion protein and purified from lysed cells by using glutathione Sepharose beads
(Amersham Biosciences). PAK2 was immunoprecipitated from cell lysates, and
beads were washed in IVKA lysis buffer and equilibrated in dephosphorylation
buffer (25 mM Tris pH 7.6, 10% glycerol, 1 mM dithiothreitol, 0.1 mM EDTA,
0.01% Nonidet P-40, 10 µg/ml aprotinin, 1 mM sodium orthovanadate and 1 mM
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PMSF. The immunoprecipitates were split into two samples and incubated with or
without GST-PTP-1B (10 µg/ml) for 30 min at 35°C. After incubation, beads were
washed in IVKA buffer and subjected to IVKA.
10. In vivo labeling and phosphoamino acid analysis (I)
Transfected cells were washed with phosphate-free medium (minimum essential
medium without sodium phosphate) supplemented with 20 mM ultraglutamine-1
(BioWhittaker) and then starved in this medium for 1 hour. [32P]orthophosphate (10
mCi/ml; Amersham Biosciences) was added to achieve a concentration of 0.5
mCi/ml, and cells were labeled for 3 hours. After pervanadate treatment, cell were
washed with ice-cold PBS and lysed in IVKA lysis buffer. Lysates were cleared by
centrifugation (10 min, 16 000 x g) and immunoprecipitated with anti-myc
antibodies. After washing with IVKA lysis buffer, the immunoprecipitates were
boiled in Laemmli sample buffer and separated by 8% SDS-PAGE gel run. Proteins
were transferred to polyvinylidene difluoride membrane (Bio-Rad) and detected by
autoradiography. After exposure, the labeled band corresponding to PAK2 was
excised. The membrane was boiled in 6 M HCl at 110°C for 1 h. Hydrolyzed amino
acids were processed as described earlier by Kamps et al. (Kamps and Sefton,
1989), mixed with unlabeled phosphoamino acid standards, and separated on
cellulose thin-layer 20 cm x 20 cm chromatography plates (Sigma) by
electrophoresis for 30 min at 2 000 V in pH 1.9 buffer (formic acid [88%]/ acetic
acid/water ratio 50:156:1,794) in the first dimension and then for 20 min at 1 600 V
in pH 3.5 buffer (acetic acid/pyridine/water ratio 10:1:189) for the second
dimension. Plates were stained with ninhydrin to visualize the unlabeled standards;
labeled amino acids were detected by autoradiography.
11. Western blotting (I-IV)
For western blotting, immunocomplexes or total protein samples were separated by
SDS-PAGE and transferred onto nitrocellulose membranes for subsequent
immunoblotting with specific antibodies. Biotinylated secondary antibodies and
streptavidin-horseradish peroxidase conjugates were used followed by enhanced
chemiluminescence (ECL).
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12. Preparation of viruses and infectivity assay (IV)
SF2 Nef wild type and the mutated variants were cloned into the pNLblue vector
containing the full length proviral DNA of HIV-1 NL4-3 (Fackler et al., 2006) and
confirmed by sequencing. Viruses were generated by transfecting proviral HIV
plasmids into 293T cells via the calcium phosphate method. Approximately 48 h
after transfection, culture supernatants were harvested, cleared by centrifugation (10
min, 400 x g), and filtrated through 0.45µm-pore-size filter. Particles were pelleted
through ultracentrifugation (90 min, 100 000 x g at  4°C) and resuspended in PBS.
The CA protein concentration of concentrated stocks was determined by p24CA
enzyme-linked immunosorbent assay (ELISA) based on a monoclonal antibody
from hybridoma cell line183 (clone H12-5C) (Konvalinka et al., 1995). The
antibody for coating ELISA plates was used at a concentration of 50 ng per well.
Wells were blocked with 5% milk in PBS, and appropriate dilutions of concentrated
virus supernatants were added. Antigen was detected by incubation with polyclonal
rabbit antiserum against HIV-1 CA, followed by horseradish peroxidase-conjugated
antiserum against rabbit immunoglobulin G. Enzyme activity was detected with
tetramethylbenzidine as substrate, and quantitative analysis was derived from the
absorbance counts with known amounts of purified HIV-1 CA protein as standard .
The relative infectivity of virus particles was determined by CA ELISA and a
standardized 96-well TZM blue cell assay. Infections were carried out in triplicate
with 0.5 ng CA input virus. Thirty-six hours after infection, cells were fixed with
cold methanol:acetone (50:50) and stained for b-galactosidase. The number of blue
cells was determined by microscopy.
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RESULTS
1.  Mechanisms of PAK2 activation and the role of activation in Nef-PAK2
association (I, II)
1.1.   Activation of PAK2 by Cdc42 and tyrosine kinases synergize
Autophosphorylation of serine and threonine residues is the key event in
maintaining the catalytically active state of PAKs. Activation is most commonly
achieved by p21-GTPases Cdc42 and Rac1, but many other intracellular stimuli can
also result in activation of PAK kinases, as discussed in the chapter Regulation of
PAK activity. Activation of PAKs by p21-GTPases was previously noted to be
accompanied by a shift in electrophoretic mobility of PAK in SDS-polyacrylamide
gels towards forms of higher molecular weight (Bokoch et al., 1998; King et al.,
2000). Because the results obtained earlier in our laboratory implied that HIV-1 Nef
was selectively associated with the low-abundancy, high-molecular-weight species
of PAK2 (Renkema et al., 1999; Renkema et al., 2001), the mechanisms that would
generate the highly active form of PAK2 became a relevant topic of more detailed
studies. To investigate the possible role of tyrosine kinase signaling pathways in
p21-GTPase-mediated PAK activation, three members of the SFKs - Lck, Fyn and
Hck - were overexpressed in 293T cells with PAK2 and with or without the
presence of a dominant active variant of Cdc42 (Cdc42V12) (comm. I, fig. 1A).
Overexpressed Src tyrosine kinases alone had hardly any effet on PAK activity was
hardly detectable, and they had no effect on the mobility of PAK2. However, when
tyrosine kinases were expressed together with Cdc42V12, PAK autokinase activity
was strongly increased. To study the role of endogenous tyrosine kinases in PAK2
activation, the cells were treated with pervanadate (PV), which is a potent tyrosine
kinase inhibitor. Similarly to cells transfected only with Src kinases, pervanadate
alone had little effect on PAK2 activity. When cells were cotransfected with
Cdc42V12, however, pervanadate treatment resulted in a significant increase of
PAK2 activity, and this activity could be inhibited in a dose-dependent manner by
pretreating cells with 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]-
pyrimidine (PP1), a pharmacological Src kinase inhibitor (comm. I, fig. 1B and 1C).
The order of events leading to PAK2 activation was tested by experiments in which
PAK2 was immunoprecipitated from pervanadate-treated but not Cdc42V12-
cotransfected cells using GTPgS-loaded recombinant Cdc42 to activate PAK2 in
vitro. No difference in PAK2 activity was found between pervanadate-treated or
control cells, suggesting that the activation of PAK2 by p21-GTPases primes it for
further activation by Src kinases, but not vice versa (comm. I, fig. 1D).
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1.2. Tyrosine phosphorylation of PAK2
The prominent phosphorylation of PAK2 by the synergistic effect of Cdc42V12 and
Src kinases raised a question whether the effect was due to direct tyrosine
phosphorylation of PAK2. Probing PAK2 immunoprecipitates from differentially
transfected and treated cells with anti-phosphotyrosine antibodies did not result in
specific signals (data not shown), suggesting that the bulk of PAK2 protein did not
become tyrosine phosphorylated upon treatment. Taking into account the very low
amount of higher-migrating, superactivated PAK2 species, immunoblotting was not
considered a practical approach for identifying phosphorylation sites. Therefore, we
used a more sensitive dual immunoprecipitation method, where radiolabeled PAK2
was eluted from beads and reprecipitated with either anti-phosphotyrosine or anti-
myc antibodies. In this assay, neither Cdc42V12 nor pervanadate stimulation could
increase PAK2 phosphorylation to the extent that would be detectable with
phosphotyrosine antibody. However, from the pervanadate-treated cells with
cotransfected Cdc42V12 yielded an abundant signal of phosphorylated PAK2 could
be precipitated with anti-pTyr antibody (comm. I, fig. 2).
Human PAK2 contains eleven tyrosine residues. To further map the exact sites of
phosphorylation, a mutational approach was used. To this end, the protein was first
chopped into two parts by caspase cleavage between residues D212 and G213
(Rudel and Bokoch, 1997); re-immunoprecipitating of these fragments revealed that
only the N-terminus was tyrosine phosphorylated. Thus, the tyrosine-to-
phenylalanine mutations were restricted to three N-terminal tyrosine residues Y130,
Y139 and Y194. By comparing anti-phosphotyrosine and anti-myc
immunoprecipitations we noticed that the Y130F mutation had the most prominent
effect on tyrosine phosphorylation by almost totally abolishing the signal (comm. I,
fig. 2). Also, the Y194F mutation decreased the relative precipitation efficiency of
the anti-pTyr antibody as compared to anti-PAK2 precipitation, making the Y194
residue an additional putative phosphoacceptor site. The Y139F mutation had less
dramatic effect on phosphorylation, and as expected the triple mutant
Y130/139/194F completely abolished the anti-pTyr binding. The subsequent
phosphoamino acid analysis from cells transfected with Cdc42V12, treated with
pervanadate and labeled in vivo with [32P]orthophosphate confirmed the loss of Tyr
phosphorylation by the triple Y130/139/194F mutant (comm. I, fig. 3A). When
similarly stimulated cells were radiolabeled in vitro in an IVKA reaction, the result
of amino acid analysis was similar to that obtained with the triple mutant, indicating
that the tyrosine phosphorylation does not take place during IVKA reaction by a
coprecipitating kinase but within cells. These results implicated that the Cdc42V12-
activated PAK2 was the target of direct phosphorylation and the most important
residue of the PAK2 regulatory domain was Y130.
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The role of Y130 as a target site of Src-mediated phosphorylation was further
characterized by comparing the synergistic effect of Cdc42 and pervanadate in
PAK2 wild type, PAK2-Y130F and PAK2-Y130/139/194F activation (comm. I, fig.
4). Unlike the strong potentiating effect of pervanadate on PAK2 wild type activity,
pervanadate had little effect on the activity of PAK2-Y130F or the triple mutant,
suggesting that the particular tyrosine residue is not only important as a site of
phosphorylation, but it is also a critical residue in Src-mediated potentiation of
PAK2 kinase activity.
To study the functional effects of Y130 phosphorylation, the effect of in vitro
tyrosine dephosphorylation on PAK2 activity was tested (comm. I, fig. 5).
Cdc42V12-activated PAK2 was either treated or left untreated, and half of the
samples were incubated with the tyrosine phosphatase PTP-1B before subjecting it
to IVKA. This treatment reduced PAK2 activity, decreasing both its
autophosphorylation (4.6-fold) and activity towards the substrate peptide (3.9-fold);
thus, the inhibitory effect of PTP-1B was specifically resulted from removing the
phosphotyrosine modification. When different tyrosine mutants (Y130F, Y139F,
Y194F, Y130/139/194F) of PAK2 activated by Cdc42 and PV were treated with
PTP-1B, a significant reduction of catalytic activity was observed only in PAK2s
mutated for Y139F and Y194F (2.9-fold and 4.3-fold, respectively), whereas Y130F
and the triple tyrosine mutant were insensitive to treatment with PTP-1B, further
confirming the role of Y130 as a major phosphoacceptor site in Src-mediated PAK2
regulation. In addition, these data demonstrated that the effect of Src kinases exerted
their effect via increased catalytic activity of PAK2.
1.3 Tyrosine phosphorylation of PAK2 requires p21-GTPase-induced
conformational changes
Activation of PAKs by p21-GTPases is associated with disrupted autoinhibitory
contacts between N- and C-termini of PAK. To examine whether p21-GTPase
stimulus and the subsequent conformational change of PAK would expose tyrosine
residues for phosphorylation, a panel of mutated PAK2 proteins with known
conformational and functional consequences was used (comm. I, fig. 6). Mutations
on H82/85L in the PAK2 PBD/CRIB domain resulting in a p21-GTPase-binding-
deficient PAK2 failed to become tyrosine phosphorylated by PV treatment, even
when Cdc42V12 was cotransfected. The PAK2-L106F mutant, mimicking the p21-
GTPase-stimulus and resulting in open conformation and kinase activity of PAK,
was also used; it was readily precipitated by anti-pTyr antibody after pervanadate
treatment and did not require prior p21-GTPase stimulation. This result was also
confirmed using another similar PAK2 mutant (PAK2-D125R), which yielded
similar results (data not shown). To further confirm the important role of PAK2
conformation in tyrosine phosphorylation, another constitutively active PAK2,
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namely PAK2-T402E, was used. This mutant is weakly responsive to p21
stimulation, but it possesses kinase activity due to the acidic residue replacement at
position 402. Despite its catalytic activity, PAK2-T402E failed to become tyrosine
phosphorylated upon PV treatment, even after cotransfection of Cdc42V12.
Altogether, results obtained with the PAK2 mutants suggest that the conformational
changes associated with p21-GTPase stimulus are required for subsequent tyrosine
phosphorylation and superactivation of PAK2.
1.4 Association of Nef with PAK2 is dependent on the molecular mechanism
of kinase activation
Kinase activity of PAK2 can be elicited by GTPase stimulation, mutation of the key
acidic residues in the PAK regulatory domain, or by mimicking the phosphorylation
event by acidic replacement of the key phosphorylation residue T402. GTPases as
well as mutations of the regulatory domain yield an active kinase due to the opening
of the conformation, whereas mutation T402E results in increased kinase activity
without the associated conformational change. Thus, these mutants represent two
structurally different approaches to mimicking PAK2 activation and serve as tools to
study the effect of conformational change of PAK2 on Nef association.
To test the ability of differently activated PAK2 to associate with Nef, 293T cells
were transfected with PAK2 (wild type or constitutively active mutants D125R and
T402E) and laboratory-adapted HIV-1 NL4-3 strain Nef either with or without
Cdc42V12 (comm. II, fig. 1). As expected, PAK2 wild type associated with Nef
only when further stimulation was provided by Cdc42V12, indicating that NL4-3
Nef is a weak activator of PAK2. In contrast, when the constitutively active PAK2-
D125R was used, it efficiently associated with Nef without the requirement of prior
activation with the GTPase. Surprisingly, however, the autoactive PAK2-T402E did
not associate with Nef both in the absence and presence of Cdc42V12, suggesting
that kinase activity per se is not sufficient for association. Rather, the inhibitory
contacts of the PAK2 N- and C-termini maintain a  conformation that does not allow
the formation of the Nef-PAK2 complex.
1.5. Association and activation of PAK2 with HIV/SIV Nef alleles
Because NL4-3 Nef proved poor in its ability to associate with PAK2 in the absence
of kinase activation by Cdc42V12 or an appropriate mutation in PAK2, we
hypothesized that NL4-3 was unable to activate PAK2. Previous studies have,
however, shown that certain Nef alleles, such as HIV-1 SF2, can stimulate PAK2
activity (Arora et  al., 2000), suggesting that Nefs may differ in their ability to
activate PAK2. Thus, we studied the capacity for PAK2 association with a panel of
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six HIV-1, HIV-2, and SIV Nefs, which have all been previously characterized for
their functionality and ability to associate with Cdc42V12-activated PAK2
(Kirchhoff et al., 2004). Of these alleles, SIVmac239 and HIV-1 O-type alleles 8161
and 13127 were the most prominent activators of PAK2 and associated efficiently
with the kinase (comm. II, fig. 2). An SIV Nef, SYK51, was as unable to stimulate
or associate with the kinase as NL4-3 Nef. One HIV-2 allele, Nefcbl, was found
particularly interesting, due to its strong ability to activate PAK2. Despite its
obvious capacity to activate PAK2, it did not associate with PAK2 in any
appreciable level. However, when PAK2 was activated with Cdc42V12, a strong
signal of NAK activity could be coprecipitated with HIV-2 Nefcbl. These data
suggest that activation and association with PAK2 are two separate functions of Nef.
The failure of some Nefs to stimulate PAK2 activity despite the general ability of
Nefs to associate with preactivated PAK2 indicates that, contrary to GTPases, PAK2
activation by Nef is not a direct consequence of binding.
1.6. Cdc42 in Nef-PAK2 association
The CRIB domain of PAK is important for its role in p21-GTPase association and
the subsequent activation of PAK2 kinase, and mutations introduced to this domain
abolish GTPase-induced PAK2 activity (Zhao et al., 1998). Previously, Renkema et
al. showed that substitution of two critical histidines with leucines in the CRIB
domain could inhibit the association of Nef and PAK2 (Renkema et al., 2001).
However, it is not clear whether the dependence of NAK complex on a functional
CRIB domain is due to lack of p21-GTPase-mediated activation of PAK2 or a direct
consequence of lost PAK2/Cdc42-interaction. Using PAK2 proteins that were
mutated within the CRIB domain (HH, H82/85L; ISP, I74N/S75P/P77A) in a
cotransfection assay, we showed that both CRIB mutants could not associate with
Nef  (comm.  II,  fig.  5A),  supporting  the  idea  that  the  presence  of  p21-GTPase  was
required for NAK complex formation. To further test this idea, we combined our
CRIB mutants with the autoactive PAK2 mutants D125R and E115K that can
associate with Nef even without Cdc42. However, even when CRIB mutations (HH
or ISP) where combined with conformationally active PAK2 variants to yield
PAK2-E115K-HH/ISP and PAK2-D125R-HH/ISP, these mutants did not associate
with Nef indicating (comm. II, fig. 5B), that presence of the p21-GTPase was
required for NAK association.
However, because the loss of Nef association with active CRIB-mutated PAK2
variants could reflect the mutants’ inability to localize to membranes, we studied the
intracellular localization of PAK2-E115K-HH/ISP and PAK2-D125R-HH/ISP
variants by transfecting them into 293T cells (comm. II, fig. 5C). Subsequently, cells
were fractionated and the localization of these constructs was followed by western
blotting. Interestingly, when cells transfected with these constructs were divided into
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cytosolic and membraneous fractions, the E115K-HH and D125R-HH  mutants were
present on the membraneous fraction in amounts at least equal to, if not greater than,
the p21-binding single mutants PAK2-E115K and PAK2-D125R. This result
strengthened the previous findings on the indispensability of Cdc42 in NAK
complex formation and led us to think that the role of p21-GTPases may physically
stabilize the Nef-PAK2 association.
1.7. Kinase activity of PAK2 in regulation of the Nef-PAK2 complex
The only means to verify the association of Nef with an active fraction of PAK2 has
thus far been the sensitive in vitro kinase activity. However, the finding of p21-
GTPase as an integral part of NAK complex formation led us to hypothesize that the
interaction of p21-GTPase with PAK2 may take place during the activation step,
with quick dissociation after kinase activity has been induced. We tested this idea by
cotransfecting kinase-deficient PAK2 (K278R) with an increasing amount of p21-
GTPase Cdc42V12 into 293T cells and followed the strength of interaction by
western blotting (comm. II, fig. 6). Indeed, in the presence of equal amounts of
PAK2-K278R and Cdc42, we could detect a visible PAK2 coprecipitation signal by
Nef, suggesting that the catalytic inactivity of PAK2 stabilizes the NAK complex. In
support of this view, the NAK complex was not detectable when a similar
precipitation/immunoblotting approach was used for PAK2 wild type.
2. Localization and composition of the Nef-PAK2 complex (II, III)
2.1. Intracellular localization of NAK complex
Nef localizes partly to the cellular membrane compartment due to the myristoyl
residue that is attached to the second amino acid, Gly2. The GTPases Cdc42 and
Rac1 also have the CAAX motif (C is Cys, A is any aliphatic amino acid, and X is
the carboxyl terminal residue) that targets them to the membrane. Once activated by
Cdc42, PAK2 has been shown to localize to the ER (Roig et al., 2000), but most of
the PAK2 is inactive during the growing phase. However, it is not clearly
established  whether  PAK2  is  activated  before  localizing  to  the  membrane  or
membrane localization is a prerequisite of kinase activation. Therefore, we studied
the cellular compartment in which the Nef-PAK2 association would take place by
transfecting 293T cells with both wild type and differentially mutated PAK2
constructs in the presence or absence of Cdc42V12 and compared the relative
abundance  of  both  PAK2 and  Nef  protein,  as  well  as  PAK2 and  NAK activity  in
cytosolic and particulate (membrane) fractions (comm. II, fig. 3). In all samples,
western blotting revealed equal amounts of Nef protein in both fractions, whereas
PAK2 protein was mainly cytosolic. However, when immunoprecipitations and
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subsequent in vitro kinase assays were performed, PAK2 activity was concentrated
on the particulate fraction, with the exception of the PAK2-T402E mutant, whose
activity remained cytosolic. Immunoprecipitations of these samples using an anti-
Nef antibody detected NAK activity in the particulate fraction alone, but no NAK
activity from either fraction was associated with PAK2-T402E. However, if PAK2-
T402E was targeted to the membrane fraction via the CAAX-box attached to its C-
terminus, this protein was capable of associating with Nef (data not shown). Thus,
these data suggest that membrane-association is required for forming the NAK
complex.
Lipid rafts, also referred to as detergent-resistant microdomains (DRMs), are by
definition resistant to the 1% Triton-X treatment routinely used in our lysate
preparation method. Because Nef was previously reported to localize to rafts (Wang
et al., 2000), we wanted to study whether the partitioning of NAK activity to the
particulate fraction is due to its localization into rafts. To this end, the lysates from
cells cotransfected with a constitutively active PAK2-E115K and NL4-3 Nef were
subjected to flotation analysis by ultracentrifugation (comm. II, fig. 4). Successful
flotation of rafts was followed by the presence of the raft marker ganglioside GM1.
The flotation results revealed that PAK2 protein did not localize to any fraction in
particular but was equally distributed throughout the fractions, whereas PAK2
activity was slightly more pronounced in the GM1-containing fraction. Nef protein
was equally distributed between the cytosolic and raft-containing fractions. NAK
activity was strongly concentrated on the raft-containing fraction indicating that
NAK activity is more specifically localized than PAK2 activity. Remembering the
association of Nef with only a small, highly active subpopulation of PAK2, this
result is not surprising but rather expected. The specificity of the Nef-PAK2
interaction in rafts was further underlined by the lack of association of these proteins
despite their presence in cytosolic fractions.
2.2. Nef-mediated recruitment of GEFs to membrane microdomains
2.2.1. Ultracentrifugation of membrane microdomains
In  literature,  GEFs  Vav, b-PIX, and DOCK2/ELMO1 have been implicated as
physical or functional mediators during NAK complex formation (Brown et al.,
1999; Fackler et  al., 1999; Janardhan et al., 2004). The previously described
presence of the NAK complex on DRMs would suggest a similar localization for the
GEF  that  mediates  the  Nef-PAK2  association,  making  DRMs  a  target  site  for
searching and validating the role of GEFs in NAK complex formation (Giese et al.,
2006; Krautkramer et al., 2004; Pulkkinen et al., 2004). To study the possible
involvement  of  Vav, b-PIX, and DOCK2/ELMO1 in NAK complex formation the
presence  of  each  candidate  GEF  in  DRMs  was  first  analyzed  by  membrane
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microdomain floatation studies (comm. III, fig. 1). Each GEF was cotransfected into
JTag cells with either GFP or with GFP fused to either wild type Nef (Nef.GFP) or
SH3-binding deficient mutant Nef-AxxA (AxxA.GFP). Membrane-residing protein
LAT and soluble transferrin receptor (Tfr) were also cotransfected and used as
markers for correct separation of DRM and cytosolic fractions in ultracentrifugation.
Separation of the raft-containing detergent-resistant membranous fraction and the
cytosolic fraction by ultracentrifugation and study of the proteins in these fractions
by western blotting showed that both Nef-WT protein and the AxxA-mutant
localized equally to DRM-containing fraction. Of the GEFs studied, however, both
components of the DOCK2/ELMO1-complex were totally absent from the DRMs.
In concert with these results, the absence of DOCK2/ELMO1 from DRMs was
further confirmed by coexpression of both units of this bipartite GEF. In addition,
the distribution of DOCK2/ELMO1 did not change by cotransfection of Nef, thus
excluding its role in NAK complex formation.
Nef had no effect on the localization of ectopically expressed b-PIX, but unlike
DOCK2 and ELMO1, b-PIX was present in DRMs regardless of the presence or
absence of Nef. Endogenous b-PIX was more prominently present in the DRM
fraction, but alike its transfected counterpart its localization did not change in the
presence of Nef.
Without Nef, transfection of Vav1 into JTag cells resulted in its total absence from
the DRM fraction. However, when either Nef-wt or Nef-AxxA was cotransfected
with  Vav1,  localization  of  Vav1  to  the  DRMs  was  clearly  detectable  with
immunoblotting, suggesting the recruitment of Vav1 to DRMs by Nef. Similar
results were obtained by studying the localization pattern of endogenous Vav1.
However, when fractions were studied for Vav2 or active, phosphorylated Vav1, a
small fraction of these proteins was detectable in DRMs in cells transfected with
GFP alone. These fractions remained unaltered by expression of Nef.GFP and its
derivatives. Altogether these results were compatible with the possible involvement
of b-PIX and/or Vav1 in Nef-PAK2 association but did not support
DOCK1/ELMO2 as a candidate GEF in Nef-PAK2 complex formation.
2.2.2. Confocal microscopy of membrane microdomains
To confirm the results obtained by ultracentrifugation and western blotting
approach, the plasma membrane microdomains of transfected JTag cells were
visualized by confocal microscopy (comm. III, fig. 2). The fluorescently labeled
cholera toxin subunit (CTx), which exclusively binds to the ganglioside GM1, was
used  to  detect  DRMs.  In  concert  with  the  fractionation  results,  the  diffuse
cytoplasmic localization of Vav1 in the presence of GFP was changed towards more
membranous localization in the presence of Nef-WT or Nef-AxxA. Both Nef
60
constructs distributed to the punctuate structure on the plasma membranes and
perinuclear membranes. The presence of the latter structures in only some Z-planal
sections of cells suggest that these structures may represent endosomal membranes
(Haller et al., 2006; Madrid et al., 2005; Thoulouze et al., 2006). The colocalization
of Nef with CTx in the punctate membrane structures identifies these spots as raft-
containing membrane microdomains and implies that Nef is involved in the
recruitment of Vav1 to these sites on cellular membranes.
Coexpression of b-PIX with GFP or Nef.GFP did not have an appreciable effect on
the localization of either protein. The b-PIX was mostly found in the cytoplasm with
occasional accumulation in the CTx-positive clusters, and this distribution remained
unaltered by Nef. However, occasional colocalization of Nef and b-PIX was found
in the CTx-containing microdomains, but that remained less than that of Vav1 and
Nef.
The two components of bipartite GEF DOCK2/ELMO1 were diffusely localized in
the cytoplasm without significant enrichment at the membrane microdomains. The
localization also remained cytosolic irrespective of coexpression of GFP or
Nef.GFP. Altogether, the similarity of these results to the ultracentrifugation
analysis further strengthened the possible role of GEFs Vav1 and/or b-PIX in Nef-
mediated signaling on membrane microdomains.
2.3. GEFs in NAK complex formation
To further address the role of the three GEFs in the association of Nef with PAK, we
developed  a  system to  reduce  the  protein  levels  by  RNAi  in  JTag  cells.  First,  the
maximal range of PAK activity inhibition was estimated by targeting the RNAi
probe against the kinase. Even though PAK2 is typically considered the Nef-
associated kinase, PAK1 has also been referred to as a possible NAK (Fackler et al.,
2000; Nguyen et al., 2006) and was therefore included in the RNAi study.
2.3.1. Knock-down of PAKs
The RNAi oligos targeted against PAK1 or PAK2 were both efficient (knockdown
of PAK1 88% +/- 15%; PAK2 94% +/-10%) and specific in knocking down the
protein  levels  of  their  respective  target  kinases  (comm.  III,  fig  3A).  When  Nef-
associated  PAK2  kinase  activity  was  studied  by  anti-Nef  precipitation  and
subsequent in vitro kinase assay from JTag cells, the control or PAK1-targeted
RNAi probes did not diminish Nef-associated kinase activity, whereas treatment
with PAK2-specific RNAi oligo reduced the activity to 70 % +/-19%, when NAK
signals obtained from IVKA experiments were quantified by phosphoimager
(comm. III, fig. 3C). As expected, the AxxA Nef mutant did not associate with PAK
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kinase to any detectable amount (comm. III, fig. 3B) (Manninen et al., 1998). These
results confirmed that PAK2 is the principal PAK contributing to Nef-associated
kinase activity. Despite the efficient knock-down of PAK2 at the protein level,
PAK2 protein is still present in cells treated with RNAi to the extent that it can be
efficiently recruited by Nef; thus, this complex accounts for the residual activity in
IVKA, most likely due to the very high sensitivity of the IVKA method.
2.3.2. Knock-down of GEFs
After determining the degree of inhibition of Nef-associated kinase activity achieved
by knocking down PAKs, the effect of knocking down the previously studied GEFs
on Nef-PAK2 complex was studied in JTag cells. All the GEF-targeted RNAi
probes resulted in a marked reduction on the expression of their corresponding
target proteins, as quantified by western blotting (comm. III, fig. 4A and 4C) (Vav1,
86% +/- 15%; Vav2, 76% +/- 10%; DOCK2, 97% +/- 5%; ELMO1, 85% +/- 9%;
and b-PIX, 86% +/- 10%). Vav1 RNAi significantly reduced NAK activity, whereas
RNAi targeted against Vav2 or ELMO1 had similar but much less pronounced
effects. No alterations on NAK activity were found as a consequence of DOCK2 or
b-PIX knock-down. Therefore, the RNAi analyses implied a role for Vav1 in the
formation of the Nef-PAK complex but did not support the involvement of b-PIX.
Together with the membrane microdomain analysis, these data suggested that of the
three GEFs previously found to associate with Nef, Vav1 had the most important
role in the formation of the Nef-PAK2 complex.
2.4.  GEF-deficient cell lines and b-PIX-binding-deficient PAK2 in
NAK activity  studies
To strengthen the results from JTag cell line on the contribution of Vav1, as well as
the dispensable role of b-PIX and DOCK2 on Nef-associated PAK2 activity, we
used either cell lines deficient for expression of Vav1 and DOCK2 or a transfection
approach using PIX binding-deficient PAK2.
First, a Vav1-deficient Jurkat cell line (Cao et  al., 2002), JVav, was used to
complement the RNAi studies on the role of Vav1 on Nef-associated PAK2 activity.
In concert with the RNAi results, the capacity of HIV-1 SF2 Nef to associate with
PAK2 activity was reduced by approximately 70% in JVav cells as compared to
JTag cell line (comm. III, fig. 5A). In addition, the reduced NAK activity in JVav
cells was conserved for SIVmac Nef, HIV-1 NL4-3 NefT71R mutant, and patient-
derived HIV-1 Nef variant RP4-11 (comm. III, fig 5B). To confirm the importance
of Vav1 for Nef-PAK2 association, JVav cells were transfected with Vav1 (comm.
III, fig. 5C). This cotransfection increased NAK activity almost to the level of NAK
activity in JTag cells. Because Nef can associate also with Vav2 (Fackler et al.,
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1999), the possible contribution of Vav2 to the residual Nef-PAK2 association in
JVav cells was examined using a Vav2 knock-down approach. Although the knock-
down efficiency of Vav2 was only partial in JVav cells, it reduced NAK activity to
54% +/- 15% for HIV-1 SF2 Nef and 41% +/- 20% for SIVmac239 Nef (comm. III,
fig. 5D). Altogether, these results support the idea that Vav1 contributes to Nef-
PAK2 complex formation, and suggest that Vav2 serves as a substitute GEF in the
absence of Vav1.
To analyze the role of DOCK2 for NAK complex formation, a DOCK2-/- BEa16-3
T-cell hybridoma cell line was used (Sanui et al., 2003). No significant difference in
association of PAK activity either with HIV-1 or SIV Nef was observed using JTag
and BEa16-3 cells (comm. III, fig. 6A), suggesting the dispensability of DOCK2 in
NAK association. Notably however, a 50% reduction in Nef-associated kinase
activity reduction was seen in BEa16-3 cells when Vav1 was knocked-down by
RNAi (comm. III, fig. 6B). Because no cell line with b-PIX-/- genetic background
was available, we used PAK2 mutated for its b-PIX binding site (P185G/R186A)
(Manser et al., 1998) in our experiments (comm. III, fig. 6C). Again, no difference
in either HIV-1 or SIV Nef-associated PAK2 activity was observed in the presence
of either PAK2-wt or b-PIX binding-deficient PAK2 mutant. Combined with the
results of the RNAi experiments and the DRM recruitment studies, these data
supported the idea that Vav1 was the GEF with the most prominent functional role
for Nef-PAK2 complex formation.
2.5.  The  role  of  Nef  residue  F195  in  Nef-PAK2  association  and  Vav1
recruitment
The highly conserved proline-rich SH3-binding domain (PxxP) of Nef has
previously been reported to be critical for association with NAK (Khan et al., 1998;
Manninen et al., 1998; Wiskerchen and Cheng-Mayer, 1996), which fits with the
finding of that SH3-containing Vav1 mediates Nef-PAK2 association. However, this
is not in concert with our data on PxxP-independent recruitment of Nef into the
DRMs. Recent literature has described a hydrophobic protein interaction surface
including a particular residue F195 of SF2Nef, that is specifically involved in
association of Nef and PAK2 (Agopian et al., 2006; Raney et al., 2005). To test the
importance of residue F195 for the formation of the Nef-PAK2 complex, two
mutations F195A and F195I were introduced to the SF2Nef sequence. Both
mutations efficiently impaired association with PAK2 by binding worse than the
previously described association-deficient controls Nef-G2A or Nef-AxxA (comm.
III, fig. 7). Using these mutants in raft flotation experiments and confocal
microscopy (comm. III, fig. 8), we confirmed that the lack of kinase association was
not a consequence of exclusion of F195 mutants from membrane microdomains or
their distinct localization pattern in T lymphocytes. In contrast, both of the mutated
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F195 variants failed to recruit Vav1 into the membrane microdomain-containing
fraction in ultracentrifugation experiments. Respectively, no relocalization of Vav1
from the cytosol to the CTx-rich sites on cell membranes could be detected in the
presence of Nef-F195 mutants. Thus, Nef residue F195 is a critical amino acid in
Nef-PAK2 association, and its involvement in Vav1 recruitment to membrane
microdomains is important for Nef-mediated signaling.
3. The role of putative dimer interface in Nef functions (IV)
Mutations residing in the PDI of Nef have previously been reported to affect several
Nef functions (Fackler et al., 2006; Liu et  al., 2000; Manninen et al., 1998). To
study the functional role of residues R105 and D123, which may contribute to the
stability of Nef dimers, we took advantage of a mutational strategy (comm. IV, fig.
1). We reasoned that reversing either of these charges by R105D or D123R
mutations should inhibit PDI-mediated Nef dimerization, whereas a double mutation
R105D/D123R might rescue the self-association capacity of Nef and the possible
functional defects associated with failed dimerization.
3.1. Enhancement of viral infectivity
HIV-1 Nef has an established role in increasing the infectivity of the virus.
Moreover, mutations within the Nef PDI have been associated with decreased virion
infectivity (Fackler et al., 2006; Liu et al., 2000). To study whether complementary
charges that stabilize the interaction surface are required for the increased viral
infectivity by Nef, we produced empty and Nef-deleted (DNef) control viruses as
well as viruses expressing either Nef wild type or its PDI-mutated counterparts in
293T cells and tested these viruses in viral infectivity assay (comm. IV, fig. 2). All
Nef constructs and viral control proteins p55Gag and p24CA were equally expressed
as analyzed by western blots from producer cells. When the infectivity of these
viruses  was  studied  in  a  single-round  replication  assay  of  TZM  cells,  viruses
expressing wild type Nef were approximately 70% more infectious than DNef
viruses. Introduction of R105D and D123R mutations into Nef dramatically reduced
virion infectivity to the level of Nef-deleted viruses, but the viral infectivity could be
fully restored when the double mutant Nef R105D/D123R was used.
3.2.  Demonstration of Nef dimers by coprecipitation
Taken the central role that has been suggested for R105 and D123 residues in the
self-association of Nef molecules, we investigated whether we could reconstitute
association of Nef molecules by direct immunoprecipitation (comm. IV, fig. 3). To
this end, we transfected 293T cells with Nef R105D, D123R or R105D/D123R
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variants tagged C-terminally either with a myc-epitope or biotinylation sequence
(Nef-PP). Using horseradish peroxidase-conjugated streptavidin detection for cell
lysates immunoprecipitated with anti-myc antibodies, we showed that biotinylated
Nef WT was efficiently pulled down by myc-tagged Nef WT. In comparison to Nef
wt, all three Nef constructs with mutations at the interaction interface showed
reduced coprecipitation efficiency, but none of the Nef variants was fully incapable
of self-association. Despite the decreased coprecipitation of the mutant Nef pairs,
our coprecipitation experiments could not confirm that a R105/D123-mediated
interaction between Nef molecules was involved in Nef dimerization or that the
rescued infectivity of Nef-R105D/D123R in infectivity assay was due to a rescued
capacity to dimerize.
3.3. Association with PAK2 activity
Association with active PAK2 is a common characteristic of HIV-1/2 and SIV Nefs
(Kirchhoff et al., 2004). In addition to the domains within the Nef core (Agopian et
al., 2006; Fackler et al., 2006; Manninen et al., 1998), a specific Nef residue F191
selectively disrupts Nef-PAK2 association without affecting other Nef functions
(Agopian et al., 2006). To test the importance of Nef’s surface charge distribution
for its interaction with PAK2, we transfected 293T cells with either Nef wild type or
Nef-R105D, D123R or R105D/D123R mutants (comm. IV, fig. 4). In addition, Nef-
F191R  was  used  as  a  negative  control  for  PAK2  association.  Cell  lysates  were
subjected to immunoprecipitation with an anti-Nef antibody; coimmunoprecipitated
active PAK was labeled in in vitro kinase assay, run on SDS-PAGE gel and detected
by autoradiography. In accordance with previously described data, wild type SF2
Nef readily associated with active PAK2 (Arora et al., 2000), whereas both Nef-
F191R and R105D did not associate with PAK2. In contrast, Nef-D123R was totally
dispensable for association with PAK2 activity. Moreover, the doubly mutated Nef-
R105D/D123R markedly, though not completely, restored the Nef-R105D-PAK2
association.
3.4. Membrane association
Membrane  association  of  Nef  is  mediated  largely  by  myristoylation  of  its  N-
terminus (Yu and Felsted, 1992). We and others have previously demonstrated that
the Nef-PAK2 complex specifically localizes to cellular membranes (Krautkramer et
al., 2004; Pulkkinen et al., 2004). Therefore it was of interest to study whether the
capacity of Nef mutants to associate with active PAK2 would correlate with their
ability to associate with membranes. To this end, we transfected 293T cells with Nef
wt or mutated Nef variants, fractionated the cells into cytosolic and particulate
fractions, and followed the distribution of Nef protein by western blot analysis of
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these fractions (comm. IV, fig. 5). As expected, most Nef protein was detected in the
cytosolic fraction. Nef wt and Nef-D123R proteins were also robustly detectable in
the particulate fraction, whereas the amount of Nef-R105D protein on the particulate
fraction was reduced. However, like PAK2 activation, this defect could be rescued
by a dual mutation, and Nef-R105D/D123R again fractionated like Nef wt.
3.5. Hck activation
Src tyrosine kinase Hck is an important mediator of Nef effects in hematopoietic
cells. Forced oligomerization and hydrophobic patch residues of Nef have
previously been shown to contribute to the association and activation of Hck by Nef
(Choi and Smithgall, 2004; Ye et al., 2004), but more detailed characterization on
the role of charged residues in Nef self-association surface is lacking. To address the
importance of the charge distribution on Nef interaction surface during Hck
activation, we transfected 293T cells with Hck fused to a biotinylation tag (Hck-PP)
together with Nef wild type or its mutated derivatives. Hck was precipitated from
cell lysates using streptavidin beads, and its phosphorylation status was detected
with a specific antibody that recognizes phosphorylated S211 and Y209 residues,
which are associated with release of Hck autoinhibition upon activation (comm. IV,
fig. 6). As expected, Nef wt induced robust phosphorylation of Hck, whereas no Hck
phosphorylation signal was detected by the negative control Nef-AxxA. When Nefs
carrying charge-reversing mutations were assayed, Nef-R105D was as efficient as
Nef wild type in its ability to activate Hck. In contrast, Nef-D123R was clearly less
efficient in Hck phosphorylation. Again, this effect could be rescued by introducing
the reciprocal D123R mutation to the PDI, resulting in wild type-like Hck activation
via Nef-R105D/D123R.
66
DISCUSSION
1. Activation of PAK2 by Src kinases and the role of activation in Nef-
PAK2 association
Compared to its relatively small size, HIV-1 pathogenicity factor Nef possesses a
stunning multiplicity of associating proteins and cellular functions. Structurally, the
flexible arm and loop domains provide conformational flexibility that enables its
adaptor function. The multitude of Nef functions and interactions has also been
envisioned as a consequence of the “Nef-cycle”: the conformational differences
between closed, membrane-bound Nef, and open, cytosolic protein (Arold and Baur,
2001).
Many Nef interactions with endogenous host cell proteins have clearly defined
functional consequences, but the in vivo effects of Nef-PAK2 association have
remained elusive. The ability of Nef to selectively associate with the highly active
PAK2 species led us to elucidate the intracellular mechanisms leading to increased
kinetic activity of PAK2. In this study, a novel mode of PAK2 superactivation by
the sequential action of p21-GTPases and SFKs was described. In resemblance to
the conformation-dependent potentiation of PAK2 activity described in
communication I, we also found that the association of PAK2 with Nef required
structural alterations in the kinase. NL4-3 Nef associated with PAK2 only after p21-
GTPase-stimulated PAK2 activation or when an ‘open-conformation’ mutant
PAK2-D125R was used. The lack of Nef association with PAK2-T402E, even after
p21 stimulation, suggested that here the opened conformation of PAK2 molecule
was critical for NAK activity. The capacity to associate with PAK2 activity is a
conserved function of various Nef alleles (Kirchhoff et al., 2004). However, Nefs
varied greatly in their ability to themselves stimulate PAK2 activity, as shown by
the results in communication II. Our findings suggest that activation of PAK2 by
Nef and Nef’s association with PAK2 are mechanistically separate functions,
although the capacity of Nef to associate with active PAK2 is used as an indicator of
its capacity to activate PAK2. The capability of the HIV-2cbl Nef allele to activate
PAK2 without associating with PAK implied that Nef may also modulate protein
activities that affect PAK activity, e.g. signaling pathways upstream of p21-
GTPases, without requirement of direct association. The fact that several described
Nef-interacting proteins are GEFs, i.e. activators of p21-GTPases, further underpins
this view.
Despite the obviously important role of catalytic PAK2 activity for its interaction
with Nef, the strong destabilizing effect of kinase activity was also a limiting factor
for Nef-PAK2 association. The cotransfection studies using kinase-dead PAK2
together with Cdc42 and Nef showed that decreased kinase activity resulted in a
more stable complex that could be visualized even with coimmunoprecipitation and
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subsequent western blotting, which has not been possible for NAK complex
possessing wild type PAK2 activity. The highly transient nature of the complex
formed by PAK2 wild type, p21-GTPase, and Nef may thus explain the difficulties
in its detection.
2. Composition of the Nef-PAK2 complex
Because both Nef and active PAK2 have previously been detected in the cell
membranes, it was not surprising that the Nef-PAK2 complex localized to rafts, also
defined as DRMs. At the time of our publication (Pulkkinen et  al., 2004), the
association of NAK with DRM was also shown by another group, but in addition to
the presence of NAK complex in DRMs, their work suggested Nef as a factor to
recruit PAK to membranes with subsequent activation (Krautkramer et al., 2004).
Our experiments did not confirm the contribution of Nef in recruitment of PAK2 to
membranes, since active PAK2 was equally present in the raft fraction both in the
presence and absence of Nef. Nef was also detected in fractions other than the raft-
specific one, yet NAK activity was clearly most abundant in the raft-containing
fraction, which may indicate that other proteins, such as GTPases, are limiting
factors that target the active NAK complex specifically to rafts (del Pozo et al.,
2004).
By using a number of doubly mutated PAK2 variants (PAK2-E115K-CRIB/ISP and
PAK2-D125R-CRIB/ISP) with open conformation and deficiency in p21GTPase-
binding, we showed that localization of PAK2 to the particulate fraction was not
dependent on the p21-GTPase activity. A very recent study by Parrini et al. has
described a three-stage activation cascade of PAK, where the authors suggest that
the first ‘semi-activation state’ of PAK is achieved by membrane targeting induced
by interaction with Nck/Grb2 adaptor proteins (Parrini et  al., 2009) required to
expose PAK for further activation by GTPases and by other associating proteins. In
concert with our findings, this model supports the role of GTPases as PAK-
stimulating, but not membrane-recruiting factor per se. Despite the ability of CRIB-
mutated PAK2-E115K and PAK2-D125R variants to traffic to membranes, they
could not associate with Nef. This implies that p21-binding has more significant
effect on NAK complex formation than solely the activation of PAK2. In support of
this view, we could indeed confirm the role of Cdc42 in stabilizing the Nef-PAK2
interaction by experiments using kinase-dead PAK2 and Nef in the
immunoprecipitation studies in communication II.
The presence of an SH3-containing protein as a mediator of Nef-PAK2 interaction
has often been discussed, because the association of the two is abolished by
mutating the SH3-binding domain in Nef (Manninen et al., 1998). The detailed
composition of the Nef-PAK2 complex has however remained elusive due to its
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transient nature and the difficulties with direct detection of associating proteins. In
communication III, we used a combination of approaches to overcome the
limitations of each method, and characterized Vav1 as a GEF binding partner
associated with the NAK complex. Indeed, Vav1 has previously been suggested as a
possible SH3-containing mediator protein required for Nef-PAK2 association
(Fackler et al., 1999; Quaranta et al., 2003; Vilhardt et al., 2002). Unexpectedly,
however, we found that the proline-rich domain in Nef was not required for
recruitment of Vav1 to the NAK complex, but the interaction was dependent on Nef
F195 residue, recently depicted as critical for the Nef-PAK2 association (Agopian et
al., 2006). This finding leaves the PxxP-binding component of the PAK2-Nef
complex uncharacterized, leaving the possibility of yet another, unidentified protein
component open. Moreover, the SH3-PxxP interaction by Nef and Vav1 may
stabilize the complex or Vav GEF activity rather than recruit protein components,
which could explain the irrelevant role of the proline-rich Nef domain in recruitment
studies.
Although both DOCK2/ELMO1 and b-PIX have been reported to associate with
Nef, the experimental strategies used here did not confirm their role in the Nef-
PAK2 complex. The absence of DOCK2/ELMO1 in DRMs or CTx clusters in cells
expressing Nef argued against a role of this GEF in Nef-PAK2 association.
Furthermore, the use of DOCK2-deficient BEa16-3  cells  verified  that  DOCK2
expression was dispensable for NAK activity. These results are not in conflict with
the original findings by Janardhan et al. on association of Nef with DOCK2/ELMO1
(Janardhan et al., 2004), but they support the idea of association of Nef-PAK2 in a
separate complex independently of DOCK2/ELMO1.
In a similar manner, RNAi knockdown of b-PIX or the use of PIX-binding deficient
PAK2 mutants did not significantly affect the association of Nef with PAK2
activity, suggesting dispensability of b-PIX for Nef-PAK2 association. Although
this GEF has previously been shown as a physical component of the Nef-PAK2
complex (Vincent et al., 2005) and as a substrate of PAK2 (Brown et al., 1999), it is
possible that b-PIX associates with Nef-PAK2 complex as a more peripheral
component that does not contribute to PAK2 activity or acts as a downstream
effector of the NAK complex (Simmons et al., 2005).
The SFK family members Fyn and Lck, studied in communication I, are both central
kinases that mediate the downstream signaling initiated by TcR stimulus and play an
important role in T cell development and activation of mature T cells (Salmond et
al., 2009). The activation of SFKs, in particular Lck and Fyn, is one of the earliest
events in intracellular signaling after TcR ligation, followed by the formation of the
proximal signaling complex that initiates the downstream signaling cascade. Several
components of the proximal signaling complex, such as ZAP-70, Nck, and Vav1
have been described as mediators of PAK activity and/or localization (Bokoch et al.,
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1996; Fackler et al., 1999; Ku et al., 2001; Lu et al., 1997). Redistribution of Lck by
Nef, as well as Nef-induced interference with cell spreading and actin remodeling
upon TcR stimulus have been associated with impaired formation of the
immunological synapse (Haller et al., 2007; Thoulouze et al., 2006). In addition, a
recent report shows that Nef can alter cell motility in a PAK-dependent manner
(Stolp et al., 2009). The identity of the protein that Nef initially targets to result in
Nef-PAK2 association is unclear. However, these current data from T cells suggests
that NAK activity may provide the virus a means to modulate host cell migratory
properties. The third SFK studied in communication I, Hck, is different from Lck
and Fyn, because it is most abundantly expressed in phagocytic cells. There, it is
involved in phagocytosis, cell movement and actin remodeling (Guiet et al., 2008).
Interestingly, the capacity of Nef to activate Hck by direct SH3-mediated binding
also places Nef as a potential upstream activator of PAK2 via Src kinases. Although
no direct evidence that Hck, PAK2 and Nef are present in the same multiprotein
complex exists, this does not exclude the possibility that these proteins and
activation events could take place within the same signalosome. Accumulating
knowledge on the multitude on proteins participating in the TcR signaling has made
it evident that these signaling cascades are not linear, starting from the TcR ligation
and ending at transcriptional regulation at the nucleus. Instead, complex feedback
and feed forward regulation is present at each step.
3. The PDI and Nef functions
Initially, evidence on Nef oligomerization was provided by X-ray crystallography
(Arold et al., 2000; Lee et al., 1996) and NMR spectroscopy studies (Grzesiek et al.,
1997) suggesting self-association of Nef core domains. These interactions were
mediated by conserved Nef core residues and further stabilized by the
complementary charges of R105 and D123. The amino acids of this hydrophobic
patch on the Nef core domain have been later reported to have roles in several Nef
functions, including downregulation of CD4 and MHC I, viral infectivity increase,
as well as NAK activity (Liu et al., 2000; Manninen et al., 1998). In communication
IV, we reciprocally mutated the stabilizing residues R105 and D123 in the PDI of
Nef. The fact that single complementary mutations of these residues led to
aberration of several critical Nef functions that could be rescued by the reciprocal
charge reversion at both sites supports the idea that the PDI can mediate self-
association of Nef and that the functional consequences of single mutations are due
to failed self-association of Nef.
Our initial hypothesis was that disrupting Nef dimerization mediated by reciprocal
charges of R105 and D123 would result in a severely defective or full loss-of-
function phenotype in Nef. Respectively, functional phenotype could be restored
when a double mutation R0109D/D123R was introduced, indicating recovery by
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restored dimerization capacity. This explanation, however, seems oversimplified.
The results obtained in immunoprecipitation experiments where mutations
introduced to the PDI had only a minute inhibitory effect on the Nef self-association
capacity also support this view. In addition to structural predictions and NMR
techniques, previous studies have used immunoblotting and Nef-fused inducible
dimerization domain approaches to demonstrate oligomerization of Nef. Our results
are not in conflict with these findings, as precipitation of Nef wt molecules also
occurred in our experiments; rather, our studies suggest that the reciprocal charges
by R105 and D123 are not a determining factor to putative dimerization of Nef.
However, they clearly contribute to Nef functions, possibly by coordinating Nef
conformation. Another contributing mechanism to the readily detectable self-
association by Nef-R105D and D123R mutants may be that, in addition to
dimerization, Nef molecules form higher oligomers in a manner that is independent
of PDI residues. Formation of such large multimers has been suggested, implicating
that Nef oligomers may have further tendency to aggregate (Fujii et al., 1996).
Altogether, results obtained in communication IV suggest that the charges provided
by Nef residues R105 and D123 coordinate its various functions. This may rather be
due to the important contribution provided by these charges to the interactions
formed between Nef and endogenous signaling proteins instead of a strong
functional role of Nef self-assembly in vivo. However, these data do not exclude the
possibility of Nef dimer formation, especially in conditions where other cellular
interaction partners are sparse. Our results provide novel in vivo insight into the self-
association of Nef, whose role in Nef functions has previously only been based on in
vitro data.
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CONCLUSIONS AND PERSPECTIVES
HIV-1 Nef affects a variety of signaling cascades and other crucial activities in an
infected cell by interacting with endogenous proteins. Given the role of Nef as a
critical pathogenicity factor of HIV-1, characterizing Nef interactions and their
functional consequences in vivo is necessary to identify potential target molecules
for therapeutical intervention.
In this work, we have analyzed the association of Nef with a serine/threonine kinase
PAK2. We identified PAK2 as a convergence point for Src kinase- and p21-
GTPase-mediated signaling. The central role of these cascades in T cell signaling
and regulation of actin remodeling suggests that the superactivation of PAK2 by the
two convergent signals may contribute to the adhesion and migratory properties of
cells. In addition to p21-GTPases, conformational changes associated with PAK2
activation were also found necessary for its association with Nef. Interestingly
however, we also showed that Nef could activate PAK2 without their direct
association within the same protein complex. This implies that Nef may modulate
PAK2 activity via currently uncharacterized mechanisms.
The association of Nef and PAK2 is dependent on the PxxP domain of Nef. As
PAK2 lacks SH3 domain, this implies the presence of an additional SH3 domain-
containing protein. In this work, SH3 domain-containing Vav1 was found to be the
GEF component of the Nef-PAK2 complex. Unexpectedly, however, Vav1
recruitment to the Nef-PAK2 ‘signalosome’ was not mediated by the Nef PxxP
domain, although Nef association with Vav1 has previously been mapped to Vav1
SH3. This leaves the identification of yet another complex component open for
future study.
Our experiments to elucidate the functional role of the Nef PDI indicated that
several Nef functions were defective upon the single mutation of the complementary
charges R105 and D123, but these functions could be rescued by the double
mutation that caused a reciprocal charge change. The importance of the
complementary charges for Nef functions suggested that the PDI could also be
envisioned as a potential target site for Nef-inhibitory drugs.
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The involvement of p21-activated kinases (PAKs) in important cellular processes such as regulation of the
actin skeleton morphology, transduction of signals controlling gene expression, and execution of programmed
cell death has directed attention to the regulation of the activity of these kinases. Here we report that activation
of PAK2 by p21 GTPases can be strongly potentiated by cellular tyrosine kinases. PAK2 became tyrosine
phosphorylated in its N-terminal regulatory domain, where Y130 was identified as the major phosphoacceptor
site. Tyrosine phosphorylation-mediated superactivation of PAK2 could be induced by overexpression of
different Src kinases or by inhibiting cellular tyrosine phosphatases with pervanadate and could be blocked by
the Src kinase inhibitor PP1 or by mutating the Y130 residue. Analysis of PAK2 mutants activated by amino
acid changes in the autoinhibitory domain or the catalytic domain indicated that GTPase-induced conforma-
tional changes, rather than catalytic activation per se, rendered PAK2 a target for tyrosine phosphorylation.
Thus, PAK activation represents a potentially important point of convergence of tyrosine kinase- and p21
GTPase-dependent signaling pathways.
The mammalian family of Saccharomyces cerevisiae Ste20-
like kinases consists of six members known as p21-activated
kinases 1 to 6 (PAK1 to -6). Phylogenetic analysis clusters the
more recently identified PAK4, PAK5, and PAK6 as a distinct
subfamily (PAK-II) separate from that of PAK1, PAK2, and
PAK3 (PAK-I subfamily) (10, 15). The majority of the pub-
lished data on PAK kinases still concern the members of the
PAK-I subfamily, which serve important cellular functions in-
volved in regulation of the actin cytoskeleton morphology,
transduction of signals controlling gene expression, and execu-
tion of programmed cell death (for reviews, see references 3
and 11).
All PAKs contain a conserved serine/threonine kinase do-
main that comprises the C-terminal half and an N-terminally
located p21-binding domain (PBD; also called the Cdc42/
Rac-1 interactive binding [CRIB] domain) (24). PAK-I mem-
bers also contain several characterized motifs for the interac-
tion with signaling molecules (3, 11). These motifs include an
N-terminal proline-rich region (PxxP motif), which can target
PAKs to the plasma membrane and mediate interactions with
transmembrane growth factor receptors via binding to the sec-
ond SH3 domain of the adapter protein Nck (4, 22, 38), and
another SH3-ligand motif that mediates binding to the alpha-
PAK-interacting exchange factor (-PIX) and -PIX (also
called COOL-1 and COOL-2, respectively) (5, 25). The cellu-
lar substrates of PAK that mediate the downstream effect of
these kinases are still incompletely characterized but have been
reported to include Bad and myosin heavy and light chains, as
well as myosin regulatory light chain kinase, LIM kinase,
Raf-1, p47phox, and MEK-1 (11).
The emerging roles of PAK kinases in regulation of multiple
fundamental cellular processes have directed significant atten-
tion into understanding how the activity of these kinases is
controlled. Biochemical and structural studies have revealed
autoinhibition of the C-terminal catalytic domain by the N-
terminal domain as the key mechanism in regulation of PAKs.
Several layers of inhibition, involving dimerization and occu-
pation of the catalytic cleft by contacts between the N- and
C-terminal domains, keep the catalytic activity of PAK kinases
in check (21; reviewed in reference 14). Autoinhibition of
PAK1 has recently been shown to occur in trans, meaning that
the inhibitory domain of one PAK1 molecule interacts with the
kinase domain of another PAK1 molecule (30). Association of
GTP-bound forms of Cdc42 or Rac1 with the PAK PBD/CRIB
domain induces conformational changes in the N-terminal do-
main that no longer support its autoinhibitory function. Thus,
the activity of PAKs can be induced by a variety of extracellular
signals that control the cellular factors that regulate the GTP
association state of Cdc42 or Rac1. As alternative or comple-
mentary mechanisms for p21-mediated PAK activation, bind-
ing of certain sphingolipids, such as sphingosine, and caspase-
catalyzed proteolytic cleavage between the N- and C-terminal
domains (in the case of PAK2) have also been shown to be able
to overcome PAK autoinhibition (7, 19).
Autophosphorylation of serine and threonine residues is
another key event in establishing and maintaining a catalyti-
cally active state of PAKs. Of the several serine residues that
become phosphorylated upon PAK activation, Ser141 (num-
bered according to PAK2) has been reported to be particularly
important (8). Similarly to that of many other kinases, phos-
phorylation of the activation loop in the kinase domain of PAK
plays a dominant role the activation process (12, 37). The site
of this phosphorylation is Thr402, which is the only threonine
residue that becomes autophosphorylated in PAK (12, 23). An
acidic T402E substitution of this residue is sufficient to render
PAK catalytically active autonomously of the N-terminal reg-
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ulatory region. It has been suggested that the earliest stages of
PAK activation in cells may involve phosphorylation of this
threonine residue by 3-phosphoinositide-dependent kinase-1
instead of by PAK autophosphorylation (17).
The catalytic activity of PAKs is accompanied by a shift in
the electrophoretic mobility in sodium dodecyl sulfate (SDS)-
polyacrylamide gels towards forms of higher apparent molec-
ular weight (7, 17). An observation that focused our interest on
PAK regulation was that pathogenicity factor Nef of human
immunodeficiency virus type 1 specifically associated with a
high-molecular-weight species of PAK2 which, despite its low
relative abundance, accounted for most of the cellular PAK2
activity (31, 32). Our present studies, aimed at characterization
of the mechanisms that govern generation of this highly active
PAK2 species, have revealed a novel and potentially important
feature of PAK regulation. Here we show that induction of
PAK2 activity via p21 GTPases can be strongly potentiated by
concurrent stimulation of cellular tyrosine kinase activity. Over-
expression of various Src kinases or treatment of cells with the
tyrosine phosphatase inhibitor pervanadate had little effect on
PAK2 activity on their own but enhanced the ability of Cdc42
or Rac1 to stimulate PAK2 activity. This potentiation was
mediated by phosphorylation of Y130 in the N-terminal regu-
latory domain. Together, the biochemical and genetic data
from these studies support a model in which p21 GTPase
binding-induced conformational changes render PAK2 a sub-
strate for subsequent Src kinase-mediated tyrosine phosphor-
ylation, leading to a robust enhancement of the catalytic activ-
ity of PAK2.
MATERIALS AND METHODS
Cell culture, transient transfections, and pervanadate treatment. 293T human
embryonic kidney cells (American Type Culture Collection) were maintained
under standard culture conditions. Transfections were performed using Lipo-
fectamine transfection reagent (Gibco BRL) according to the manufacturer’s
instructions. Cells were used for experiments 48 h after transfection. Pervanadate
was freshly made for every experiment by incubating 100 l of 100 mM sodium
orthovanadate with 9 l of 30% H2O2 in a final volume of 200 l for 15 min at
room temperature and was kept on ice until use. Pervanadate was added to the
transfected cell in a final concentration of 250 M for 15 min, after which the
cells were placed on ice, washed with ice cold phosphate-buffered saline, and
lysed.
Plasmids and construction of PAK2 mutants. The PAK2-encoding insert was
cloned in a pEBB eukaryotic expression vector with either a MycHIS-HA (hem-
agglutinin) multiepitope (ME) tag (32) or a MycHIS (MH) tag. Since the ME tag
used in our previous studies contains a HA tag with potential tyrosine phosphor-
ylation sites, the MH-tagged proteins were used in most experiments. Unless
otherwise indicated in the respective figure legend, the PAK2 constructs were
MH tagged. All PAK2 mutants were made by overlap PCR, using a specific
mutant primer pair and common outer primers containing restriction sites used
for cloning. The expression plasmid for dominant active (V12) Cdc42V12 was
kindly provided by B. Mayer.
As a substrate for the PAK2-kinase assays, we cloned three tandem copies of
the 7-amino-acid peptide of the Rous sarcoma virus nucleocapsid (KKRKSGL)
in frame with glutathione S-transferase (GST) into the bacterial expression
vector pGEX-4T-1 (Amersham Biosciences). This peptide was shown by Tuazon
et al. to contain the consensus substrate sequence for PAK2 (36). In contrast to
myelin basic protein, this substrate did not promote p21-independent activation
of PAK2 (data not shown).
Immunoprecipitations and in vitro kinase assays. Immunoprecipitations using
anti-Myc (9E10) antibodies and subsequent in vitro kinase assays (IVKA) were
performed as described previously (32). When indicated, bacterially produced
GST-substrate peptide fusion protein (100 g/ml) was added to the IVKA
reaction mixture. To visualize incorporation of 32P into the substrate peptide, a
fraction of the kinase assay was analyzed using SDS–12% polyacrylamide gel
electrophoresis (PAGE).
Tyrosine dephosphorylation using PTP-1B. Protein tyrosine phosphatase 1B
(PTP-1B) was expressed in bacteria as a GST fusion protein and purified from
the lysed cells by using glutathione Sepharose beads (Amersham Biosciences).
PAK2 was immunoprecipitated from cell extracts, and beads were washed in
IVKA lysis buffer and equilibrated in dephosphorylation buffer (25 mM Tris [pH
7.6], 10% [vol/vol] glycerol, 1 mM dithiothreitol, 0.1 mM EDTA, 0.01% Nonidet
P-40, including protease inhibitors). The beads were split in two identical sam-
ples and incubated with or without GST-PTP-1B (10 g/ml) for 30 min at 35°C.
After the incubation, the beads were washed in IVKA buffer and subjected to
IVKA.
In vivo labeling and phosphoamino acid analysis. Transfected cells were
washed with phosphate-free medium (minimum essential medium without so-
dium phosphate) (Sigma) supplemented with 20 mM Ultraglutamine-1 (Biowhit-
taker) and starved in this medium for 1 h. [32P]orthophosphate (10 mCi/ml;
Amersham Biosciences) was added to achieve a concentration of 0.5 mCi/ml, and
cells were labeled for 3 h. After pervanadate treatment, the cells were washed
with ice-cold phosphate-buffered saline and lysed in IVKA lysis buffer. Lysates
were cleared by centrifugation (10 min, 16,000  g) and immunoprecipitated
with anti-Myc antibodies. After extensive washing with IVKA lysis buffer, the
immunoprecipitates were boiled in SDS-PAGE sample buffer and separated by
SDS–8% PAGE. Proteins were transferred to polyvinylidene difluoride mem-
brane (Bio-Rad), and after exposure to X-ray film, the labeled PAK2 band was
excised. The membrane piece was boiled in 6 M HCl at 110°C for 1 h. Hydrolyzed
amino acids were processed as described previously (16), mixed with unlabeled
phosphoamino acid standards, and separated on cellulose thin-layer chromatog-
raphy plates (20 cm long by 20 cm wide; Merck) by electrophoreses, using a
HTLE-7000 system for 30 min at 2,000 V in pH 1.9 buffer (formic acid [88%]/
acetic acid/water ratio, 50:156:1,794) in the first dimension and for 20 min at
1,600 V in pH 3.5 buffer (acetic acid/pyridine/water ratio, 10:1:189) for the sec-
ond dimension. Plates were stained with ninhydrin to visualize the unlabeled
standards; labeled amino acids were visualized by autoradiography.
RESULTS
Synergistic regulation of PAK2 activity by Cdc42 and Src
family tyrosine kinases. As analyzed by IVKA and SDS-gel
electrophoresis, activation of PAK2 by cotransfection of a
dominant active variant of Cdc42 (Cdc42V12) into 293T cells
resulted in increased PAK2 autokinase activity and the appear-
ance of slower-migrating, differentially phosphorylated PAK2
species (Fig. 1A, two leftmost lanes). In agreement with the
previous data of Renkema et al. (32), the Cdc42-induced high-
molecular-weight PAK2 species exhibited a very high specific
activity, as this band became intensely labeled in the kinase
reaction whereas only the PAK2 species migrating below was
abundant enough to be detected by immunoblotting. Similar
results were obtained when a dominant active variant of Rac1
was used instead of Cdc42 (not shown).
To study possible involvement of tyrosine kinase signaling
pathways in modulation of p21 GTPase-mediated PAK activa-
tion, we transfected cells with various combinations of PAK2,
Cdc42V12, and different Src family tyrosine kinases, including
Fyn, Hck, and Lck. As shown in Fig. 1A, overexpression of
these kinases alone had only a marginal effect on PAK2 kinase
activity and no effect on the mobility of PAK2 protein. Strik-
ingly, however, overexpression of both Cdc42V12 and a Src
kinase resulted in a significant potentiation of PAK2 autoki-
nase activity.
To study whether endogenous tyrosine kinases could have a
similar effect on PAK2 activation, we treated the Cdc42V12-
transfected cells with pervanadate, a potent inhibitor of ty-
rosine phosphatases. This also resulted in a strong increase in
PAK2 kinase activity (Fig. 1B), which was equally evident when
assayed as autophosphorylation (top panel) or as kinase activ-
ity towards a peptide containing three copies of a PAK2-sub-
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strate consensus sequence (36) (bottom panel). As was ob-
served by transfecting Src kinases, pervanadate stimulation had
little effect unless the cells were cotransfected with an active
p21 GTPase. Similar synergistic PAK2 activation by pervana-
date was observed in COS-7 cells and in 3T3 cells transfected
with either Cdc42V12 or Rac1V12 (data not shown). Pretreat-
ment of cells before the pervanadate stimulation with PP1, a
pharmacological inhibitor of Src kinases, abolished the poten-
tiation of Cdc42-induced PAK2 activation in a dose-dependent
manner (Fig. 1C). We therefore concluded that the endoge-
nous tyrosine kinase involved in the synergistic activation of
PAK2 was likely to be a Src kinase family member also.
When PAK2 was immunoprecipitated from pervanadate-
treated cells that had not been transfected with Cdc42V12 and
was only subsequently activated in vitro by using GTPS-
loaded recombinant Cdc42, no difference in the extent of ac-
tivation of PAK2 derived from pervanadate-treated or control
cells was observed (Fig. 1D). This suggested that induction of
cellular tyrosine phosphorylation could not prime PAK2 for
subsequent activation by p21 GTPases and that the reverse
order of events was the case.
PAK2 becomes directly tyrosine phosphorylated. We next
wanted to determine whether the synergy of Src kinases and
p21 GTPases involved direct tyrosine phosphorylation of
PAK2. Probing anti-PAK2 immunoprecipitates from differen-
tially transfected and stimulated cells with anti-phosphoty-
rosine antibodies gave no specific signal, indicating that, re-
gardless of whether Cdc42V12 was transfected or not, the bulk
of PAK2 did not become tyrosine phosphorylated even upon
pervanadate treatment (data not shown). However, consider-
ing that the slower-migrating, superactivated species of PAK2
was not abundant enough to be detected by anti-PAK2 immu-
noblotting (Fig. 1), anti-phosphotyrosine Western blotting
would not be expected to be a suitable strategy for examining
the phosphorylation status of this subpopulation of PAK2.
Therefore, a more sensitive experimental strategy was
adopted. PAK2, radiolabeled by IVKA, was eluted from the
immunobeads and reprecipitated using an anti-phosphoty-
FIG. 1. Potentiation of Cdc42-induced catalytic activation by overexpression of Src family kinases or by inhibition of cellular tyrosine kinase
activity. (A) PAK2 was transfected into 293T cells in various combinations with or without different Src kinases and Cdc42V12, as indicated. PAK2
proteins were precipitated with an anti-Myc antibody and subjected to autophosphorylation in the presence of [32P]ATP. Half of the radiolabeled
reaction mixtures were analyzed by anti-Myc Western blotting (lower panel), and the other half were analyzed by direct autoradiography of the
gel (upper panel). PAK2 autophosphorylation in each lane was quantified by phosphorimager analysis of the gel and is indicated as a severalfold
increase relative to the value obtained without cotransfection of Cdc42V12 and a Src kinase. (B) PAK2 expression, autokinase activity, and kinase
activity towards the substrate peptide, with () or without () cotransfection of Cdc42v12, was examined as for panel A. Instead of Src kinase
overexpression, however, tyrosine phosphorylation was induced by addition of pervanadate (PV) 15 min before lysis of the cells as indicated. PAK2
autophosphorylation and kinase activity in each lane was quantified by phosphorimager analysis of the gel and is indicated as a severalfold increase
relative to the value obtained without activation. (C) Graph representation of phosphorimager-quantified autophosphorylation of PAK2 from cells
cotransfected with PAK2 and Cdc42V12, analyzed as for panel B. The leftmost bar is normalized to 100% and represents PAK2 autokinase activity
without pervanadate treatment (). The four other bars indicate PAK2 activity in cells treated with pervanadate alone () or in combination with
a 45-min pretreatment with Src kinase inhibitor PP1 (1, 5, or 15 M). (D) The effect of pervanadate treatment of cells on PAK2 activity was
examined as described above, except that PAK2 was transfected in the absence of Cdc42V12 or other activator proteins. Instead, PAK2 activity
in half of the immunoprecipitated material was induced in vitro by addition of recombinant GTPS-loaded Cdc42 into the IVKA reaction mixture
as indicated.
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rosine antibody (PY20) or an anti-PAK (anti-Myc-tag) anti-
body as a positive control. As shown in the upper panel of Fig.
2, cotransfection of Cdc42V12 together with pervanadate
treatment resulted in a PAK2 subpopulation that could be
readily reimmunoprecipitated with the anti-pTyr antibody. By
contrast, cotransfection of Cdc42V12 alone did not give rise to
a PAK2 subpopulation that could be detected by the anti-pTyr
antibody. Most notably, pervanadate treatment of cells not
transfected with Cdc42V12 failed to induce significant tyrosine
phosphorylation of PAK2. Similar results were also obtained
with a different monoclonal anti-pTyr antibody (4G10; data
not shown). In anti-pTyr precipitates from pervanadate-
treated cells, an additional upper band was also seen. We have
previously noted this protein to be phosphorylated in anti-
PAK2 IVKA assays. And we believe it to be PIX or a PIX-
associated protein, as its presence was dependent on an intact
PIX-binding motif in PAK2 (32). Indeed, when a PAK2 mu-
tant with a disrupted PIX-binding motif was used, this protein
was not seen (data not shown). Notably, this had no effect on
the ability of the anti-pTyr antibodies to reimmunoprecipitate
PAK2, indicating that PIX or another PIX-associated phos-
phoprotein, such as G-protein-coupled receptor kinase-inter-
acting target (GIT) or paxillin, did not help to mediate pre-
cipitation of PAK2 by the anti-pTyr antibodies.
To determine which tyrosine residues in PAK2 were the
targets for phosphorylation, a mutagenesis approach was un-
dertaken. Since human PAK2 contains 11 tyrosine residues, we
first determined in which part of the protein the target tyrosine
residue(s) was located by making use of the ability of PAK2 to
be cleaved by caspase 3 between residues 212 and 213 (35).
Reimmunoprecipitations of the caspase 3 cleavage fragments
of PAK2 indicated that only the N-terminal half of PAK2 was
tyrosine phosphorylated (data not shown). Therefore, we mu-
tated the three tyrosine residues found in the N-terminal half
of PAK2 into phenylalanines to create the mutants Y130F,
Y139F, and Y194F and used the reimmunoprecipitation assay
to test their capacity to become tyrosine phosphorylated (Fig.
2, bottom panel). Comparison of the abilities of the anti-Myc
and anti-pTyr antibodies to precipitate the mutant proteins
revealed that the Y130F mutation alone almost completely
abolished tyrosine phosphorylation. By contrast, the Y139F
could still be recognized by the anti-pTyr antibody. Also, the
Y194F mutation appeared to decrease the relative ability of
anti-pTyr (compared to anti-Myc) to precipitate this protein,
suggesting that Y194 may be an additional phosphoacceptor
site. As expected, when all three mutations were combined into
the same molecule (Y130/139/194F), the anti-pTyr precipita-
tion was completely lost.
In agreement with the reimmunoprecipitation findings,
phosphoamino acid analysis of cells labeled in vivo with
[32P]orthophosphate revealed a phosphotyrosine signal from
the wild-type PAK2-expressing cells but not the Y130/139/
194F-expressing cells cotransfected with Cdc42V12 and stim-
ulated with pervanadate (Fig. 3A). No 32P-labeled phosphoty-
rosine was detected from wild-type PAK2 immunoprecipitated
from similarly activated unlabeled cells and subsequently ra-
diolabeled in vitro by IVKA (Fig. 3B), indicating that tyrosine
phosphorylation of PAK2 takes place in the cells, rather than
during the IVKA assay due to a coprecipitating kinase. From
these results, we concluded that Cdc42V12-activated PAK2 is
susceptible to direct tyrosine phosphorylation and that Y130 in
its regulatory domain is the main target residue.
Tyrosine phosphorylation increases the intrinsic catalytic
activity of PAK2. To directly study the role of Y130 in the
tyrosine phosphorylation-mediated activation of PAK2, we
compared the ability of Cdc42V12 and pervanadate to syner-
gistically activate wild-type PAK2, PAK2-Y130F, and PAK2-
Y130/139/194F. As is evident in Fig. 4, unlike its effect on that
of the wild type, pervanadate had little additional effect on
kinase activity of Y130F and Y130/139/194F mutant proteins.
Thus, we concluded that Y130 in the N-terminal regulatory
domain is not only the predominant site for tyrosine phosphor-
FIG. 2. P21-activated PAK2 becomes a target for Y130 phosphor-
ylation. 293T cells were transfected with wild-type PAK2 (upper panel)
or PAK2 constructs with individual point mutations or a triple muta-
tion disrupting the three potential N-terminal tyrosine phosphoryla-
tion sites (lower panel) and were cotransfected with Cdc42V12 and
treated with pervanadate (PV) as indicated. After immunoprecipita-
tion and IVKA, the labeled PAK2 proteins were eluted and split into
three identical fractions that were subsequently reimmunoprecipitated
with empty beads (control), anti-phosphotyrosine antibodies (anti-
pTyr), or anti-PAK antibodies (anti-Myc).
FIG. 3. Phosphoamino acid analysis of PAK2. (A) Analysis of wild-
type PAK2 and PAK2-Y130/139/194F from cells that were cotrans-
fected with Cdc42v12 and treated with pervanadate and labeled in vivo
with [32P]orthophosphate. (B) Analysis of wild-type PAK2 labeled in
vitro by IVKA reaction with [32P]ATP after immunoprecipitation from
cells that were cotransfected with Cdc42v12 and treated with pervana-
date.
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ylation but is also the critical target residue for Src kinase-
mediated potentiation of PAK2 kinase activity.
To further characterize the functional role of PAK2 Y130
phosphorylation, we tested the effect of in vitro tyrosine de-
phosphorylation on PAK2 kinase activity. To this end,
Cdc42V12-pervanadate-activated PAK2 was treated with the
tyrosine phosphatase PTP-1B before subjecting it to IVKA
(Fig. 5). This treatment potently reduced PAK2 activity, de-
creasing its autophosphorylation by 4.6-fold and its activity
towards the substrate peptide 3.9-fold, thus virtually abolishing
the superactivating effect of pervanadate. By contrast, the ac-
tivity of PAK2 induced by Cdc42V12 alone without pervana-
date stimulation was not sensitive to PTP-1B, indicating that
the inhibition by this treatment was indeed specifically due to
removal of the phosphotyrosine modification.
When the different tyrosine mutants of PAK2 activated by
Cdc42V12 plus pervanadate were treated with PTP-1B, a sig-
nificant reduction in the catalytic activity of Y139F and Y194F
(2.9-fold and 4.3-fold, respectively) was observed, whereas the
Y130F and the Y130/139/139F mutants were completely insen-
sitive to PTP-1B treatment. Although tyrosine 194, in addition
to the major phosphoacceptor site Y130, was also found to be
phosphorylated (Fig. 2), modification of Y194 did not seem to
be involved in positive regulation of PAK2 by Src kinases. In
fact, the activity of PAK-Y194F in Cdc42V12 plus pervana-
date-stimulated cells was slightly higher than that of wild-type
PAK2. In conclusion, these data further confirm the critical
role of Y130 in tyrosine kinase-mediated regulation of PAK2
activity and provide a direct demonstration that this regulation
is achieved via an increased intrinsic catalytic activity of PAK2.
Tyrosine phosphorylation is dependent on p21-induced con-
formational changes in PAK2. Activation of PAKs by Cdc42
involves disruption of the autoinhibitory interactions between
the N-terminal regulatory domain and the C-terminal kinase
domain (14, 21, 30). Since PAK2 tyrosine phosphorylation was
dependent on prior activation by Cdc42, we considered the
possibility that p21 binding-induced changes in the PAK2
structure would lead to exposure of potential sites for tyrosine
phosphorylation. To test this possibility, we examined a panel
of previously characterized function-modifying PAK2 muta-
tions for their effects on tyrosine phosphorylation of PAK2.
Mutations H82L and H85L, which inactivate the PBD/CRIB
domain, result in a PAK2 protein (PAK2-CRIB) that has
some constitutive activity but is resistant to further activation
by Cdc42V12. In agreement with our previous conclusions
regarding the requirement of prior action by a p21 GTPase for
PAK2 tyrosine phosphorylation, PAK2-CRIB failed to be-
come tyrosine phosphorylated in pervanadate-treated cells
even when cotransfected with Cdc42V12 (Fig. 6). A very dif-
ferent picture was seen when the PAK2-L106F mutant was
tested. The L106F mutation mimics the action of p21 GTPases
by partially abolishing the autoinhibition exerted by the N-
terminal domain and results in a PAK2 mutant which has an
increased preference for an open conformation and significant
FIG. 4. PAK2-Y130 is critical for synergistic activation by Cdc42
and pervanadate treatment. 293T cells were transfected with wild-type
PAK2, PAK2-Y130F, or PAK2-Y130/139/194F and were cotransfected
with Cdc42V12 and treated with pervanadate (PV) as indicated. Pro-
tein expression and autokinase activity and kinase activity towards the
substrate peptide was examined as for Fig. 1B.
FIG. 5. Tyrosine phosphorylation increases the specific activity of
PAK2. PAK2 and tyrosine mutants were immunoprecipitated from
cells that were cotransfected with Cdc42V12 and treated or not treated
with pervanadate (PV) as indicated. Half of the immunocomplexes
were incubated with PTP-1B, as indicated, to remove phosphate from
tyrosine residues before they were subjected to IVKA. Numbers indi-
cate the severalfold decrease (compared to the untreated sample) in
autophosphorylation or kinase activity towards the substrate peptide,
as determined by phosphorimager analysis of the gels.
FIG. 6. PAK2 tyrosine phosphorylation is dependent on Cdc42-
induced conformational changes. Different PAK2 mutants carrying the
ME tag were transfected with or without cotransfection of Cdc42V12
as indicated and treated with pervanadate (PV). After primary im-
munoprecipitation and IVKA, samples were eluted and reimmu-
noprecipitated, using empty beads (control), anti-phosphotyrosine
antibodies (anti-PTyr), or anti-PAK antibodies (anti-Myc). The auto-
radiograph showing results obtained with wild-type PAK2 was exposed
six times longer then the other panels.
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constitutive activity. Similarly to that of Cdc42-stimulated wild-
type PAK2, however, the fraction of total cellular PAK2-
L106F present in the shifted conformation remained too small
to be readily detected by Western blotting (data not shown).
Unlike wild-type PAK2, PAK2-L106F became intensely phos-
phorylated on tyrosine residues in pervanadate-treated cells
even in the absence of Cdc42V12 (Fig. 6). Identical results
were obtained when another conformationally activating mu-
tant (PAK-D125R) was used (data not shown). To confirm that
the open conformation of PAK2-L106F, rather than its in-
creased catalytic activity per se, was important for its targeting
to tyrosine phosphorylation, we tested another type of consti-
tutively active PAK2 mutant. PAK2-T402E is catalytically ac-
tive because of an acidic substitution involving the T402 auto-
phosphorylation site in its kinase domain. This mutant is also
poorly responsive to activated p21 GTPases, as indicated by
only a small further increase in kinase activity in Cdc42V12-
transfected cells (Fig. 6 and results not shown). Despite its
constitutive activity, PAK2-T402E did not become tyrosine
phosphorylated upon pervanadate treatment when transfected
alone, and unlike wild-type PAK2 and PAK2-L106F, it did not
become significantly tyrosine phosphorylated in pervanadate-
stimulated cells even when cotransfected with Cdc42V12 (Fig.
6). Of note, despite an intact PBD/CRIB motif, PAK2-T402E
resembled PAK-CRIB in that it failed to undergo the char-
acteristic shift in mobility indicative of an altered conformation
and/or autophosphorylation status when cotransfected with
Cdc42V12.
Thus, collectively these data suggest a model in which con-
formational changes associated with p21-mediated activation
target PAK2 for subsequent tyrosine phosphorylation, which in
turn leads to robust enhancement of the catalytic activity of
PAK2.
DISCUSSION
In this study, we describe a new signaling mechanism that
regulates PAK kinase activity. Activation of PAK2 by p21
GTPases was found to be significantly potentiated by overex-
pression of Src family tyrosine kinases or treatment of cells
with pervanadate, a potent inhibitor of cellular tyrosine phos-
phatases. This effect of pervanadate could be abolished by the
presence of the Src kinase inhibitor PP1. The enhancement of
PAK2 activity by Src kinases involved tyrosine phosphorylation
of PAK2 itself, which occurred in the N-terminal regulatory
domain, where Y130 was identified as the major phosphoac-
ceptor site. The positive effect of tyrosine phosphorylation on
the catalytic activity of PAK2 was direct, since specific removal
of these phosphates using the tyrosine phosphatase PTP-1B
also abolished the increased activity of PAK2.
Perhaps the most interesting aspect of this phosphotyrosine-
based regulation was its strict dependence on prior activation
of PAK2 by p21 GTPases. Wild-type PAK2 could only become
phosphorylated on tyrosine residues when an active Cdc42 or
Rac1 was cotransfected, whereas a mutant form of PAK2 un-
able to interact with p21 GTPases (PAK2-CRIB) did not
undergo tyrosine phosphorylation, even when such an activator
was provided. The major acceptor site for tyrosine phosphor-
ylation in PAK2 was mapped to residue Y130. The crystal
structure of PAK1 (21) shows that this residue would be hid-
den when PAK2 is in its autoinhibited conformation. Binding
of a GTP-loaded p21 GTPase results in an open, catalytically
active conformation of PAK2 in which Y130 would become
exposed and available for phosphorylation by Src kinases. In
direct support of such conformational regulation of PAK2
tyrosine phosphorylation, we observed that PAK2 mutants that
were constitutively active (because of amino acid changes that
oppose the closed conformation of PAK2 by interfering with
the autoinhibitory contacts between its N- and C-terminal do-
mains [L106F and D125R]) could be tyrosine phosphorylated
independently of p21 GTPases. By contrast, this was not the
case with PAK2-T402E, which is constitutively active because
of a mutation in its catalytic apparatus. In addition to such
activation-associated changes in PAK structure, it is of course
possible that other concurrent effects of Cdc42/Rac1 binding
on PAK2, such as membrane recruitment (33) and breakdown
of dimers (30), also contribute to the observed p21 GTPase-
dependent Src kinase action on PAK2.
While the concept of Cdc42/Rac-dependent PAK tyrosine
phosphorylation leading to subsequent catalytic superactiva-
tion is novel, previous studies have implicated certain non-Src
tyrosine kinases in PAK regulation. Traugh and colleagues
have reported that overexpression of c-Abl can result in phos-
phorylation of a significant fraction of cellular PAK2 (34).
However, in contrast to the effect of Src kinases reported here,
phosphorylation by c-Abl was not dependent on cotransfection
of an active p21 GTPase, and instead of potentiating PAK2
activity, it caused a sixfold decrease in the specific activity of
PAK2. By contrast, tyrosine phosphorylation by the Etk/Bmx
kinase (2) or by v-ErbB (28) has been reported to be associated
with an increased activity of PAK1. Although the transforming
action of v-ErbB itself appeared to be Rho dependent (6, 28),
in neither of these cases did PAK tyrosine phosphorylation
require activated Cdc42 or Rac, which led the authors of the
latter study to suggest that tyrosine phosphorylation represents
a p21 GTPase-independent mechanism of PAK activation
(28). The sites of tyrosine phosphorylation of PAK by c-Abl,
v-ErbB, or Etk/Bmx were not mapped in any of these studies,
but it would seem logical to assume that these sites are differ-
ent from that of the PAK2 Y130 (or those of the corresponding
residues in PAK1 and PAK3).
The coordinated regulation of PAK2 by p21 GTPases and
tyrosine phosphorylation bears intriguing resemblance to reg-
ulation of Raf-1, another important and more extensively stud-
ied upstream regulator of cellular serine/threonine kinase cas-
cades. Raf-1 is synergistically activated by binding to the p21
GTPase protein Ras and by tyrosine phosphorylation by Src
(reviewed in reference 29). In this case also, prior action by
Ras is required for the stimulatory phosphorylations to occur
at Ser338 and Tyr341 of Raf-1 (27). The role of Ras in this
process is to translocate Raf-1 to the membrane where these
modifications take place (20, 26), but notably, a cysteine-rich
domain adjacent to the Ras binding domain of Raf-1 has also
been implicated in autoinhibition by a physical interaction with
the catalytic region of this kinase, in direct analogy with PAK
regulation (9). Moreover, similar to the multistep process of
PAK2 activation described here, only a small proportion of
total cellular Raf-1 becomes activated by stimuli that activate
Ras (13), and therefore, despite the importance of Tyr341
phosphorylation for maximal Raf-1 activity, only a small sub-
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population of Raf-1 molecules becomes tyrosine phosphory-
lated by Src, which may explain why this modification has not
been observed in all studies (see references 1 and 18, for
example). Thus, although a number of differences in PAK and
Raf-1 regulation are also apparent, the complex molecular
mechanisms that govern the catalytic activities of these kinases
may have more in common than has been previously appreci-
ated.
In conclusion, the p21 GTPase-dependent tyrosine phos-
phorylation of the Y130 residue, leading to superactivation of
PAK2, represents a novel point of convergence for signal
transduction pathways mediated via small G proteins and Src
family tyrosine kinases. This mechanism may be important in
providing additional plasticity and complexity to the regulation
of cellular activities of PAK and thus allowing a cell to respond
appropriately to different extracellular stimuli and could also
have relevance for development of novel therapeutic strategies
based on protein kinase inhibitors.
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Nef Associates with p21-Activated Kinase 2 in a
p21-GTPase-Dependent Dynamic Activation
Complex within Lipid Rafts
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We have previously reported that Nef specifically interacts with a small but highly active subpopulation of
p21-activated kinase 2 (PAK2). Here we show that this is due to a transient association of Nef with a PAK2
activation complex within a detergent-insoluble membrane compartment containing the lipid raft marker
GM1. The low abundance of this Nef-associated kinase (NAK) complex was found to be due to an autoregu-
latory mechanism. Although activation of PAK2 was required for assembly of the NAK complex, catalytic
activity of PAK2 also promoted dissociation of this complex. Testing different constitutively active PAK2
mutants indicated that the conformation associated with p21-mediated activation rather than kinase activity
per se was required for PAK2 to become NAK. Although association with PAK2 is one of the most conserved
properties of Nef, we found that the ability to stimulate PAK2 activity differed markedly among divergent Nef
alleles, suggesting that PAK2 association and activation are distinct functions of Nef. However, mutations
introduced into the p21-binding domain of PAK2 revealed that p21-GTPases are involved in both of these Nef
functions and, in addition to promoting PAK2 activation, also help to physically stabilize the NAK complex.
The Nef protein is a 25- to 34-kDa accessory protein of
primate immunodeficiency viruses (i.e., human/simian immu-
nodeficiency virus [HIV/SIV]) and a major determinant of in
vivo pathogenicity of these lentiviruses. Nef promotes viral
replication via numerous, but incompletely understood strate-
gies (13, 14). Nef has been found in lipid rafts (35), which are
important microdomains in signal transduction. Nef modulates
cellular signaling events, downregulates major histocompatibil-
ity complex class I and CD4 cell surface expression, and con-
tributes to the infectivity of virus particles (7, 27). One poten-
tially important cellular effector of Nef is the Nef-associated
serine/threonine kinase (NAK) (23, 30), later identified as p21-
activated kinase 2 (PAK2) (1, 25). The interaction between
Nef and PAK2 takes place in a multiprotein complex (12) and
critically depends on the stabilizing effects of other compo-
nents of this complex, which remain unidentified but appar-
ently include at least one protein that can bind to the SH3
domain-binding site of Nef (21). NAK has been implicated as
an effector of Nef in inhibition of Bad-mediated apoptotic
death and in increasing virus production in HIV-infected cells
(19, 36).
The PAKs are mammalian homologues of yeast Ste20-like
protein kinases and can be divided into two subfamilies:
PAK-1, -2, and -3 (the PAK-I subfamily) and PAK-4, -5, and -6
(the PAK-II subfamily). Signaling via PAKs is involved in reg-
ulation of actin cytoskeleton, apoptosis, and malignant trans-
formation (2, 5, 11, 16, 33, 34). Catalytic activation of PAKs
typically results from binding of the GTP-loaded Rho p21-
GTPases Cdc42 or Rac1 to the Cdc42/Rac interaction/binding
(CRIB) domain (also known as p21-binding domain) located
in the N-terminal regulatory domain. This binding relieves its
autoinhibitory contacts with the C-terminal kinase domain and
is followed by phosphorylation on Thr402 (PAK2; Thr423 in
PAK1), as well as other key autophosphorylation sites and
kinase activation (4, 22).
In addition to a net increase in cellular GTPase activity,
PAKs may also be activated by their increased recruitment
toward active GTPases, for example, by Nck-mediated plasma
membrane targeting of PAK1 (3, 20). On the other hand,
Cdc42-independent activation mechanisms induced by lipids,
such as sphingosine, have been reported for both PAK1 and
PAK2 (3, 28). Sphingosine stimulation can induce a similar
level of activity as do p21-GTPases, as well as a similar pattern
of autophosphorylation, and is associated with translocation of
PAK2 to a membrane-containing cellular fraction (28).
Among the total cellular pool of PAK2, only a small but
highly active fraction associates with Nef (1, 26). Because of
the selective association of HIV type 1 (HIV-1) Nef with the
catalytically active fraction of cellular PAK2, we have under-
taken here a detailed analysis of the relationships between
p21-GTPase binding, catalytic activity, subcellular localization,
and association with Nef by PAK2. These results provide new
insights into the role of p21-GTPases in Nef/PAK2 complex
formation, as well as in the process of PAK activation itself.
MATERIALS AND METHODS
Cell culture and transient transfections. 293T human embryonic kidney fi-
broblast-derived cells were maintained in Dulbecco modified Eagle medium
supplemented with 10% fetal calf serum and Glutamax. Transfections were
* Corresponding author. Mailing address: Institute of Medical Tech-
nology, FIN-33014, University of Tampere, Tampere, Finland. Phone:
358-3-215-7029. Fax: 358-3-215-8597. E-mail: kalle.saksela@uta.fi.
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performed by using Lipofectamine transfection reagent (Invitrogen) according to
the manufacturer’s instructions. Cells were harvested 48 h after transfection.
Plasmid constructs. The generation of PAK2-HH (H82/85L) and PAK2-
T402E has been described earlier (26). The PAK2 mutants ISP (I74N/S75P/
P77A), E115K, and D125R were made by overlap PCR with a specific mutant
primer pair and common outer primers containing restriction sites for cloning.
All constructs were cloned into pEBB-ME with BamHI-KpnI to generate a
multiepitope (ME)-tagged construct (26). The PAK2 double mutants with
E115K or D125R mutations combined to HH or ISP mutations were made by
cloning the HH- or ISP-mutated N-terminal fragment to the pEBB-PAK2-ME
vector containing the respective autoinhibitory mutation. All constructs were
confirmed by sequencing. The expression plasmid for dominant active Cdc42V12
was kindly provided by B. Mayer. pEBB-NL4-3-Nef R71 has been described
previously (29). All divergent Nef alleles were cloned into pCG plasmid, and they
are described elsewhere (15), except for HIV-2 cbl and SIV SYK51. HIV-2 cbl
Nef was amplified from an HIV-2-infected culture obtained through the NIH
AIDS Research and Reference Reagent Program. The Nef allele SYK51 was
kindly provided by Beatrice Hahn (Department of Medicine, University of Al-
abama at Birmingham [B. Hahn, unpublished data]).
Cell lysates and fractionation. To obtain whole-cell lysates, cells were washed
once with cold phosphate-buffered saline (PBS) and suspended in in vitro kinase
assay (IVKA) lysis buffer (50 mM HEPES [pH 7.4], 150 mM NaCl, 10% glycerol,
1% Triton X-100, 1 mM EDTA, 1.5 mM MgCl2, 1 mM sodium orthovanadate,
1 mM phenylmethylsulfonyl fluoride, 10 g of aprotinin/ml). After 10 min on ice,
the extract was centrifuged (13,000 rpm, 10 min), and the supernatant was
collected. For fractionation of PAK2 into cytosolic and particulate fractions, cells
were washed with PBS, suspended in hypotonic buffer (50 mM Tris [pH 7.5], 5
mM MgCl2, 1 mM EDTA, 1 mM EGTA) for 10 min on ice, and homogenized
by 20 strokes with a Dounce homogenizer. After centrifugation (13,000 rpm for
10 min) the supernatant was collected. The particulate fraction was washed once
with hypotonic buffer and resuspended in IVKA lysis buffer. After 10 min on ice,
the extract was centrifuged at 13,000 rpm for 10 min, and the solubilized partic-
ulate fraction was collected.
Raft fractionation by membrane flotation. Cells were washed once with PBS
and lysed with ice-cold isolation buffer (150 mM NaCl, 5 mM EDTA, 25 mM
Tris-HCl [pH 7.4], 1% Triton X-100, 1 mM sodium orthovanadate, 1 mM
phenylmethylsulfonyl fluoride, 10 g of aprotinin/ml). After 20 min incubation
on ice, samples were cleared by centrifugation (1,000  g, 10 min). Lysates were
adjusted to 40% Optiprep (Life Technologies), pipetted into Sorvall TH-660
centrifuge tubes, overlaid with 2.5 ml of 28% Optiprep in isolation buffer and
with 0.6 ml of isolation buffer, and centrifuged for 3 h at 35,000 rpm at 4°C. Eight
500-l fractions were collected from the top and subjected to immunoprecipi-
tations with anti-Myc or anti-Nef antisera followed by IVKA analysis. A small
part of each immunoprecipitate was boiled in sample buffer, separated in 8%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels, and transferred
to nitrocellulose membrane for Western blot analysis. From each fraction, 50 l
was transferred to polyvinylidene difluoride membranes by slot blotting and
probed with 200 ng of horseradish peroxidase-conjugated cholera toxin (CTx;
Sigma)/ml to detect the raft marker GM1.
Immunoprecipitations and IVKAs. Immunoprecipitations with anti-Myc
(9E10), anti-AU1 (Babco, Richmond, Calif.), or a monoclonal antibody (2F2;
FIT Biotech, Tampere, Finland) and subsequent IVKAs with [-32P]ATP were
performed as described previously (26). To visualize the autophosphorylation
activity of PAK2, a fraction of the kinase assay was subjected to sodium dodecyl
sulfate–8% polyacrylamide gel electrophoresis and exposed to X-ray film.
RESULTS
Nef association depends on the molecular mechanism of
PAK2 activation. Mutations affecting acidic residues in the
regulatory domain of PAK1 have been shown to result in a
constitutively active kinase by disrupting intramolecular auto-
inhibitory interactions that suppress the catalytic domain (18,
38). Here, we have produced constitutively active PAK2 vari-
ants by mutating the corresponding residues in it (E115K and
D125R) or, alternatively, by a strategy commonly applied to
generate constitutively active protein kinases, namely, acidic
replacement of a key phosphorylation site in the kinase acti-
vation loop (T402). 293T cells were transfected with wild-type
or different constitutively active PAK2 variants and HIV-1
NL4-3 Nef, together or without the dominant active p21-
GTPase (Cdc42V12). In accordance with our previous data
(26), when wild-type PAK2 was used, Nef-associated PAK2
activity (i.e., NAK) was only observed if Cdc42V12 was cotrans-
fected (Fig. 1, lanes 1 and 2). Thus, under the experimental
conditions used here, the NL4-3 Nef allele did not substitute
Cdc42V12 as a PAK2 activator. Unlike wild-type PAK2, how-
ever, the constitutively active PAK2 derivatives carrying muta-
tions in the amino-terminal regulatory region (E115K or
D125R) readily associated with this Nef allele also without
Cdc42V12 cotransfection (Fig. 1; see also Fig. 5).
Interestingly, a very different picture was seen when the
PAK2 mutant T402E was tested. In contrast to the PAK2
mutants defective in autoinhibition, PAK2-T402E failed to
associate with Nef in the absence or presence of cotransfected
Cdc42V12 (Fig. 1, lanes 3 and 4). Thus, the molecular mecha-
nism underlying PAK2 activation can determine whether or
not PAK2 associates with Nef. Conformation associated with
PAK2 activation via loss of inhibitory contacts between its N-
and C-terminal domains, rather than catalytic activity per se,
therefore appears to be critical for driving Nef/PAK2 complex
formation.
Nef alleles differ greatly in their capacity to stimulate PAK2
activity. The requirement of NL4-3 Nef to precipitate NAK
activity in the absence of Cdc42V12 or an appropriate activating
mutation in PAK2 suggested that this Nef allele was unable to
stimulate PAK2 activity in the transfected cells. However, since
previous studies have reported PAK activation by certain Nef
alleles, such as SF2 (1), we addressed this question by exam-
ining PAK2 activity in cells transfected with PAK2 alone or
together with different SIV, HIV-1, and HIV-2 Nef alleles.
Figure 2 shows data on comparing NL4-3 Nef with a divergent
panel of mainly primary Nef alleles. These Nef alleles have
FIG. 1. Activation-dependent association of PAK2 with Nef. 293T
cells were transfected with HIV-1 NL4-3 Nef, together with wild-type
(WT) PAK2 or constitutively active PAK2 variants (D125R and
T402E). In some transfections Cdc42V12 was also included, as indi-
cated in the figure. Cell lysates were immunoprecipitated with anti-
Myc-tag antibodies (PAK; top panel) or anti-Nef antibodies (-Nef;
middle panel), followed by an IVKA in the presence of [-32P]ATP.
The expression of total PAK2 and Nef proteins was detected by West-
ern blotting (WB PAK and WB Nef, respectively).
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been recently extensively characterized for their functionality,
and all were shown to be able to associate with PAK2 if co-
transfected with Cdc42V12 (15). As can be seen from Fig. 2A,
some of these alleles were equally poor PAK2 activators, as
was NL4-3 Nef, whereas others could clearly stimulate the
catalytic activity of cotransfected PAK2, some being almost as
efficient as Cdc42V12 in this function.
This differing capacity to activate PAK2 was even more
striking when NAK activity (i.e., PAK2 activity coprecipitated
with Nef antibodies) in the absence of cotransfected Cdc42V12
was examined. Nef alleles such as mac239, 8161, and 13127,
capable of inducing kinase activity in anti-PAK2 immunocom-
plexes, were also associated with intense NAK activity. Thus,
the capacity to stimulate PAK2 activity clearly differs greatly
among Nef alleles, which is in contrast to the virtually uniform
ability of divergent Nef alleles to associate and coprecipitate
activated PAK2 (15).
Intrestingly, however, HIV-2 cbl Nef, which was one of the
most potent PAK2 activators among this panel of Nef alleles
(Fig. 2B, lane 4, of panel IVKA PAK), coprecipitated only
modest amounts of NAK activity (Fig. 2B, lane 4, of panel
IVKA Nef). As observed previously (15), when Cdc42V12 was
cotransfected HIV-2 cbl Nef efficiently precipitated NAK ac-
tivity (Fig. 2B, lane 3, of panel IVKA Nef). Thus, despite its
capacity to activate PAK2 HIV-2 cbl Nef remained dependent
on Cdc42V12 for efficient association with activated PAK2,
possibly reflecting the dual role of p21-GTPases in NAK com-
plex formation described elsewhere in this study (see discus-
sion of the role of Cdc42 in Nef/PAK interaction below).
The different patterns of the Nef alleles tested here in stim-
ulating cellular PAK2 activity and in associating with PAK2
clearly indicate that these are distinct and separable functions
of Nef. Indeed, the failure of some Nef alleles (such as NL4-3)
to stimulate PAK2 activity despite their capacity to associate
with (preactivated) PAK2 demonstrates that, unlike p21-
GTPases, Nef does not activate PAK2 as a direct consequence
of binding.
This feature of NL4-3 Nef (its dependence for Cdc42V12 or
activating mutations in PAK2 in order to assemble a NAK
complex) also provides a practical means to specifically study
questions related to Nef/PAK2 complex assembly indepen-
dently of effects of Nef on PAK2 activity, which is the experi-
mental strategy that we have used in the studies described
below.
Nef/PAK2 complex associates with membrane rafts. Due to
myristoylation of its N terminus, a significant fraction of Nef is
associated with cellular membranes (37). On the other hand, a
subpopulation of cellular PAK2 becomes recruited to mem-
branes upon activation (20, 28). Considering the dependence
of Nef/PAK2 complex formation on PAK2 activation, it was
therefore of interest to study the cellular compartment in
which Nef/PAK2 interaction takes place. To this end, we trans-
fected cells with NL4-3 Nef and different PAK2 variants and
compared the relative amounts of PAK2 protein and PAK2 or
NAK activity in the cytosolic and particulate (membrane) frac-
tions. Notably, PAK2 activity was highly enriched in the par-
ticulate fraction in all cases, except for PAK2-T402E, whose
activity was mainly cytosolic (Fig. 3, panels labeled IVKA
PAK). In contrast to kinase activity, the bulk of PAK2 protein
was in all cases found in the cytosol (Fig. 3, panels labeled WB
PAK2). In accordance, immunoprecipitation of the same
fractions with an anti-Nef-antibody detected NAK activity only
in the particulate fraction (Fig. 3, panels labeled IVKA Nef).
On the other hand, Nef protein was found in both fractions
(Fig. 3, panels labeled WB Nef). Notably, no NAK signal was
detected from the cytosolic fraction even in the case of PAK2-
T402E, whose activity was mainly found in this fraction. Thus,
we conclude that NAK complex is restricted to cell mem-
branes. However, this is probably not the sole reason for the
failure of PAK2-T402E to associate with Nef, because this
situation was not remedied when PAK2-T402E was artificially
targeted to the membranous fraction by attaching a CAAX-
box element to its C terminus (data not shown).
Lipid rafts remain insoluble after treatment with 1% Triton
X-100 and can be enriched to low-density fractions by flotation
ultracentrifugation. Since localization of Nef in rafts has been
demonstrated earlier (35), we transfected cells with the active
PAK2 variant E115K with or without Nef (Fig. 4, lower or
upper panels, respectively) to study whether partitioning of
FIG. 2. (A) Capacity to stimulate PAK2 activity differs among Nef
alleles. PAK2 was transfected into 293T alone (no Nef) with or without
Cdc42V12 or together with one of the indicated HIV-1 and SIV Nef
alleles. 8161 and 13127 are both HIV-1 subtype-O Nef alleles. Total
(IVKA PAK) and Nef-associated (IVKA Nef) kinase activity of
PAK2 from these cells was studied as in Fig. 1. The total amount of
PAK2 and Nef protein in each lysate was examined by Western blot-
ting (WB PAK and Nef). (B) Despite a capacity to activate PAK2,
HIV-2 cbl Nef depends on Cdc42V12 to associate with PAK2. PAK2
alone or with HIV-2 cbl Nef was transfected into 293T cells with or
without Cdc42V12 and analyzed for total and Nef-associated PAK2
kinase activity as in panel A.
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NAK activity to the particulate fraction was due to its raft
association. Successful flotation of rafts was confirmed by de-
tection of the raft marker ganglioside GM1 by using labeled
CTx (Fig. 4, panels labeled GM1). In fractionation, PAK2
protein was not enriched in rafts and instead was detected in
all fractions, including the bottom ones (fractions 5 to 8 in Fig.
4) in accordance with its mainly cytosolic localization shown in
Fig. 3. In contrast, PAK2 activity was enriched in the GM1-
containing fractions and less abundant in the bottom fractions.
However, raft association of PAK2 activity was much less strik-
ing than its highly selective association with the membraneous
fraction (Fig. 3), indicating that at least two-thirds of PAK2
activity is associated with membranes other than rafts. A sim-
ilar but more pronounced raft association of PAK activity was
recently reported by Krautkramer et al. (17). Their data also
suggested a marked role for Nef in recruiting PAK to rafts,
which was not evident in our experiments.
Interestingly, however, NAK activity was exclusively found
in fractions 1 and 2 (Fig. 4B, panel labeled IVKA Nef),
suggesting that NAK activity is more selectively associated with
rafts than is total PAK2 activity. In agreement with previously
published data (35, 39), a subpopulation (estimated 20%) of
Nef protein localized to rafts but was also found in other
fractions (Fig. 4, panel labeled WB Nef). Thus, the selective
localization of the NAK complex to the rafts cannot be ex-
plained simply by the lack of Nef and PAK2 in other subcel-
lular compartments.
Role of Cdc42 in Nef/PAK2 interaction. The Cdc42/Rac-
binding domain (CRIB) connects PAKs to these p21-GTPases,
and mutations introduced to CRIB abolish p21-mediated stim-
ulation of PAK activity (38). We have previously noticed that
leucine substitution of two critical histidine residues (H82 and
H85) in the CRIB domain of PAK2 (mutant dubbed PAK2-
HH) prevented Nef/PAK2 complex formation (26). Therefore,
a question arises whether the CRIB motif dependence of NAK
complex is due to lack of p21-mediated PAK2 activation or a
direct consequence of the loss of Cdc42V12/PAK2 interaction.
To address this issue, we first constructed another p21-bind-
ing deficient PAK2 mutant containing amino acid substitutions
in three other critical CRIB motif residues (I74N;S75P;P77A
[38], mutant dubbed PAK2-ISP). PAK2-ISP failed to associate
with Nef (Fig. 5A, bottom panel, lanes 3 to 6), confirming the
observation made with PAK2-HH and therefore supporting
the idea that these mutations probably affected Nef association
by PAK2 specifically by preventing p21 binding. Because the
constitutively active PAK2-E115K and PAK2-D125R could as-
sociate with NL4-3 Nef without Ccd42V12 cotransfection (Fig.
1 and 5), we created PAK2 double mutants containing both a
conformationally activating mutation (E115K or D125R) and a
CRIB-inactivating mutation (HH or ISP). However, even
when combined with D125R or E115K mutation, HH- and
FIG. 3. Membrane localization of PAK2 and NAK activity. NL4-3
Nef and wild-type PAK2 or different activated mutants were trans-
fected with or without Cdc42V12 as indicated. Cell lysates were frac-
tionated into particulate (left panels) and cytosolic (right panels) frac-
tions. Part of both fractions was subjected to Western blotting analysis
(two bottom panels) with antibodies against PAK2 and Nef. The rest
of the fractions were used for immunoprecipitation analysis of total
(IVKA PAK) and Nef-associated (IVKA Nef) PAK2 activity as in
Fig. 1.
FIG. 4. Nef associates with PAK2 in a raft-containing membrane
population. Lysates of cells transfected with PAK2-E115K with or
without Nef NL4-3 were subjected to membrane floatation on Opti-
prep gradient centrifugation. Eight fractions (starting from top; lanes
1 to 8) were collected and analyzed for total (IVKA PAK2) and
Nef-associated (IVKA Nef) PAK2 activity as in Fig. 2. PAK2 and Nef
protein expression in these fractions was examined by Western blotting
(WB PAK and WB Nef), whereas the raft marker GM1 present in
these fractions was detected by slot blotting and visualization with
labeled CTx subunit B (GM1).
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ISP-mutated PAK2 variants still failed to associate with Nef
(Fig. 5B, lanes 2 and 3 and lanes 5 and 6). Since the formation
of the Nef/PAK2 complex was found to be restricted to cellular
membranes, the failure of the E115K/HH and D125R/HH
combination mutants to associate with Nef could simply reflect
their inability to localize to cell membranes. When the subcel-
lular localization of these double mutants was examined, how-
ever, their activity was found to be equally or even more se-
lectively membrane-associated compared to E115K and
D125R with intact CRIB motifs (Fig. 5C, lanes 5 to 8).
These data show that a functional CRIB domain is required
for NAK complex formation for reasons that cannot be as-
signed only to its enabling p21-mediated activation of PAK2. A
plausible explanation for this observation would be that a p21-
GTPase is physically involved in stabilization of the Nef/PAK2
complex. Since PAK2-E115K and PAK2-D125 with an intact
CRIB motif could associate with NL4-3 Nef without Cdc42V12
cotransfection, enough endogenous active p21-GTPases ap-
pear to be present in the lipid rafts of these cells to help in
stabilizing the NAK complex, although this low p21-GTPase
activity is insufficient to drive activation and membrane relo-
calization of native PAK2.
Kinase activity of PAK2 promotes disassembly of the Nef/
PAK2 complex. Nef efficiently associates with the catalytically
active subpopulation of PAK2, but this represents only a small
fraction of total cellular PAK2 protein (1, 26). As a conse-
quence, sensitive immunocomplex phosphorylation assays
(Fig. 1 to 5) have until now been the only practical means to
study the NAK complex. The notion that a p21-GTPase may
be directly involved in Nef/PAK2 complex formation (Fig. 6)
led us to hypothesize that this interaction might take place
during the process of PAK2 activation and fall apart after the
kinase activity of PAK2 has been induced.
To test this idea, we examined whether a kinase-deficient
mutant of PAK2 (K278R) could associate more stably with Nef
than wild-type PAK2. Indeed, by cotransfecting increasing
amounts of Ccd42V12, together with PAK2-K278R, a corre-
sponding increase in PAK2 coprecipitation with Nef could be
observed by Western blotting (Fig. 6). This result supports the
idea that catalytic activity of PAK2 is involved in destabilizing
the NAK complex and shows that using a kinase-defective
FIG. 5. Cdc42-binding in the association of PAK2 with Nef and
localization to the particulate fraction. (A) CRIB domain of PAK2 is
essential for Nef association. Nef and wild-type (WT) PAK2 or differ-
ent Cdc42-binding deficient mutants, PAK2-HH or PAK2-ISP, were
transfected, together with Cdc42V12, where indicated. Total PAK2
activity (top panel) and Nef-associated PAK2 activity (bottom panel)
were studied by anti-Myc (for PAK2) or anti-Nef immunoprecipita-
tions and IVKA. Expression of PAK2 and Nef proteins was studied by
Western blotting (WB PAK and WB Nef). (B) Release of autoin-
hibition does not substitute for Cdc42-binding deficiency for associa-
tion with Nef. Total PAK2 activity (top panel) and Nef-associated
PAK2 activity were studied as in panel A from cells that were trans-
fected with Nef and PAK2-E115K or PAK2-D125R either with a
functional (WT) or mutated (HH or ISP) CRIB motif. (C) Membrane
localization of PAK2 is Cdc42-binding independent. Wild-type (WT)
PAK2, different activated mutants (E115K and D125R), or Cdc42-
binding-deficient mutants (HH, E115K/HH, and D125R/HH) were
transfected. Total cell lysates, as well as the particulate and cytosolic
fractions, were collected from these cells, and the total PAK2 activity
was studied from both fractions as in panel A.
FIG. 6. Kinase activity of PAK2 destabilizes the NAK complex. Nef
and wild-type (WT) PAK2 or the kinase-dead (KD) PAK2-K278R
variant were cotransfected, together with increasing amounts of
Cdc42V12 as indicated. Lysates were immunoprecipitated with anti-Nef
or anti-PAK2 antibodies, followed by anti-PAK2 Western blotting to
visualize Nef-associated (IP Nef) and total (IP PAK) PAK2. Ex-
pression of total Nef protein in each lysate was examined by Western
blotting (WB Nef).
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PAK2 results in accumulation of a sufficient amount of Nef/
PAK2 complex in cells and that this interaction can be visual-
ized by a traditional coprecipitation/immunoblotting approach.
In contrast, the amount of wild-type PAK2 coprecipitating
under these conditions was too small to be consistently de-
tected, even when the highest amount (200 ng) of Cdc42V12
expression vector was cotransfected. Attempts to increase the
association between wild-type PAK2 and Nef by transfecting
even larger amount of Cdc42V12 have not been successful and
have instead resulted in substantially decreased PAK2 protein
levels (data not shown), possibly through increased PAK2 deg-
radation and/or cytostasis (10).
DISCUSSION
We have previously reported that Nef selectively associates
with catalytically active PAK2, but the role of Nef-induced
PAK activation in assembly of the NAK complex has remained
unclear. NAK activity in anti-Nef immunocomplexes has been
commonly interpreted as evidence of a capacity of Nef to
stimulate PAK activity, but few studies have directly addressed
this issue. Recently, Arora et al. reported that an increase in
PAK2 kinase activity could be demonstrated in SF2 Nef-trans-
fected cells compared to control-transfected cells (1). How-
ever, results of similar experiments by us with the NL4-3 Nef
allele (26) (Fig. 1) have been negative and less than convincing
when SF2 Nef was used (unpublished data). By testing a panel
of diverse Nef alleles we show here that Nef should indeed be
considered a PAK2 activator, but this property is weak or
lacking in many Nef alleles available for study. Most of the Nef
alleles that showed potent PAK2 activation were molecular
clones isolated without passage of the virus in cell culture.
Although this correlation is not sufficient for drawing any con-
clusions, it is possible that potent PAK2 activation by Nef
might for some reason be counterselected during in vitro
growth. In any case, given that some Nef alleles clearly have a
capacity to stimulate PAK2 activity, the differing results ob-
tained with “weaker” alleles may simply have reflected differ-
ences in assay sensitivity.
Unlike the varying capacity of Nef alleles to promote PAK2
kinase activity, the ability to associate with active PAK2 is a
highly conserved Nef function (15, 26, 31). Therefore, a failure
to stimulate PAK2 activity rather than a failure to associate
with the NAK complex probably explains the lack of serine/
threonine kinase activity reported to be associated with some
Nef alleles. The segregation of these properties among differ-
ent Nef alleles also implicates that these two Nef functions are
mechanistically distinct. Thus, Nef is not mimicking an active
p21-GTPase, which acts by pushing PAK2 into an active con-
formation via binding to its CRIB motif. Instead, Nef appears
to act upstream of the p21-GTPase to promote their capacity
to stimulate PAK2 activation. This scenario agrees with the
model proposed based on studies from the Peterlin laboratory,
where Nef acts as an adaptor to recruit proteins, including
phosphatidylinositol 3-kinase and Vav into a “signalosome” in
which PAK activation could occur (9, 19, 24). On the other
hand, an alternative model was recently proposed by a study
from the Skowronski laboratory, which reported that Nef stim-
ulates cellular guanine nucleotide exchange factor activity and
consequently p21-GTPase-regulated signaling cascades by as-
sociating with the DOCK2/ELMO1 complex (12). Of course,
these two models need not to be mutually exclusive, and Nef
might possess redundant strategies for stimulating cellular p21-
GTPases.
When the terms “upstream” and “downstream” are used to
describe effects of Nef on cellular signaling, it is important to
note that they refer to the order of events but do not imply that
these processes would have to be spatially separated. Indeed,
the dual role of Cdc42V12 revealed by the present study sug-
gests that, although PAK2 activation and association are mech-
anistically distinct functions of Nef, they take place in the same
multiprotein complex. Specifically, we found that, apart from
enabling conformational activation of PAK2, its CRIB motif
served an additional important role in the Nef/PAK2 complex.
This suggested that an active p21-GTPase is also physically
involved in stabilizing the NAK complex. Moreover, the idea
that PAK2 activation and association by Nef involve a common
protein assembly is also supported by the fact that Nef-induced
increase in cellular p21-GTPase activity results in selective
activation of PAK2 but not PAK1 (1)[our unpublished data],
although Cdc42 and Rac1 have no intrinsic preferences as
activators of these two PAK family kinases.
Our fractionation studies revealed that the NAK complexes
are restricted to membrane domains known as lipid rafts. Such
raft specificity is striking, since active PAK2 as well as Nef
could also be found in most other membrane fractions. This
observation might be explained by the critical role of lipid rafts
in regulation of the cellular activity of the p21-GTPase Rac1
(6). Although active PAK2 may leave these membrane do-
mains, the role of an active (GTP-bound) p21-GTPase in sta-
bilizing the Nef/PAK2 interaction could account for restriction
of this complex to rafts.
Another factor that was found to contribute to limiting the
NAK activity close to its origin, i.e., the membrane-associated
p21-GTPase-containing activation complex, was the apparent
destabilizing effect of PAK2 kinase activity on the NAK com-
plex. This suggested a model where a p21-GTPase is required
for assembly of the NAK complex, but CRIB-mediated cata-
lytic activation of PAK2 subsequently promotes rapid dissoci-
ation of this complex. This dynamic and transient nature of the
NAK complex could also explain its low abundance even when
Nef and PAK2 are overexpressed in cells. This scenario was
suggested by the observation that cotransfection of Nef and
Cdc42V12 together with a kinase-deficient PAK2 mutant
(K278R) led to a significantly more stable Nef/PAK2 complex.
Indeed, Nef/PAK2-K278R interaction could be readily dem-
onstrated by a standard coimmunoprecipitation and Western
blot procedure, which has been difficult in the case of a regular
NAK complex. This approach should provide new experimen-
tal opportunities for elucidation of the functional role of the
Nef/PAK2, for example, by facilitating proteomics studies
aimed at complete characterization of the proteins required
for the assembly and involved in effector functions of the NAK
complex.
Despite its constitutive catalytic activity PAK2-T402E dif-
fered starkly from PAK2 activated by mutations that mimic the
effect of p21 binding (E115K and D125R) in that it failed to
associate with Nef as well as with cell membranes. We specu-
late that such direct activation of the PAK2 catalytic apparatus
by the T402E mutation may result in a conformation/autophos-
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phorylation pattern that differs from PAK2 activated via a
physiological p21-GTPase-mediated mechanism. As a conse-
quence of its aberrant conformation PAK2-T402E might be
unable to support an interaction(s) that normally couples ac-
tivated PAK2 to its membrane-associated partners. Whatever
the reason, the strikingly different biological behavior of these
two different types of dominantly active PAK2 mutants has
important implications for future research on Nef/PAK2 inter-
action, as well as on PAK family kinases in general. Although
it is obvious that only PAK2-E115K and PAK2-D125R but not
PAK2-T402E can be used as a “dominant active NAK,” our
data also suggest that the choice of the activating mutation is
also likely to profoundly influence studies on other aspects of
PAK in cell biology.
Protection from cell death via NAK-mediated phosphoryla-
tion and inactivation of the proapoptotic Bad protein has been
described as an important function of Nef, which could in part
explain its pathogenic effect in HIV infection (36). NAK has
also been implicated as an effector of Nef in increasing HIV
gene expression and virion production in the infected cells (8,
32) and thus represents a potentially useful therapeutic target.
Detailed understanding of the composition and function of the
NAK multiprotein complex could allow the design of com-
pounds that would target a cellular (and hence nonmutating)
factor and thereby specifically block Nef-mediated PAK2 ac-
tivation without interfering with the normal functions of this
important kinase.
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Human Immunodeficiency Virus Type 1 Nef Recruits the Guanine
Exchange Factor Vav1 via an Unexpected Interface into Plasma
Membrane Microdomains for Association with p21-Activated
Kinase 2 Activity
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Alterations of T-cell receptor signaling by human immunodeficiency virus type 1 (HIV-1) Nef involve its
association with a highly active subpopulation of p21-activated kinase 2 (PAK2) within a dynamic signalosome
assembled in detergent-insoluble membrane microdomains. Nef-PAK2 complexes contain the GTPases Rac
and Cdc42 as well as a factor providing guanine nucleotide exchange factor (GEF) activity for Rac/Cdc42.
However, the identity of this GEF has remained controversial. Previous studies suggested the association of Nef
with at least three independent GEFs, Vav, DOCK2/ELMO1, and Pix. Here we used a broad panel of
approaches to address which of these GEFs is involved in the functional interaction of Nef with PAK2 activity.
Biochemical fractionation and confocal microscopy revealed that Nef recruits Vav1, but not DOCK2/ELMO1
or Pix, to membrane microdomains. Transient RNAi knockdown, analysis of cell lines defective for expression
of Vav1 or DOCK2 as well as use of a Pix binding-deficient PAK2 variant confirmed a role for Vav1 but not
DOCK2 or Pix in Nef’s association with PAK2 activity. Nef-mediated microdomain recruitment of Vav1
occurred independently of the Src homology 3 domain binding PxxP motif, which is known to connect Nef to
many cellular signaling processes. Instead, a recently described protein interaction surface surrounding Nef
residue F195 was identified as critical for Nef-mediated raft recruitment of Vav1. These results identify Vav1
as a relevant component of the Nef-PAK2 signalosome and provide a molecular basis for the role of F195 in
formation of a catalytically active Nef-PAK2 complex.
The Nef protein of human immunodeficiency virus (HIV)
and simian immunodeficiency virus (SIV) is a multifunctional
factor that is critical for high virus titers in vivo. Consequently,
disease progression in individuals infected with nef-deficient
viruses is very slow or absent (16, 30, 32). These effects are
thought to mirror several independent activities of Nef that
prevent immune recognition of virally infected cells and boost
HIV replication (18, 36, 57, 72). In order to achieve such an
optimized spread in the infected host, Nef manipulates a va-
riety of transport and signal transduction processes in cells
infected by HIV type 1 (HIV-1). Modulation of cellular trans-
port pathways by Nef affects the surface presentation of a large
number of cell surface receptors, such as CD4, major histo-
compatibility complex class I and II molecules, and chemokine
receptors, to prevent superinfection and to facilitate immune
evasion of productively infected cells (8, 15, 22, 45, 65, 70).
Equally widespread are Nef effects on host cell signaling, in-
cluding various alterations of the T-cell receptor (TCR) cas-
cade in T lymphocytes (6, 7, 40, 43, 44, 59, 61, 64, 66, 68). Since
resting T lymphocytes are largely resistant to productive HIV
infection, activation of target T lymphocytes is a prerequisite
for efficient spread of HIV-1 in vivo (reviewed in reference 69).
At the same time, high activation levels induced by potent
extracellular stimulation drive cells into activation-induced cell
death. According to an emerging view, Nef acts as an intracel-
lular inducer of TCR-triggered distal signaling events in the
absence of exogenous stimulation, while signaling via TCR
from outside of the cell is tuned down by Nef (21, 27, 62, 71;
see reference 17 for a review). By balancing these mechanisms,
Nef may thus ensure both target cell permissiveness and sur-
vival for optimal virus production.
Nef alters host cell processes by interacting with components
of cellular machines. Previous studies have identified a number
of protein interaction surfaces in Nef that are vital for specific
activities of the viral protein (3, 4, 23). Since an increasing
number of host cell factors that interact with each of these Nef
interfaces have been reported, the functional relevance of in-
dividual ligands have remained largely elusive. Regarding its
signal transduction properties, Nef is known to associate with
a number of cellular kinases, including members of the protein
kinase C, Src tyrosine, and p21-activated kinase (PAK) kinase
families (reviewed in reference 56). In particular, the associa-
tion of Nef with PAK has been studied in more detail, dem-
onstrating that PAK2 is the preferred PAK isoform that asso-
ciates with Nef (5, 19, 54). The interaction of Nef with PAK2
activity is conserved for many Nef proteins derived from
HIV-1, HIV-2, and SIV strains (50, 51, 60) and is readily
detectable in HIV-1-infected T lymphocytes as well as HIV-1
provirus transgenic mice (59, 75). Many Nef alleles also aug-
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ment overall cellular PAK2 activity, but PAK2 activation is less
well conserved and dispensable for the association of Nef with
PAK2 activity (51). Some studies using Nef mutants that fail to
associate with PAK2 activity but are also defective in other Nef
functions concluded that the Nef-PAK2 association may con-
tribute to the elevated pathogenic potential of Nef-positive
viruses in vivo (31, 61, 75). These reports are at odds with a
similar study in which viruses encoding a Nef mutant with
disruption of an interaction motif critical for Nef’s association
with PAK2 activity caused acute disease (35). If relevant for
the pathogenic potential of lentiviruses, the underlying mech-
anism of the Nef-PAK2 association is not well understood but
might involve established consequences such as upregulation
of HIV transcription, remodeling of the actin cytoskeleton,
prevention of apoptosis, and enhancement of virion infectivity
(11, 19, 20, 27, 40, 76, 77). Thus, as for most protein interac-
tions of Nef, the exact role and relevance of the Nef-PAK2
complex for virus propagation in the infected host remain to be
defined.
The Nef-PAK2 association occurs in the context of a larger
signalosome of approximately 1 MDa in size (19). Assembly of
this complex occurs at cellular membranes, where it selectively
segregates in detergent-resistant microdomains of the plasma
membrane, and disruption of these microdomains potently
blocks Nef’s association with PAK2 activity (34, 51, 53). The
association of Nef with the kinase is therefore mediated selec-
tively by a small subpopulation that associates with these mi-
crodomains (24, 34, 51). While it has been demonstrated that
Nef recruits PAK2 to membrane microdomains similarly to the
physiological PAK2 activators Rac1 and CDC42 (34, 51, 53),
further analysis of the composition of the Nef-PAK2 complex
and its regulation has been hampered by its low stability. Al-
though Nef-associated PAK2 activity can readily be demon-
strated experimentally, Western blot detection of PAK2 pro-
tein in Nef immunoprecipitates has been challenging (2, 40, 48,
51, 59, 61). This may reflect the specific association of Nef with
a highly active PAK2 subpopulation whose activity triggers
rapid disassembly of the complex (51, 55).
More detailed information is available on the determinants
in Nef that govern assembly of the Nef-PAK2 signalosome.
Consistent with its membrane microdomain localization, Nef’s
N-terminal myristioylation, a prerequisite for its association
with membranes, is essential for the functional interaction with
PAK2 (60). Earlier studies also identified a di-arginine motif as
a critical determinant. Mutation of this motif, however, has
pleiotropic effects, including decreased protein stability, and it
has thus been questioned whether this interface is actively
involved in Nef-PAK2 complex formation (23, 49, 60). Re-
cently, a novel protein interaction surface in Nef surrounding
the key residue F195 was identified as essential for the associ-
ation of Nef with active PAK2 (1, 2, 49). One study suggested
that this interface facilitates the recruitment of PAK2 into the
complex; the molecular basis for this role of F195, however,
has not been addressed in more detail (2). Finally, Nef con-
tains a highly conserved, proline-rich Src homology 3 domain
binding (PxxPxR) motif that represents another key determi-
nant for assembly of an enzymatically active Nef-PAK2 com-
plex (31, 42, 76). Since functional Nef-PAK2 association de-
pends on the activity of the upstream small GTPases Rac1 and
Cdc42 (40, 48), it has been assumed that an SH3-mediated
interaction by Nef directly or indirectly recruits a guanine
nucleotide exchange factor (GEF) to ensure PAK2 activity
within the complex. The identity of this GEF, however, has
remained a matter of debate. With Vav1, Pix/Cool, and
DOCK2/ELMO1, at least three GEFs containing an SH3 do-
main and providing GEF activity toward Cdc42 and/or Rac
were reported to associate with Nef (9, 20, 28, 67). Vav1 was
previously suggested as a critical component for the functional
association of Nef and PAK2; this was based, however, exclu-
sively on overexpression of a dominant-negative variant (20).
Conflicting data exist on the role of Pix in the Nef-PAK2
signalosome (9, 55, 75), and DOCK2/ELMO1 has not been
analyzed with respect to Nef’s association with active PAK2
(28). To address which of these GEFs play functional roles in
the Nef-PAK2 complex, their recruitment into membrane mi-
crodomains by Nef and the effects of reduced GEF expression
levels upon specific RNA interference (RNAi) or genetic
knockout on the efficiency of the Nef-PAK2 association were
used in this study as independent criteria. Our results demon-
strate the involvement of Vav1 in the association of Nef with
PAK2 activity and unexpectedly reveal that this GEF is re-
cruited into the complex via the F195 surface rather than the
PxxPxR motif.
MATERIALS AND METHODS
Cells, reagents, and plasmids. Jurkat Tag (JTag), JVav, and BE16-3 cells
were cultivated in RPMI 1640 supplemented with 10% fetal calf serum, 1%
L-glutamine, and 1% penicillin-streptomycin (all from Invitrogen). JVav and
BE16-3 cells are Jurkat derivatives and T-cell hybridoma cells that lack Vav1 or
DOCK2 expression (12, 58), respectively, and were kindly provided by Daniel
Billadeau and Yoshinori Fukui. Expression constructs for Vav1.myc, green flu-
orescent protein (GFP), various Nef.GFP proteins, PAK2, and Pix binding-
deficient Pak2 proteins were described elsewhere (13, 20, 25, 27, 34). Nef from
HIV-1 SF2 was used throughout. Constructs for expression of Nef.GFP carrying
the F195A or F195I mutation were generated by site-directed mutagenesis
(QuikChange site-directed mutagenesis kit; Stratagene), and the Nef-coding
sequences were verified by sequencing. Expression plasmids for Pix.myc, Flag-
.DOCK2, and ELMO1.His were kindly provided by Ivan Dikic, Shinya Tanaka,
and Yoshinori Fukui, respectively (47, 58, 63).
The following antibodies were used: polyclonal rabbit anti-ELMO1, polyclonal
rabbit anti-Vav2, and monoclonal mouse anti-myc (clone 9E10) (all obtained
from Santa Cruz Biotechnology); monoclonal mouse anti-flag (clone M2), mono-
clonal mouse anti-GFP (clone GFP20), and polyclonal mouse anti-cholera toxin
(anti-CTx) (all from Sigma-Aldrich); polyclonal rabbit anti-PAK1/2/3 and poly-
clonal rabbit anti-Vav (both from Cell Signaling Technology); polyclonal rabbit
anti-PIX and monoclonal mouse anti-His6 (clone BMG-His-1) (Roche); poly-
clonal rabbit anti-linker of activated T cells (LAT) (Upstate Biotechnology); and
monoclonal mouse anti-transferrin receptor (anti-Tfr) (clone H68.4) (Zymed
Laboratories, Inc.). Secondary fluorescent antibodies and Alexa Fluor 555-con-
jugated CTx subunit B were obtained from Molecular Probes, and protease
inhibitor cocktail was purchased from Sigma. Polyclonal rabbit serum against
GFP was kindly provided by Hans-Georg Kra¨usslich, and polyclonal sheep serum
against Nef was a kind gift from Mark Harris (14).
Western blotting. For Western blot analysis, samples were boiled in sodium
dodecyl sulfate (SDS) sample buffer, separated by 10% SDS-polyacrylamide gel
electrophoresis, and transferred to a nitrocellulose membrane. Protein detection
was performed following incubation with appropriate first and secondary anti-
bodies using the Super Signal Pico detection kit (Pierce) according to the man-
ufacturer’s instructions.
IVKA. Nef-associated PAK2 activity was analyzed in an in vitro kinase reaction
following immunoprecipitation of Nef.GFP essentially as described previously
(24, 34). Cells were transfected with the respective plasmids and RNAi oligonu-
cleotides via electroporation and incubated for 24 h (BE16-3 and JVav cells),
48 h (PAK1 RNAi), or 72 h (all other RNAi constructs). For this, 15 to 50 g
DNA and 500 pmol of RNAi specific for the targeted sequences, or unspecific as
a control, were added to 1 107 cells in 4-mm cuvettes, and electroporation took
place at 250 V (JTAg and JVav) or 230 V (BE16-3), 950 F, in a GenePulser
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Xcell (Bio-Rad). Sequences targeted by RNAi were 5 UCU GUA UAC ACA
CGG UCU GTT 3 for PAK1, 5AGA AGG AAC UGA UCA UUA ATT 3 for
PAK2, 5 CGU CGA GGU CAA GCA CAU UTT 3 for Vav1, 5 AGU CCG
GUC CAU AGU CAA CTT 3 for Vav2, 5 ACC ACU GUC UGC AAU AAU
ATT 3 for ELMO1, 5 GGA ACG ACA UCU ACA UUA CTT 3 for DOCK2,
5 GGA UGA AGU UCA AGA AUU ATT 3 for Pix, and 5 AGG UAG
UGU AAU CGC CUU GTT 3 as an unspecific control (all from MWG-
Biotech). Cells were lysed in KEB (137 mM NaCl, 50 mM Tris HCl [pH 8], 2 mM
EDTA, 0.5% Nonidet P-40, Na3VO4, and protease inhibitors) and subjected to
immunoprecipitation using rabbit anti-GFP serum as described (27). After ex-
tensive washing in KEB, beads were resuspended in 50 l KAB (50 mM HEPES
[pH 8], 150 mM NaCl, 5 mM EDTA, 10 mM MgCl2, 0.02% Triton X-100).
Treatment with 10 Ci [-32P]ATP (5 min, room temperature [RT]) allowed the
detection of PAK2 autophosphorylation. Following extensive washing in KEB, in
vitro kinase assay (IVKA) reaction products were separated by SDS-polyacryl-
amide gel electrophoresis and blotted on a nitrocellulose membrane. Radioac-
tive signals were visualized and quantified with a PhosphorImager (Bio-Rad).
Immunoisolated proteins were detected by Western analysis using anti-GFP
antibodies and quantified using the QuantityOne software (Bio-Rad). Radioac-
tive signals were normalized against the amount of isolated Nef in the Western
blot, and signals of wild-type (wt) Nef.GFP were arbitrarily set to 100%. Statis-
tical significance was determined by Student’s t test.
Isolation of DRMs. Detergent-resistant membranes (DRMs) were isolated by
flotation experiments as described previously (34). In brief, JTAg cells were
transfected via electroporation as described for the IVKA and incubated for
48 h. A total of 4  107 cells were transfected for each sample. Cells were lysed
in 400 l TXNE buffer (1% Triton X-100, 50 mM Tris HCl [pH 7.4], 150 mM
NaCl, 5 mM EDTA) for 20 min on ice, homogenized with a Dounce homoge-
nizer, and loaded on an Optiprep (Life Technologies) gradient (lysates were
adjusted to 40% Optiprep and overlaid with 2.5 ml 28% Optiprep and 600 l
TXNE), followed by ultracentrifuged (35 000 rpm, 3 h, 4°C). Eight fractions of
500 l each were collected from the top. For further analysis, fraction 2, which
represented the DRM fraction, and fraction 8, which was indicative of the
soluble fraction, were used in a Western blot. The quality of the flotation was
addressed by using Tfr (excluded from DRMs) and LAT (incorporated in
DRMs).
CTx clustering. The generation of CTx-positive clusters (CTx clusters) was
performed as described before (34). A total of 1  107 JTAg cells were trans-
fected via electroporation and incubated with 25 g of Alexa 555-conjugated
CTx/ml in 0.1% bovine serum albumin–phosphate-buffered saline for 30 min at
4°C, followed by addition of anti-CTx antibody (1:200; 30 min at 4°C and 10 min
at 37°C). Cells were bound to poly-L-lysine-coated coverslips (5 min, RT), fixed
with 3% paraformaldehyde (10 min, RT), and extracted with 0.1% Triton X-100
(1 min, RT). Cells were stained using the respective anti-tag antibodies (1:50
anti-His and 1:500 anti-flag and anti-myc for 1 h), followed by Alexa 660-
conjugated secondary antibody (1:2,000 for 30 min at RT), and were mounted in
Histomount (Linaris). Samples were analyzed in a confocal laser scanning mi-
croscope (LSM 510; Zeiss) using a 100 oil immersion objective lens. Images
were processed with Adobe Photoshop.
RESULTS
Nef-mediated recruitment of Vav1 to membrane microdo-
mains. The aim of this study was to evaluate the relative
involvement of three cellular GEFs, Vav, Pix, and DOCK2/
ELMO1, which have been reported to interact functionally or
physically with the Nef/PAK2 complex. Since the Nef-PAK2
association is confined exclusively to the detergent-insoluble
fraction in microdomain flotation experiments and microdo-
main association of Nef correlates with its ability to associate
with PAK2 (24, 34, 51), we used the presence in such microdo-
mains as the first criterion to define a GEF relevant for the
Nef-PAK2 complex. In order to allow parallel biochemical and
microscopic analyses, Nef.GFP fusion protein from the HIV-1
strain SF2 was used. This fusion protein has previously been
shown to be functionally equivalent to native Nef (24, 27, 34).
Using previously validated experimental procedures (24, 34),
microdomain association was first assessed by flotation analysis
of DRMs after Triton X-100-based lysis at 4°C of transiently
transfected JTag T lymphocytes. Effects of Nef on GEF seg-
regation were assessed by comparing cells expressing Nef.GFP,
a GFP control, or a Nef.GFP mutant protein that fails to
associate with active PAK2 due to disruption of its SH3 do-
main-interacting motif (AxxA.GFP). In addition to expression
plasmids for GFP/Nef.GFP, either these cells were cotrans-
fected with expression constructs for epitope-tagged GEFs or
endogenous GEFs were analyzed. Following microdomain flo-
tation, equal volumes of DRM and soluble fractions as well as
total cell lysate were analyzed by Western blotting (Fig. 1).
Exclusion of Tfr from the DRM fraction and the nearly equal
distribution of LAT between the DRM and soluble fractions
served as quality controls for the DRM isolation procedure.
As expected, soluble GFP was excluded from DRMs while
Nef.GFP was detected in small but significant amounts in
DRMs. In comparison, the AxxA.GFP mutant was expressed
at somewhat reduced levels, as previously noted (13). While
these lower levels of expression resulted in relatively small
absolute amounts of DRM association, the distributions be-
tween the DRM and soluble fractions were approximately sim-
ilar for Nef.GFP and AxxA.GFP. Coexpressed Vav1 was un-
detectable in DRMs in GFP-expressing control cells. In
contrast, detectable amounts of the GEF were present in
DRMs upon coexpression of Nef.GFP, suggesting recruitment
of Vav1 by Nef. Consistent results were obtained when endog-
enous Vav1 was analyzed. Surprisingly, Vav1 was also enriched
in DRMs in the presence of AxxA.GFP. Indeed, when taking
the reduced relative expression levels and specific DRM local-
FIG. 1. Analysis of Nef-mediated DRM recruitment upon transient
expression of cellular GEFs. Membrane microdomain flotation anal-
ysis from JTag T lymphocytes transiently expressing different Nef.GFP
fusion proteins or GFP is shown. Cell lysates (1% Triton X-100) were
separated by Optiprep gradient ultracentrifugation, and eight fractions
were collected from the top (fraction 1) to the bottom (fraction 8) of
the gradient. The DRM (fraction 2) and the soluble fraction (S) (frac-
tion 8) were analyzed together with the unfractionated cell lysate
(L) by Western blotting for the distribution of GFP/Nef.GFP and the
GEF. TfR and LAT were analyzed as markers for S and DRM frac-
tions, respectively. For DRM and S, 4% of each fraction was loaded;
L corresponds to 1% of the total lysate. When indicated, expression
constructs of epitope tagged GEFs were cotransfected with GFP/
Nef.GFP. The results presented are representative of at least four
independent experiments.
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ization of this Nef mutant into account, DRM recruitment by
AxxA.GFP occurred essentially with efficiencies comparable to
those by Nef.GFP. In contrast, the analogous analysis for Pix,
Vav2, and tyrosine-phosphorylated, active Vav (pVav) re-
vealed the presence of a minor fraction of these proteins in
DRMs already in the presence of GFP. This residual DRM
association remained unaltered by coexpression of Nef.GFP or
its AxxA mutant. The distribution of DOCK2/ELMO1 was
analyzed upon coexpression of both units of the bipartite GEF
and revealed its virtual absence from DRMs irrespective of
whether GFP or Nef.GFP was coexpressed. Together, these
results were compatible with potential roles of Vav1 and/or
Pix in the Nef-PAK2 complex but did not support an involve-
ment of DOCK2/ELMO1.
Vav1 is targeted to plasma membrane microdomains by Nef.
To verify the above results by an independent experimental
approach, plasma membrane microdomains were visualized in
parallel by confocal microscopy via clustering of fluorescently
labeled CTx (24, 34) (Fig. 2). While Vav1 was found diffusely
distributed in the cytoplasm of GFP-expressing JTag T lym-
phocytes (Fig. 2A), the presence of Nef.GFP and AxxA.GFP
led to a marked redistribution of Vav1 to the plasma mem-
brane. Both Nef.GFP variants localized to punctuate struc-
tures at the plasma membrane as well as intracellular perinu-
clear membranes that were detectable in only some z-sections
of the cells and likely represent endosomal compartments (27,
41, 71). The Nef-positive plasma membrane punctae partially
colocalized with CTx clusters, identifying them as membrane
microdomains. In typically two to three of these clusters per
optical section, Nef.GFP and Vav1 were found to colocalize.
Thus, Nef triggers plasma membrane recruitment of Vav1 and
leads to some incorporation of the GEF in plasma membrane
microdomains. Coexpression of Pix did not have appreciable
effects on the localization of Nef.GFP (Fig. 2B). Likewise, this
GEF was found in the cytoplasm as well as at the plasma
membrane, where it sometimes accumulated at CTx-positive
clusters. This localization remained unaltered in the presence
of Nef, and both proteins were occasionally found to colocalize
in membrane microdomains, albeit less frequently than Nef
and Vav1. Finally, DOCK2 (Fig. 2C) and ELMO1 (Fig. 2D)
were found diffusely in the cytoplasm without marked plasma
membrane enrichment or microdomain localization irrespec-
FIG. 2. Analysis of Nef-mediated recruitment of cellular GEFs into plasma membrane microdomains. Aliquots of the transfected JTag T
lymphocytes analyzed in Fig. 1 were subjected to raft clustering by incubation with CTx conjugated with Alexa 555 fluorescent dye and subsequently
cross-linked with anti-CTx antibody. The GEFs were stained with anti-tag antibodies and detected with Alexa 660 coupled to the appropriate
secondary antibodies. Cells were analyzed by confocal microscopy, and single representative sections are presented. The merge panels depict the
overlay of all three fluorescence channels, with GFP/Nef.GFP in green, CTx in red, and the respective GEF in blue. Arrows indicate colocalization
of Nef with a GEF in plasma membrane microdomains. The results presented are representative of at least three independent experiments.
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tive of coexpression of GFP or Nef.GFP. This independent
analysis therefore confirmed a possible role of Vav1 and Pix
in signaling events initiated by Nef from membrane microdo-
mains.
Nef-associated kinase activity following PAK knockdown.
We next sought to address the role of the three GEFs more
directly using RNAi-mediated reduction of protein levels. To
this end, we first estimated the range of inhibition of PAK
enzymatic activity that can be achieved by RNAi targeted
against the kinase itself. Furthermore, while PAK2 has been
identified as the preferred PAK isoform associated with Nef,
some reports also suggested the involvement of PAK1 (19, 46).
We therefore compared the effects of RNAi against these two
kinases on Nef-associated PAK activity. As shown in Fig. 3A,
RNAi oligonucleotides directed against target sequences in
PAK1 or PAK2, respectively, effectively and specifically re-
duced the protein levels of the respective PAKs (knockdown
efficiency as quantified by Western blotting: PAK1, 88% 
15%; PAK2, 94%  10%). Following immunoprecipitation of
various Nef.GFP fusion proteins and subsequent IVKA reac-
tion, Nef-associated phosphorylated PAK2 was visualized by
autoradiography (Fig. 3B). When an irrelevant RNAi oligonu-
cleotide was used, Nef.GFP associated with robust PAK activ-
ity resulting in PAK autophosphorylation (62 kDa, pPAK2) as
well as phosphorylation of an 80-kDa substrate. As expected,
AxxA.GFP failed to associate with detectable kinase activity.
The substantial reduction of PAK1 expression did not result in
diminished Nef-associated PAK activity, whereas treatment
with the PAK2-specific RNAi oligonucleotide caused about
35% inhibition of Nef-associated kinase activity. When the
Nef-associated PAK activity from five experiments was quan-
tified by phosphorimager analysis relative to the amounts of
immunoisolated Nef.GFP, PAK2 RNAi reduced the kinase
reaction to 65% 19% (P	 0.001), while PAK1 RNAi had no
effect. Consistently, PAK2 but not PAK1 could be detected in
anti-Nef immunoprecipitates by using highly sensitive lumino-
metric detection of PAK-luciferase fusion proteins (data not
shown). These results suggest that PAK1 does not contribute
to Nef-associated kinase activity in our experimental system
and indicate that PAK2 protein still present in the RNAi-
targeted cells (approximately 6% of the levels in control cells)
can be efficiently recruited by Nef to give rise to a relatively
high (65% of control) residual Nef-associated kinase activity.
RNAi knockdown of Nef-associated GEFs. Having deter-
mined the degree of inhibition of Nef-associated PAK2 activity
that can be achieved by direct RNAi knockdown of PAK2
itself, we next tested the effect of knockdown for the GEFs
previously implicated in Nef-associated protein assemblies.
RNAi against Vav1, Vav2, Pix, and ELMO1 caused a marked
reduction in the expression levels of the corresponding endog-
enous proteins (knockdown efficiency as quantified by Western
blotting: Vav1, 86%  15%; Vav2, 76%  10%; DOCK2,
97%  5%; ELMO, 85%  9%; Pix, 86%  10%). Potent
silencing of DOCK2 protein expression was confirmed using a
transfected vector expressing an epitope-tagged version of
DOCK2 (Fig. 4A). IVKA analysis revealed a significant reduc-
tion of Nef-associated PAK2 activity upon Vav1 RNAi treat-
ment. The magnitude of this effect was comparable to that
obtained with direct knockdown of PAK2 (reduction to 68%
20% for Vav1 and 65%  19% for PAK2). RNAi against Vav2
and ELMO1 (reduction to 71%  20% and 67%  15%,
respectively) also had statistically significant effects on the Nef-
PAK2 association (Fig. 4B and C; P values indicate statistical
significance in comparison to reaction after treatment with
RNAi control oligonucleotides). Knockdown of DOCK2 and
Pix caused no significant alterations in Nef-associated PAK2
activity (reduction to 89%  20% and 88%  25%). These
results further suggested a critical role for Vav1 in the Nef-
PAK2 complex and argued against the involvement of DOCK2
and Pix.
Impairment of Nef-PAK2 association in Vav1-deficient T
lymphocytes. Because inhibition of Nef-associated PAK2 ac-
tivity was only partial upon RNAi-mediated reduction of Vav
protein levels, we next turned to the JVav cell line, a Jurkat
T-lymphocyte derivative that lacks Vav1 expression due to
FIG. 3. Effect of RNAi knockdown of PAK1 and PAK2 on Nef-
associated PAK activity. (A) JTag T lymphocytes were transfected with
small interfering RNA oligonucleotides specific for PAK1 or PAK2 or
a nonspecific control oligonucleotide (con) and analyzed by Western
blotting for PAK1 and PAK2 expression levels at 48 and 72 h post-
transfection, respectively. 14-3-3 was used as a loading control.
(B) Analysis of Nef-associated PAK activity following PAK1 and
PAK2 knockdown. JTag T lymphocytes were transfected with small
interfering RNA oligonucleotides specific for PAK1 or PAK2 or the
control oligonucleotide together with an expression plasmid for Nef-
.GFP or the AxxA.GFP mutant, and an IVKA following anti-GFP
immunoprecipitation (IP) was performed at 48 (PAK1) or 72 (PAK2)
hours posttransfection. Nef-associated PAK activity is revealed by the
phosphorylated 62-kDa band (IVKA, pPAK2). (C) Quantification of
the Nef-associated PAK activity. Intensities of autophosphorylated
PAK2 signals were quantified relative to the amounts of immunoiso-
lated Nef.GFP. The relative associated PAK activity for Nef.GFP in
the presence of a control oligonucleotide was arbitrarily set to 100%.
Data are means  standard deviations from at least five independent
experiments. Statistical significance is indicated by the P values derived
from Student’s t test analysis. wt, wild type.
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genetic knockout (12). Consistent with the previous RNAi
experiments, the Nef protein from HIV-1 SF2 associated up to
fourfold less efficiently with PAK2 activity in the absence than
in the presence of Vav1 (Fig. 5A, compare JVav with JTag).
Although with various degree of reduction in Nef-associated
PAK2 activity in the absence of Vav1, the involvement of Vav1
in Nef-PAK2 association was also conserved for SIVmac239
Nef, the T71R mutant of Nef from HIV-1 NL4-3, and the
patient derived HIV-1 Nef variant RP4-11 (Fig. 5B). To verify
that this reduction in Nef-associated PAK2 activity was really
due to the lack of Vav1, a myc-tagged version of Vav1 was
coexpressed with Nef in JVav cells (Fig. 5C). Under conditions
where expression levels of overexpressed Vav1.myc were in the
range of endogenous Vav1 in JTag cells, Nef-PAK2 association
was markedly enhanced, reaching levels that almost matched
those in parental JTag cells. Since Nef can associate with Vav2
as well as with Vav1 (20), we next tested whether the residual
Nef-PAK2 association in JVav cells was due to the presence of
Vav2 and performed RNAi knockdown experiments targeting
Vav2 (Fig. 5D). As seen before in JTag cells, Vav2 knockdown
was only partial in JVav cells; however, it reduced the residual
Nef-associated PAK2 activity (to 54%  15% and 41%  20%
for HIV-1 SF2 and SIVmac239 Nef, respectively). Together
these results support an important role of Vav1 in the Nef-
PAK2 complex and suggest that Vav2 can substitute for the
Vav1 isoform.
DOCK2 expression and Pix binding of PAK2 are dispens-
able for the association of Nef with PAK2 activity. Following
the genetic knockout approach, the role of DOCK2 in the
association of Nef with PAK2 activity was tested using
DOCK2
/
 BE16-3 T-cell hybridoma cells (58). No signifi-
cant difference was observed in the PAK2 association of Nef
proteins from HIV-1 and SIV between BE16-3 and JTag cells
(Fig. 6A), strongly suggesting that DOCK2 is dispensable for
Nef-PAK2 association. Of note, reduction of Vav1 expression
using RNAi in BE16-3 cells caused a twofold reduction of
Nef-PAK2 association (Fig. 6B). Experiments on a Pix
/

genetic background were precluded due to the lack of a Pix
knockout cell line. Since Pix directly binds to PAK2 (29), we
tested instead whether a PAK2 mutant carrying a mutation in
the Pix binding site would be able to associate with Nef in its
catalytically active form. As presented in Fig. 6C, association
with PAK2 activity was equally efficient for HIV-1 as well as
SIV Nef in the presence of wt and Pix binding-deficient
FIG. 4. Effect of RNAi knockdown of cellular GEFs on Nef-associated PAK2 activity. (A) Western blot analysis of JTag cells transfected with
small interfering RNA oligonucleotides specific for the indicated GEFs or a nonspecific control oligonucleotide (con) for GEF expression levels,
as in Fig. 3. Note that endogenous protein levels were analyzed, except in the case of DOCK2, where an expression plasmid for DOCK2.flag was
cotransfected with the RNAi oligonucleotides. (B) Nef-associated PAK2 activity following GEF knockdown. JTag T lymphocytes transfected with
GEF-specific small interfering RNA or the control oligonucleotide together with the indicated Nef.GFP expression plasmids were subjected to
IVKA following anti-GFP immunoprecipitation (IP). (C) Quantification of the Nef-associated PAK2 activity following GEF knockdown. Inten-
sities of autophosphorylated PAK2 signals were quantified relative to the amounts of immunoisolated Nef.GFP. The relative associated PAK2
activity for Nef.GFP was arbitrarily set to 100%. Data are means  standard errors of the means from at least five independent experiments.
Statistical significance is indicated by the P values derived from Student’s t test analysis. wt, wild type.
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PAK2 variants. In conjunction with the RNAi experiments,
these results suggested that Pix is dispensable for the associ-
ation of Nef with active PAK2. Taking together analyses on
GEF membrane microdomain recruitment, GEF RNAi, and
the use of GEF knockout cell lines, we conclude that among
the three GEFs previously associated with Nef function, only
Vav1 fulfils the criteria for a GEF with a major role in the
Nef-PAK2 complex.
Residue 195 is critical for the Nef-PAK2 association and
Vav1 recruitment. The identification of the SH3 domain-con-
taining Vav1 protein as the relevant GEF in the Nef-PAK2 com-
plex was at odds with the fact that its recruitment into membrane
microdomains occurred independently of the highly conserved
SH3 binding (PxxP) motif of Nef. Recent studies identified a
novel protein interaction surface involving residue F195 in Nef
that is required for the Nef-PAK2 association (2, 49). We there-
fore tested whether this surface is involved in the recruitment of
Vav1 by Nef and created expression vectors for F195A and F195I
Nef.GFP proteins. Compared to wt Nef, both mutants displayed
less than 5% of Nef-associated PAK2 activity and scored
lower than the AxxA.GFP or the membrane binding-deficient
G2A.GFP controls (Fig. 7). DRM flotation experiments and con-
focal microscopy revealed that this lack of kinase association was
not a consequence of exclusion of the F195 mutants from mem-
brane microdomains (Fig. 8A) or other mislocalization in T lym-
phocytes (Fig. 8B). Rather, the association with DRM fractions
appeared to be slightly elevated relative to Nef.GFP. In sharp
contrast, both Nef variants with mutations at position F195 failed
to recruit Vav1 into DRMs. Consistently, F195A.GFP (Fig. 8B)
and F195I.GFP (data not shown) were defective in targeting
Vav1 to the T-lymphocyte plasma membrane and did not induce
colocalization of the GEF with CTx membrane microdomains.
We conclude that the F195 protein interaction surface is a critical
determinant for the membrane microdomain recruitment of
Vav1 and thus for the association of Nef with PAK2 activity.
DISCUSSION
The composition of the Nef-PAK2 complex has remained
controversial largely due to its low stability and the concomi-
tant difficulties in detecting associated proteins directly rather
than based on their activity. In a first step toward understand-
D
FIG. 5. Vav1 deficiency reduces Nef-PAK2 association in T lymphocytes. (A) IVKA for Nef-associated PAK2 activity in JTag and Vav1-
deficient JVav T lymphocytes. IVKA reactions were performed for Nef from HIV-1 SF2. Vav1 expression levels are shown in the upper panels;
the middle panel depicts PAK2 autophosphorylation levels and amounts of immunoisolated Nef. The graphs present relative levels of Nef-
associated PAK2 activity, with values for wild-type (wt) Nef in JTag cells set to 100%. Data are means  standard errors of the means from three
independent experiments. IP, immunoprecipitation. (B) IVKA reaction and Western blot analysis for immunoisolated Nef from SIVmac239,
HIV-1 RP4-11, and HIV-1 NL4-3. T71R, HIV-1 RP4-11, and SIVmac239. (C) Rescue of HIV-1 SF2 Nef-associated PAK2 activity in JVav cells
by Vav1 overexpression. Shown are the IVKA reaction, amounts of immunoisolated Nef, and Vav1 expression levels. (D) Residual Nef-associated
PAK2 activity in JVav cells is sensitive to RNAi against Vav2. JVav cells were treated with the indicated RNAi oligonucleotides, and knockdown
efficiency was evaluated by Western blotting (upper panel). From the same lysates, an IVKA was performed (middle panel). The bottom panel
presents the quantification of Nef-associated PAK2 activity, with values for wt Nef in JVav cells treated with a control oligonucleotide set to 100%.
Data are means  standard errors of the means from three independent experiments.
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ing the organization and regulation of this signalosome, we
addressed here which of the reported Nef-associated cellular
GEFs plays a role in the association of Nef with PAK2 activity.
Microdomain recruitment, subcellular localization, GEF-spe-
cific RNAi, genetic knockout cells, and GEF binding-deficient
PAK2 variants were applied as independent assays and tools to
answer this question. Taken together, the results reveal a role
for Vav1 in the association of Nef with PAK2 activity and
argue that Pix and DOCK2 are dispensable for this Nef
function. Surprisingly however, a recently described protein
interface surrounding F195 rather than the SH3 binding
PxxPxR motif in Nef mediates the recruitment of Vav1 into the
signalosome.
Since each individual experimental strategy used here to
dissect the role of cellular GEFs in functional Nef-PAK2 as-
sociation had its specific limitations, it is important to consider
the combined interpretation of the independently obtained
results. The isolation of DRMs demonstrated Nef-mediated
recruitment of Vav1 but not DOCK2/ELMO1, while Pix was
found to be DRM resident with no detectable alteration upon
Nef expression. Due to possible artifacts during detergent
treatment, these results were compared with microdomain
cluster colocalization. Besides providing overall confirmation
of the biochemical analyses, this approach also allowed us to
appreciate the specific recruitment of Vav1 by Nef to the
plasma membrane on a single-cell level, which was overall
more pronounced than the microdomain targeting judged by
FIG. 7. F195 is critical for the association of Nef.GFP with PAK2
activity. (A) IVKA analysis from JTag T lymphocytes transiently ex-
pressing the indicated Nef.GFP fusion proteins. IP, immunoprecipita-
tion. (B) Quantification of PAK2 activity associated with the Nef.GFP
variants analyzed in panel A. The relative associated PAK2 activity for
Nef.GFP was arbitrarily set to 100%. Data are means  standard
deviations from at least three independent experiments. wt, wild type.
FIG. 6. Nef-PAK2 association is functional in the absence of DOCK2 or the presence of Pix binding-deficient PAK2. (A) IVKA for
Nef-associated PAK2 activity in JTag and DOCK2-deficient BE16-3 cells. The IVKA reaction for Nef from HIV-1 SF2 and SIVmac239 and
amounts of immunoisolated Nef are shown in the upper panels; the lower panel depicts relative levels of HIV-1 and SIV Nef-associated PAK2
activity, with values for wild-type (wt) Nef in JTag cells set to 100%. Data are means  standard errors of the means from four independent
experiments. IP, immunoprecipitation. (B) Nef-associated PAK2 activity is reduced upon Vav1 knockdown. BE16-3 cells were treated with the
indicated RNAi oligonucleotides. Knockdown efficiency was evaluated by Western blotting (upper panels). IVKA analysis and quantification of
amounts of immunoisolated Nef.GFP are presented in the middle panels. The bottom panel presents the quantification of Nef-associated PAK2
activity, with values for Nef in BE16-3 cells treated with a control oligonucleotide set to 100%. Data are means  standard errors of the means
from three independent experiments. (C) Pix binding is dispensable for functional Nef-PAK2 association. PAK2 association was analyzed for Nef
from HIV-1 SF2 and SIVmac239 in the presence of wt or Pix binding-deficient PAK2. From top to bottom, the panels show expression levels
of Nef and PAK2, the IVKA reaction, and the amounts of immunoisolated Nef.
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biochemical criteria. The lack of detection of DOCK2/ELMO1
in DRMs or CTx clusters in Nef-expressing cells argued against
a functional role of this bipartite GEF for the Nef-PAK2 as-
sociation; however, the catalytic relevance of undetectable pro-
tein amounts could not be excluded. However, since the re-
cruitment of other catalytic components of the Nef-PAK2
complex, such as PAK2, Rac1, and Cdc42, can readily be dem-
onstrated (34), a critical involvement of DOCK2/ELMO1
seemed unlikely. The microdomain analysis also did not yield
information on the functional relevance of membrane mi-
crodomain-associated GEFs and could thus not differentiate
between the roles of Vav and Pix. GEF-specific RNAi was
therefore used in further analyses. Knockdown of PAK1 and
PAK2 established the dynamic range that could be expected
for this approach: despite reduction of PAK2 expression to less
than 10% of the levels in control cells, only an approximately
30% decrease in Nef-associated PAK activity was observed.
Similar difficulties in functional knockdowns of cellular en-
zymes, including PAK2, have been encountered by other in-
vestigators (37–39, 73) and possibly reflect cells’ ability to
maintain a relatively constant pool of active enzymes even
upon significant reduction of overall enzyme abundance. Al-
ternatively, and not mutually exclusive, these results could also
indicate the presence of a PAK2 phosphorylating activity in the
complex other than just PAK2 itself. These findings are in
agreement with the finding that Nef specifically associates with
a small but highly active PAK2 subpopulation (51, 55). Pro-
viding specificity to these results, similarly efficient knockdown
of PAK1 expression did not affect Nef-associated PAK activity.
In a previous study we had concluded that PAK1 can serve as
a Nef-associated kinase based on the inhibitory effect of an
interfering PAK1 fragment (19). This fragment was, however,
subsequently shown to also interfere with the activity of PAK2.
Use of specific antibodies and sensitivity to caspase cleavage
then identified PAK2 as the Nef-associated kinase (5, 54). The
RNAi data presented here confirm that PAK2 is the relevant
Nef-associated PAK isoform in JTag T lymphocytes by an
independent experimental approach. Within the limits of this
incomplete inhibition of Nef-associated PAK2 activity, efficient
knockdown of Pix and DOCK2 had no significant effect on
Nef’s association with PAK2 activity. Consistently, binding of
Pix to PAK2 was fully dispensable for efficient association of
Nef with PAK2 activity. More directly, BE16-3 cells allowed
us to verify the involvement of DOCK2 in a cellular environ-
FIG. 8. Role of F195 in microdomain recruitment of Vav by Nef. (A) Western blot analysis of DRM flotation from JTag T lymphocytes
transiently expressing the indicated Nef.GFP fusion proteins or GFP together with myc-tagged Vav1 (see legend to Fig. 1 for details). (B) Raft
clustering analysis of the JTag T lymphocytes analyzed in panel A. Cells were analyzed by confocal microscopy, and single representative sections
are presented (see legend to Fig. 2 for details). The merge panel depicts the overlay of all three fluorescence channels, with GFP/Nef.GFP in green,
CTx in red, and Vav1 in blue. Arrows indicate colocalization of Nef with Vav1 in plasma membrane microdomains. The results presented are
representative of at least three independent experiments.
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ment of genetic DOCK2 deficiency. The results clearly dem-
onstrated that DOCK2 expression is dispensable for the asso-
ciation of Nef with PAK2 activity. Thus, Pix and DOCK2
could be excluded as constituting limiting factors in the Nef-
PAK2 complex. In contrast, Vav1, and to a lesser extent Vav2,
were identified as relevant for functional Nef-PAK2 interac-
tions, with the effects of Vav1 knockdown being as pronounced
as knockdown of the kinase itself. Analysis of T lymphocytes
devoid of Vav1 expression confirmed a critical role of Vav1 in
Nef’s association with PAK2 activity. Importantly, Nef-PAK2
association was rescued in these cells by reintroduction of
Vav1, and residual Nef-PAK2 association was sensitive to ex-
pression levels of Vav2. Together with the microdomain anal-
ysis, these results demonstrate a functional role for Vav1 and
Vav2 but not DOCK2 or Pix in the Nef-PAK2 complex.
DOCK2/ELMO1 associate with Nef in a PxxP-dependent
manner and have been implicated in the inhibition of T-lym-
phocyte chemotaxis by the viral protein (28). This effect likely
depends on the exchange activity of this GEF for Rac1, which
is exerted only in the context of a direct interaction of both
subunits of this bipartite GEF (10, 58). Since DOCK2 was
found to be entirely dispensable for the association of Nef with
active PAK2, this GEF appears not be involved in this function
of Nef. In line with these findings, Janardhan and colleagues
did not detect PAK2 or Vav1 proteins in their Nef-associated
DOCK2-ELMO1-Rac complex (28). Together, these results
suggest that the association of Nef with PAK2 and with
DOCK2/ELMO1 occurs in the context of two independent
protein complexes. Thus, Nef, via its PxxPxR motif, assembles
multiple protein complexes in T lymphocytes that differ in
abundance, composition, and possibly subcellular localization
to modulate select effector functions. In contrast to DOCK2,
however, knockdown of ELMO1 partially affected the func-
tional Nef-PAK2 association, suggesting that ELMO1 can af-
fect Nef-PAK2 independently of DOCK2. As ELMO1 was
undetectable in Nef-positive microdomains, we favor the idea
that these effects are indirect consequences of reduced
ELMO1 expression levels, possibly reflecting the regulation of
Rac signaling pathways by ELMO1 in conjunction with DOCK
family members other than DOCK2 (26).
Regarding the role of Pix in the Nef-PAK2 complex, it
was previously reported that this GEF is physically present
in the complex (75) and serves as a substrate of Nef-asso-
ciated active PAK2 (9). On the other hand, we show here
that the Pix-PAK2 interaction is dispensable for Nef’s abil-
ity to associate with active PAK2. Together these results
suggest that Pix, possibly facilitated by its constitutive mi-
crodomain association and recruited via its interaction with
PAK2, associates with the Nef-PAK2 complex as a periph-
eral complex component which does not contribute to PAK2
activity levels in this context. Rather, Pix might act as a
downstream effector of Nef-PAK2 signalosomes. In line
with such a model, Pix was recently shown to associate with
Nef in membrane microdomains to regulate the activity of
the ubiquitin ligase c-Cbl (67).
Vav1 is the only GEF tested here that was recruited to
membrane microdomains by Nef and whose expression lev-
els directly correlated with the efficiency of the association
of Nef with PAK2 activity. These results thus identify endo-
genously expressed Vav1 as a critical component for the
function of the Nef-PAK2 complex, thereby confirming and
extending previous reports on the interaction of Nef with
this particular GEF (20, 52, 74). Although not experimen-
tally addressed here, this role most likely involves its GEF
activity toward Rac1 and Cdc42, which, in their GTP bound
state, ensure activity of PAK2 in the complex prior to its
disassembly. Nef was previously shown to interact directly
with the C-terminal SH3 domain of Vav1 in vitro via its
PxxPxR motif, and the association of Nef and Vav1 in cells
was also shown to depend on these interaction surfaces (20,
52, 74). These results suggested that Vav1 might be re-
cruited into the Nef-PAK2 complex via this interaction.
Unexpectedly, however, we find here that this recruitment
occurs via the F195 patch rather than the Nef SH3 binding
motif. In addition to Vav1, the association of PAK2 with Nef
also depends on the F195 interaction surface (2). These data
do not allow us to identify the direct interaction partner of
this Nef interface, which could represent either one of the
two proteins or a yet-unidentified adapter protein. The re-
sults presented also raise the question of which SH3 protein
interacts with Nef’s PxxPxR motif to facilitate functional
Nef-PAK2 interactions. While the C-terminal SH3 domain
of Vav1 might indeed interact with this interface within the
complex, our data argue that this interaction would not
significantly contribute to the stability of the Nef/Vav1/
PAK2-containing signalosome. In this scenario, the PxxP-
SH3 interaction might ensure correct positioning of the
complex and/or Vav activity and thus provide activation
instead of recruitment of critical complex components. Af-
finity screening of a library containing the complete collec-
tion of human SH3 domains did not reveal any SH3 domains
expressed in T cells that would show distinct affinity for Nef
(29), thus indirectly supporting the idea that the critical
function of the Nef PxxP motif in Nef/Vav1/PAK2 assembly
might be mediated via such a low-affinity SH3 interaction.
Alternatively, the activity of the complex would also be
facilitated by the association with yet-to-be-identified SH3
domain-containing factors that may well lack GEF activity.
The association of Nef with PAK2 activity was among the
first protein interactions described for this viral pathogenicity
factor (59) and represents one of the most conserved features
of the different HIV and SIV Nef variants (33). However, due
to the low stability of the Nef-PAK2 complex and the involve-
ment of protein interaction surfaces required for complex as-
sembly in several other independent Nef activities, the physi-
ological role and the molecular principles of this complex have
remained largely elusive. Based on the new insights into the
Nef-PAK2 complex organization presented here, future stud-
ies can now focus on determining the full composition of the
Nef-PAK2 complex and on the specificity of its downstream
effector functions.
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